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Economic evaluations are increasingly used in healthcare decision-making. An iterative 
approach to economic evaluation has been proposed as good practice in which economic 
evaluations are re-performed as new evidence becomes available throughout the lifecycle 
of health technology. Decision analytical models play a key role within this process as 
they provide a structure in which evidence from a range of sources can be synthesised 
along with Bayesian updating in order to answer the cost-effectiveness problems. This 
allows the use of the value of information (VoI) methods that help inform further research 
priority setting. 
Physical activity (PA) interventions, in general, are considered good value for money 
however little is known about the cost-effectiveness of very brief interventions (VBIs) in 
PA promotion. The thesis aims to explore the feasibility of using an iterative approach to 
decision-making in the context of the cost-effectiveness of VBIs to promote PA. Using VBI 
as a case study, this thesis explores the practical and methodological issues of applying 
an iterative approach to economic evaluation and considers potential reasons as to why 
the framework has not been widely implemented to date. 
Using VBI as a case study provided the opportunity to examine the challenges involved 
in undertaking an economic evaluation of very brief PA interventions in real time. This 
thesis explored the feasibility of applying the iterative process to evaluate the cost-
effectiveness of VBIs in PA promotion in a time-constrained setting. A decision analytic 
model was developed at the outset of the thesis and employed iteratively to handle the 
evolving evidence base of VBIs in PA promotion. Although there are several merits of 
applying such a framework in real life economic evaluation, in the case of the VBI study, 
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Chapter 1 Background 
 
1.1 Introduction 
Economic evaluation provides a framework in which to measure costs and benefits in 
order to inform decision makers to make informed decisions about the adoption of new 
technologies, intervention or to decide what represents acceptable value for money (1). 
In the face of scarce resources, economic evaluation enables decision makers to 
maximise health gain to the population by ensuring the efficient allocation of resources. 
Health technology assessment (HTA) organisations such as the United Kingdom (UK) 
National Institute for Health and Care Excellence (NICE) require cost-effectiveness data 
in decisions about the reimbursement of health technologies (2). Although the requirement 
for cost-effectiveness data provides challenges, they provide an opportunity to 
demonstrate the value for money. In recent years, the use of economic evaluations in 
healthcare decision-making has increased (3). 
Decision making in health care is a dynamic process. The process of decision-making is 
based on existing information and new information affecting the decision which becomes 
available throughout the life cycle of all technologies. An iterative framework to economic 
evaluation has been proposed for the evaluation of health technologies (4,5). Decision 
modelling is a key process within this framework. The premise underpinning the iterative 
framework is that rather than using one-off economic evaluation, the process should be 
iterative throughout the research process. That is from the process of synthesising 
evidence from a range of sources to populate the decision model and continually updating 
in order to answer the decision problem (5,6). The use of the value of information (VoI) 
methods in decision analysis provides the justification for whether future research ought 
to be conducted and if so, on which uncertain parameters that research should focus (7-
10). 
This opening first chapter introduces the main academic disciplines underpinning the 
thesis: the use of economic evaluation to inform decision-makers with a particular focus 
on decision analytic modelling as a vehicle to economic evaluation and the use of the 
iterative approach in decision-making. This is followed by a brief background on the 
applied topic, very brief interventions (VBIs) in physical activity (PA) promotion, used as 
a case study in this thesis. The following sections explore the grounds for economic 
2 
evaluation, both alongside a clinical trial and using a decision model, of healthcare 
interventions and the use of the iterative framework in economic evaluation. The first 
section describes economic evaluations, discusses the types of economic evaluations, 
and a ten step framework for conducting economic evaluations. The subsequent sections 
describe ‘trial based’ vs ‘decision model’ based economic evaluation, use of the iterative 
framework in decision making, and finally provides an overview of brief interventions in 
PA promotion. 
The main aim of this thesis is to examine the feasibility of using an iterative framework for 
economic evaluation using the case of VBI study. This thesis further explores the practical 
and methodological issues while applying the iterative framework in practice to assess the 
merits and limitations of the framework. 
1.2 Economic evaluation in healthcare 
There are finite health resources, and the demands for health services are increasing 
because of unlimited wants or needs of patients. In the face of limited resources 
(budgetary constraints), decision makers have to decide between alternative interventions 
or health technologies, deciding which intervention or health technology to adopt. There 
is often a trade-off between efficiency (how best to allocate resources) and equity 
(fairness) in allocating resources (11). Economic evaluations facilitate the comparison of 
two or more alternative interventions that consider both the costs and consequences of 
alternative interventions (1). They assist decision makers in setting priorities, making 
resource allocation decisions and designing health services by efficient use of scarce 
resources. 
Economic evaluations are becoming an integral part of modern healthcare evaluation, and 
their use in healthcare decision-making has increased over recent decades (3,12). They 
provide a valuable framework to evaluate alternative options or healthcare interventions 
and enable decision makers to maximise health gain to the population by efficient 
allocation of scarce resources (13). Economic evaluation can take a number of forms, and 
the selection of the type of economic evaluation mainly depends on the purpose of the 
study and may also be influenced by factors such as availability of data on outcomes or 
target audience. 
3 
1.2.1 Types of economic evaluation 
There are four types of full economic evaluation used (1: p.11). They are cost-benefit 
analysis (CBA), cost-effectiveness analysis (CEA), cost-utility analysis (CUA) and cost-
minimisation analysis (CMA). These four forms of economic evaluations approach costs 
in a common format but vary in terms of how they measure health benefits (outcomes). 
In CBA, both costs and benefits are measured in monetary terms, and the analysis reports 
a net monetary gain (or loss) or a cost-benefit ratio. The CBA decision rule, as to whether 
or not to select the intervention, rests in the principle of whether the monetary value of 
additional benefit exceeds the additional cost. That means the intervention in question 
should be selected if the health outcome benefits are greater than the resource use cost. 
This type of analysis overcomes the problem of comparing interventions with multiple 
outcomes as both costs and outcomes are measured in monetary terms. Although this 
type of analysis offers a sound theoretical form of economic evaluation, its use in 
healthcare is limited due to practical issues with placing monetary valuations on health 
outcomes (14). 
Cost-effectiveness analysis attempts to identify whether more health benefits can be 
achieved for a lower cost. Unlike CBA, CEA measures health outcomes in natural units, 
for example, life years gained (LYG), moving one inactive adult to an active category, or 
reduction in blood pressure. The results in CEA are presented in terms of incremental 
costs per unit of health gain known as an incremental cost-effectiveness ratio (ICER). The 
ICER is calculated by dividing the difference between the costs of two interventions by the 
difference in the health effects. Although CEAs are relatively simple and straightforward 
to carry out, this approach is not comprehensive. The analysis cannot incorporate other 
aspects of health effects such as quality of life into the cost-effectiveness ratio. For 
example, cost per life-year saved will not capture potentially important aspects of patients’ 
quality of life. A further limitation of this approach is that health interventions with different 
outcomes cannot be compared. For example, cost per metabolic equivalent of task (MET) 
-hour gained cannot meaningfully be compared with the cost per cardiovascular event 
avoided. 
The CUA is often seen as an extension of CEA where the health benefit is measured in 
quality-adjusted life-years (QALYs) gained or disability-adjusted life-years (DALYs) 
avoided. QALYs and DALYs adjust life expectancy for morbidity, using quality of life and 
disability weighting respectively (15,16). The advantage of using CUA over CEA is that it 
allows comparison between, as well as within, healthcare interventions. In CEA, if we are 
comparing interventions, for example, deaths averted, we can only compare interventions 
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designed to prevent deaths. However, using generic measures of health-related quality of 
life such as QALYs, we can make comparisons between interventions, for example, an 
intervention designed to prevent deaths and intervention designed to increase PA levels. 
This type of economic evaluation is extremely useful for decision makers because the 
outcome measure is comparable across disease conditions and interventions. The ICER 
outcome would be the incremental cost per QALY gained or DALYs averted. However, 
this approach has challenges, in particular, deriving the health state utilities (17-20) used 
to facilitate generalised comparison between health states. 
CMA is a specific subset of CEA which is utilised in situations where the outcomes of 
comparator interventions have been proven to be equivalent. Therefore, the least 
expensive comparator intervention is preferred (21). However, this method has been 
criticised mainly because it can only compare input costs and has often been used 
assuming outcomes to be equivalent (22,23). In practice, it ought to be used where there 
is clear evidence demonstrating  clinical equivalence between comparator interventions. 
Given the heterogeneous nature of study populations and health outcomes, it may not be 
possible to determine the exact clinical equivalence.  
1.2.2 Steps for conducting an economic evaluation 
Drummond et al. (24) provide the most well-known and popular framework in health 
economic evaluation. In the framework, they define ten elements of conducting an 
economic evaluation. The elements are described below: 
1.2.2.1  Define the question in answerable form 
A well-designed economic evaluation must define the study question in an answerable 
form by specifying the interventions being compared, study population, the perspective of 
the analysis and timeframe of interest. The study perspective is the viewpoint from which 
costs and benefits of an intervention are evaluated. Specifying the study perspective is 
important because it defines the basis of analysis and determines the relevant costs that 
need to be accounted for (25). There are a number of alternative perspectives but can be 
broadly categorised into healthcare providers, patients and society. The societal 
perspective is the preferred perspective for an economic evaluation. It involves broader 
consideration of costs and benefits (26) taking into account both direct, i.e. medical and 
non-medical, and indirect costs such as productivity costs due to mortality and morbidity, 
potentially capturing all the financial consequences of the different interventions. The 
healthcare provider perspective concerns with the costs related to health service delivery 
whereas patients’ perspective include costs incurred by the patient. Although the societal 
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perspective is recommended for economic evaluation, the choice of the perspective 
depends on the aim of the study. 
1.2.2.2 Provide a comprehensive description of competing alternatives 
As the economic evaluation involves a comparison between two or more competitive 
options (interventions), it is necessary to specify what is being compared with what. A 
clear description of the relevant comparators included within the analysis allows the 
decision maker to understand what is being evaluated. Relevant comparators may include 
the ‘current standard practice’, ‘usual care’, or ‘do nothing’. The NICE requires the use of 
the ‘best alternative practice’ as the most appropriate comparator in economic evaluation 
(2). 
1.2.2.3 Establish the effectiveness of each competing alternative 
The evidence on the effectiveness of an intervention may come either from a single study 
such as a clinical trial or from a good quality systematic review. This depends on the 
implementation of the economic evaluation that is whether the analysis is trial based or 
model-based. When the economic evaluation is carried out alongside a clinical trial, the 
effectiveness evidence is derived from the clinical trial itself. In the model-based economic 
evaluation, effectiveness evidence is taken from the systematic review or meta-analyses. 
While establishing the effectiveness of all relevant comparators, particular attention 
should be given to the risk of bias in the estimate of intervention effectiveness. For 
example, when the effectiveness evidence of intervention is based on a single study, it is 
essential to check whether the evidence base is representative of the whole body of the 
evidence base for the comparators concerned (24). Likewise, when the effectiveness 
evidence is taken from a systematic review or meta-analysis, it is essential to clearly state 
the reasons for inclusion or exclusion of a particular source of evidence. A well-designed 
randomised controlled trial (RCT) provides less biased evidence than observational 
studies. Further details on trial and model-based economic evaluations are provided in 
sections 1.3 and 1.4 respectively. 
1.2.2.4 Identify all the important and relevant costs and consequences for each 
comparator 
The choice of the perspective of the economic evaluation determines which costs and 
benefits to include in the analysis. All likely costs and benefits of an intervention should 
be defined as comprehensively as possible and be consistent with the chosen 
perspective. The costs can be divided into direct (health service), indirect (non-health 
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service) and intangible costs. Direct costs are those immediately associated with an 
intervention such as nurse time, consumables, treatment, hospitalisation and medication 
as well as may include patients’ out-of-pocket expenses (e.g. travel costs). Indirect costs 
are those incurred by the reduced productivity resulting from illness (morbidity cost), death 
or treatment (mortality costs). Intangible or non-resource costs are the costs related to 
issues such as pain, anxiety, deterioration of the quality of life in a patient. The benefit, or 
intervention effect, could be an intermediate effect (number of sedentary people becoming 
active, lowering blood pressure), survival effect (life-year saved), utility effect (QALYs, 
healthy-year equivalents) or an economic benefit. 
1.2.2.5 Measure all costs and consequences accurately in appropriate physical 
units 
Once the costs and effects of the intervention are identified, the next step is to approach 
measuring the likely costs and benefits of intervention as comprehensively as possible. 
All the relevant costs and benefits of an intervention must be measured in an appropriate 
physical unit such as hours of staff time and number of General Practitioner (GP) surgery 
visits. If the economic evaluation is being conducted alongside clinical trial prospectively 
or retrospectively, healthcare resource use data can be collected using mechanisms such 
as resource use questionnaires, medical records, case report forms, interviews or diaries. 
Resource use questionnaires are either filled in by patient themselves or completed by 
research staff. To assess patient medical notes, appropriate approvals should be in place. 
When the economic evaluation is conducted in retrospect, cost data are estimated using 
questionnaires. 
1.2.2.6 Value the cost and consequences credibly 
When prices are available, it is relatively easy and straightforward to value resource use. 
The cost of an intervention is simply the amount of resources used multiplied by the unit 
cost (27). Various sources exist for standard costs related to health service delivery such 
as the National Health Service (NHS) reference costs, and the Personal Social Services 
Research Unit (PSSRU) unit costs for GP and community-based services (28). These 
standard costs are usually the average costs and should be used with care, for example 
by carrying out sensitivity analysis (further discussed in section 1.2.2.9). However, 
sometimes the prices for goods and services may not exist (for example leisure or 
volunteer time), and the prices available may not reflect the societal value of resources. 
In such a case, there needs to be some sort of adjustment made to approximate market 
values. This is especially important while making comparison across studies. One method 
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of valuing these items is to use market wages however this could be problematic while 
valuing leisure time as people are not generally paid for their leisure. 
One strategy is to value the changes in resource use however this approach requires 
substantial time and efforts and runs the risk of being specific to the particular context. 
Another approach is to use gross costing, the top down costing, which simply divides the 
total budget allocated by the number of participants to arrive cost per participant. 
1.2.2.7 Adjust costs and consequences for differential timing 
The measurement of costs and benefits may not occur within one time period. There may 
be more than one intervention and may have different time profile for costs and benefits, 
for example, the costs of PA intervention are incurred in the present but the benefits of 
PA interventions such as reduced risk of stroke will occur mostly in the future. Thus there 
needs to be an adjustment for timing between costs and benefits. Moreover, individually 
and as a society, we prefer to have money or resources now, as opposed to later (24). 
Adjusting costs and benefits for differential timing allows comparability between 
competing interventions. The concept of discounting allows adjustment of all future costs 
and benefits to their present value. In the UK, the Treasury recommends that the costs 
and benefits of the programme be discounted at an annual rate of 3.5% (29). 
1.2.2.8 Perform an incremental analysis of costs and consequences of 
alternatives 
In economic evaluation, an incremental analysis of costs and benefits is necessary to 
make a comparison between competing interventions. The incremental analysis 
examines the additional costs and benefits between two interventions and combined into 
an incremental cost-effectiveness ratio (ICER). The ICER is calculated by dividing the 








< 𝜆 (1-1) 
Where 𝐶1 is the cost of new intervention; 𝐶0 is the cost of usual care or a comparator 
intervention; 𝐸1 and 𝐸0 are the consequences (health benefits) of new and the comparator 
intervention respectively; ∆𝐶 and ∆𝐸 are the increments (changes) in cost and health 
benefits respectively; λ is the society’s willingness to pay threshold. 
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A larger ICER value equates to a greater cost per unit of health benefit; therefore the 
intervention is less cost-effective in comparison to the comparator intervention. This value 
should be compared against a monetary threshold of maximum willingness to pay (λ) for 
a unit of health benefit. If the ICER value is less than or equal to the threshold value (λ) 
then the intervention is considered to be cost-effective in comparison to the alternative 
intervention. In the UK, NICE strongly recommends a cost per QALY threshold value of 
£20,000 to £30,000 (2). There have been debates, and a number of calls for further 
research on the value of threshold (30,31) as the current threshold has not changed in the 
NICE methods guidance since 2004. Recently Claxton et al. (32) estimated the threshold 
value to be just under £13,000 per QALY in the English NHS in 2008-09. However, the 
methods used for new estimates of the threshold ICER have been debated (33). 
A fundamental principle of decision theory is that an individual seeks to maximise his or 
her expected utility or payoff (1). The policymakers and health economists within the 
context of economic evaluation use similar criteria putting forward net benefit (NB) as the 
appropriate measure of this payoff (34). This can be shown by a simple rearrangement of 
cost-effectiveness decision rule as presented in Equation (1-2). The net benefit is the 
value of the benefits of a course of action less the cost of any consequences; the 
incremental net benefit (INB) is the difference in net benefit between two courses of action. 
In other words, the net benefit approach monetises the health benefit by multiplying the 
measurement of health benefits by a threshold value. Alternatively, if we rearrange the 
ICER to express inequalities on effect, it gives the net health benefit (NHB) (35,36) as 
illustrated in Equation 1-3. 
INB: (𝜆 × ∆𝐸) − ∆𝐶 > 0 (1-2) 
NHB: ∆𝐸 − (∆𝐶/𝜆) > 0 (1-3) 
The net benefit framework makes comparisons between more than two interventions 
easier because the NBs for individual interventions can be calculated. In addition, it 
overcomes the difficulty in calculating confidence intervals for the ICER (36). The decision 
rule is to adopt the new intervention if the INB is positive. When more than two 
interventions are being compared, the decision rule is to adopt the intervention with the 
highest NB. 
1.2.2.9 Undertake analysis of uncertainty 
Regardless of whether the economic evaluation is based on a single clinical trial data or 
a decision analytic model, the results will be subject to uncertainty. Analysis of uncertainty 
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is thus essential to give confidence in the results. The uncertainty can arise from many 
sources and can relate to individual variability, heterogeneity, or uncertainty in 
methodology, model structure, model parameters or in decision itself (37,38). Variability 
which is also called the first order uncertainty refers to differences that are found by 
chance. Heterogeneity refers to differences between characteristics of the study 
population that can be mostly explained such as age, gender and ethnicity. 
In economic evaluations, decision models aim to capture uncertainty in the estimates of 
means and associated standard error of the mean. Variability and heterogeneity are not 
the subjects of analysis of uncertainty. In RCTs, sampling variation is typically dealt 
through randomisation and analysis of baseline statistics such as calculation of 95% 
confidence intervals (CIs). Heterogeneity is assessed by considering various study 
population subgroups. It allows an assessment of whether the study outcome is influenced 
by these subgroups.  
Uncertainty within decision models can be classified into parameter uncertainty, 
methodological uncertainty and structural uncertainty (39). Parameter uncertainty refers 
to uncertainty in the point estimates used to reflect specific parameters in the model such 
as intervention effect. On the other hand, structural uncertainty refers to uncertainty in the 
relevant clinical pathways included in the model which is associated with costs and 
outcomes. The methodological uncertainty exists in at least two levels, first in the process 
of synthesising the evidence to inform decision models and second in the choice of 
modelling methods. 
Sensitivity analyses are performed to examine the impact of uncertainty in model inputs. 
Sensitivity analysis refers to the process of varying model input values and recording the 
impact of those changes on the model outcome i.e. cost-effectiveness results. Five 
different types of sensitivity analyses are reported in the literature: one-way (univariate) 
sensitivity analysis, multivariate sensitivity analysis (scenario analysis), threshold 
analysis, analysis of the extreme case (worst-and best-case scenario), and probabilistic 
sensitivity analysis (40,41). Details on handling uncertainty in the decision model are 
further discussed in section 1.4.5. 
1.2.2.10 Presentation and discussion of study results  
While presenting the results of an economic evaluation, it is important to evaluate whether 
the conclusions of the analysis incorporated all relevant considerations. Cost-
effectiveness results can guide decision-making but are not a decision itself. Decision 
making is a complex process which needs to take into account several aspects while 
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evaluating the economic evaluation results. The summary indices from the economic 
evaluations such as cost-effectiveness ratios are helpful in decision-making process but 
should be used with care by critically examining the output. Some economic evaluations 
may report more than one summary index, e.g. cost per additional person being active, 
and cost per QALY gained for a PA intervention. 
The above mentioned Drummond et al. (24) framework provides a guide to how to 
organise an economic evaluation. However, there are limitations to this approach. Firstly, 
this approach does not take into consideration the costs and consequences of a wrong 
decision (42). Economic evaluations also often exclude the importance of distribution of 
costs and consequences among different patient groups into the analysis. In addition, 
there are various forms of economic evaluation (as described in section 1.2.1) which value 
health outcome differently. Decision makers should be aware of these considerations 
when selecting a particular type of analytic technique (1).  
In healthcare, economic evaluations can be undertaken by taking a prospective or 
retrospective approach. In the trial based evaluation, economic evaluations are conducted 
prospectively alongside RCTs whereas in decision modelling, mathematical models are 
used to synthesise existing evidence retrospectively in order to evaluate the interventions. 
The following sections describe these two approaches to economic evaluation in 
healthcare. 
 
1.3 Trial based economic evaluation  
Clinical trials are often viewed as the ‘best vehicle’ for economic evaluation (43,44). They 
not only provide the best chance of ensuring internal validity through a prospective 
collection of patient-specific data but also provide an opportunity to collect additional data, 
for example, economic data, with a low marginal cost alongside clinical data (45). Use of 
intervention effectiveness data directly from a rigorously designed clinical trial helps 
overcome the issue of selection bias (46). To maximise the potential benefit of conducting 
economic analyses alongside clinical trials, it is essential to incorporate an economic 
component into the study protocol. This allows statistical analyses on cost, effectiveness 
and quality of life data. Glick et al. (27) set out a methodology for undertaking economic 
evaluation alongside clinical trials and specify some ‘gold standard’ characteristics for an 
economic evaluation as part of a clinical trial to strengthen the design of research and 
improve the quality of an economic evaluation. 
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In recent years, there are advances in design, conduct and analysis of trial-based 
economic evaluation such as developments in improving external validity of trial-based 
cost-effectiveness analysis, use of VoI analysis for sample size calculations. In addition, 
there are various guidelines available for conducting and reporting such studies (45,47). 
However, there remains a great deal of variation in methodology and reporting of such 
studies (48,49). In experimental studies, economic analysis is rarely the primary purpose 
of the study. Sample size in clinical trials is determined to detect primary clinical 
intervention effects; and as a consequence, a trial may not be powered enough to detect 
economic outcomes (intervention cost-effectiveness) (50). 
It may not be possible to compare all relevant alternatives from a single trial. For example, 
PA interventions have both short-term (e.g. improvements in mood) and long-term (e.g. 
reduction in stroke risk) health benefits (51). It may be difficult to measure these benefits 
from a single trial thus often requires a modelling component to estimate the overall 
change in health-related quality of life and quantity of life as a result of the change in PA 
level to extrapolate primary data beyond the short-term endpoint of a trial (46). 
1.4 Decision analytic modelling 
In contrast to trial based economic analysis, economic evaluation can be conducted 
retrospectively by utilising the existing evidence on resource use, cost, intervention 
effectiveness and quality of life. Decision models provide a framework to synthesise 
evidence on health outcomes and costs from a range of sources. A decision model can 
be defined as a logical mathematical framework that synthesises evidence on clinical and 
economic outcomes, and aids decision making about clinical practices and healthcare 
resource allocations (52). They play an important role at each stage of the economic 
evaluation process (53). Briggs et al. (54) proposed six distinct stages of a framework 
incorporating decision analytic modelling into economic evaluations. These involve 
specifying the decision problem, defining the model boundaries, specifying the model 
structure, identifying and synthesising evidence, dealing with uncertainty, and assessing 
the value of additional research. These key components are discussed below: 
1.4.1 Specifying the problem 
The first step involves clearly defining the question that needs to be addressed in the 
analysis. Usually, in an economic evaluation, the new intervention is compared to a control 
or ‘current practice’ or ‘standard care’, however, the evaluation may involve more than two 
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interventions which should be clearly specified. The outcome measure of the study should 
be defined. 
Moreover, disease area of interest, study population and the study setting to which it 
relates should be specified. The perspective chosen should be specified as this affects 
the type of costs and outcomes to include in the analysis. For example, the health system 
perspective includes costs related to health service delivery but societal perspective 
includes indirect costs incurred by patients and carers on top of the healthcare costs.  
1.4.2 Defining model boundaries 
This stage involves considering what is relevant and not relevant to be included in the 
analysis. Decision models are simplified reflection of reality, and it is not possible to 
include all the potential consequences of the particular option being considered (54). 
Thus, it is essential to clearly state the scope of the model which refers to its limitations or 
boundaries. For example, either the outcomes are modelled over the patients’ lifetime or 
shorter duration. This also influences what disease conditions to include in the model. 
While defining the boundaries, the potential impact of inclusion or exclusion of relevant 
factors on costs and outcomes should be considered. 
1.4.3 Structuring a decision model 
Once the decision problem is specified, and model boundaries are defined, an appropriate 
model structure should be determined. The availability of data plays a significant role in 
determining the structure of the model (55). Brennan et al. (56) suggested that practical 
considerations such as availability of data (e.g. natural history of the disease, clinical 
pathways, intervention effectiveness evidence, health state utilities and costs), the 
background skill of the researcher and type of software available also have a considerable 
role in determining the model structure. There are several guidelines for good research 
practices in modelling (55,57-61), and these guidelines focus mainly on transparent 
structure, appropriate and systematic use of evidence, and handling uncertainty. 
Economic models use two common approaches, aggregate or ‘cohort’ models and 
individual-level models also called patient-level simulation, to estimate the expected costs 
and outcomes (56,58). In a patient-level simulation, the cost and health outcomes are 
modelled for individual patients. While in a cohort-level model, the health and cost 
outcomes are modelled for the cohort as a whole, and this does not consider the outcomes 
for individual patients within that cohort. The patient-level simulation accounts for 
variability in all included parameters which can be characterised with empirical 
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distribution. The models often used in the economic evaluation are the former cohort 
models. Microsimulation models use mathematical equations to simulate the behaviour of 
an individual taking into account the heterogeneous composition of the target population 
without focusing on a representative or average individual. 
Decision Trees are the simplest and most familiar structures. They are graphical models 
that map patient pathways, assign costs and outcomes to alternative pathways throughout 
the tree and useful for short-term analyses (61). However, they have limited use for 
modelling complicated disease conditions involving longer time period. As the decision 
options increase over time, the size of the tree becomes unmanageable. In addition, they 
lack an explicit time variable. 
Markov models are increasingly used in economic evaluation as they overcome the 
limitations of decision trees. It is possible to model the complicated disease conditions 
using Markov model over a time period as they can deal with the pattern of recurring 
disease over time. They involve a transition between various health states and outcomes 
over time (53). The main limitation with this approach is that they do not account for the 
history of progression in the model. 
Discrete event simulation (DES) models are another type of models that use a stochastic 
process to simulate time-dependent behaviour of a system. The three components 
included in the DES are entities, event and time (62). Entities refer to the items that evolve 
through the simulation such as patient characteristics. These values are defined at the 
start of the simulation and may be updated as required: for example, age increases, 
disease severity may increase or decrease. An event is anything that can occur during 
the simulation such as an adverse event, remission from the disease, and events can 
occur sequentially, simultaneously or both. Events can be dependent on any attributes 
such as patient characteristics, and the function of an event can change over time as 
appropriate. Time is the fundamental component of a DES and makes handling time much 
more flexible compared to the Markov model. 
The selection of the particular type of model structure and complexity requires decisions 
about descriptive realism, computational burden, data requirement and usability (63). 
1.4.4 Identifying and synthesising evidence 
This stage involves a systematic approach to synthesise all the relevant evidence from a 
range of sources in order to inform the decision model. This involves combining data on 
intervention effects, clinical events, health state utilities, resource use or unit cost 
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information. Ideally, the evidence on intervention effectiveness should be from an RCT. 
In the absence of head-to-head randomised controlled trials, evidence from a well-
conducted meta-analysis of RCTs with direct or mixed treatment comparison has been 
proposed as the least biased source of data to inform clinical effect sizes, adverse events 
and complications parameters in the model (64). Clinical event parameters used in the 
model tend to be probabilities, which are simply the likelihood of an event occurring in a 
given time period and the value always lies between zero and one. However, 
epidemiological studies often report rates rather than probabilities. Rates refer to the 
number of occurrences of an event for a given number of patients per unit of time and 
range from zero to infinity. Probabilities and rates differ in terms of how they account time. 
It is possible to convert rates to a probability over a specified time period. This assumes 
that the rate to be constant over a time period (65). Equation (1-4) details how the 
probability (𝑝) can be calculated given the instantaneous rate (𝑟) and time period (𝑡) is 
assumed to be constant: 
𝑝 = 1 −  𝑒𝑟𝑡 (1-4) 
As the parameters in the model are assigned from various sources, there are issues 
related to different follow-up times and intervention comparison. To deal with this issue, 
there are a variety of methods including indirect and mixed comparisons and meta-
regression to synthesise the evidence from multiple sources (66). 
1.4.5 Handling uncertainty and heterogeneity 
Economic evaluations are subject to uncertainty because they are concerned with 
estimating the expected future costs and outcomes of competing interventions 
irrespective of whether they are based on decision models or informed by a single clinical 
trial. It is necessary to identify the sources of uncertainty that can impact upon the cost-
effectiveness results. Uncertainty in the decision model presents in many forms, and they 
need to be dealt with differently (38). Uncertainty can be related to sampling variation, 
heterogeneity, parameter uncertainty, structural uncertainty, methodological uncertainty 
and decision uncertainty. 
Much of the evidence synthesis in economic modelling is obtained from observational or 
experimental studies. In these studies, data are captured for a subset of a population of 
interest. Well designed and rigorously conducted studies such as pragmatic RCTs provide 
unbiased estimates of clinical outcomes. Randomisation gives an unbiased comparison 
between intervention groups as it controls for both known and unknown factors which yield 
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intervention groups that are balanced with regard to prognostic variables (67). Handling 
variability and heterogeneity were discussed earlier in section 1.2.2.9. 
Decision models require input parameters that need to be carefully estimated in order to 
appropriately characterise parameter uncertainty. Parameter uncertainty refers to the 
uncertainty in the point estimates used to reflect specific inputs to the model. Uncertainty 
in parameters can be dealt deterministically through univariate, multivariate or 
probabilistic sensitivity analysis.  
In univariate (one-way) sensitivity analysis, the value of a single parameter is changed at 
a time whilst holding the values of other parameters constant, and the impact on the 
predicted costs and outcomes are observed. However, this approach assumes that there 
is no causal relationship between the value taken by one parameter and the value taken 
by other parameters. Threshold analysis is a specific form of one-way sensitivity analysis. 
It considers what value a specific parameter must take in order to achieve a target result, 
for example changing values of treatment effect to set an ICER equal to the threshold 
value.  
In multivariate sensitivity analysis, two or more parameters are varied at once, and the 
impact of the different combinations of changes on the model output is examined. 
Although this approach allows more than one parameter to change at a time, it becomes 
infeasible as the number of parameters used in the model increases. In addition, 
multivariate sensitivity analysis treats all possible combination of parameter values as 
equally valid which is likely to be conflict with the underlying relationship. As a result, there 
is a chance of misleading decision makers unless a set of specific parameter values are 
accessed for their face validity and are relevant to the decision problem. This is also called 
a scenario analysis. Another form of this analysis is the analysis of extremes, also known 
as worst-best case analysis which looks at the impact on results by setting one or more 
parameters at the highest or lowest possible value. 
Probabilistic sensitivity analysis (PSA) is used to adequately address parameter 
uncertainty in the model (38). This method assigns an appropriate distribution to each 
parameter used in the model and allows the value of each parameter to be varied 
simultaneously. The values of parameters are drawn randomly from each distribution. 
Then the outputs of the model for each draw are recorded. By repeating the process of 
drawing parameter values from the distributions and capturing the model outputs gives 
the probability distributions for costs and outcomes of the interventions being compared.  
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Methodological uncertainty arises due to the choice of the modelling approach. In cost-
effectiveness models, this exists at least two levels: first in the process of synthesising 
evidence to populate the model, and second in the choice of modelling methods. There 
are good practice guidelines for decision analytic modelling (55,57) which help to address 
methodological uncertainty. Structural uncertainty relates to the uncertainty associated 
with structuring the model (68,69). It refers to the differences in the model output as a 
result of the inclusion or exclusion of a clinical pathway in the model.  
Handling decision uncertainty using PSA is discussed in more detail in Chapter 3. 
1.4.6 Assessing the value of additional research 
Decision models provide a framework within which it is possible to begin an assessment 
of the cost-effectiveness of additional research. Assessing the value of additional research 
is also an important component of the modelling process. The value of information (VoI) 
analysis is an economic approach to setting research priorities that puts a value on 
reducing uncertainty. The VoI analysis has its origins in the work of Raiffa and Schlaifer 
(70) in statistical decision theory. 
Decisions based on existing information will be uncertain, and there will always be a 
chance of making the wrong decision. If the wrong decision is made, there will be costs in 
terms of health benefits forgone. The expected cost of uncertainty is determined jointly by 
the probability that a decision based on existing information will be wrong and the 
consequences of a wrong decision (71,72). 
In recent years, interest has grown in healthcare decision making to apply the VoI concept 
(73). Pilot studies have been undertaken to inform the prioritisation process within the 
NICE Health Technology Assessment (HTA) programme (72,74), and published 
economic evaluations are increasingly reporting VoI analyses (75-81). 
 
1.5 Overview of using an iterative approach in decision making 
The above sections provide an overview of economic evaluation and decision analytic 
modelling. Decision models play an important role in evaluating the cost-effectiveness of 
a healthcare programme or intervention beyond the duration of a clinical trial. The process 
of decision making in health care is based on currently available information, and new 
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information affecting the decision becomes available throughout the life cycle of all 
technologies (5). The process of decision making in health care is not static because each 
decision has to be reviewed once new information is available. An iterative framework to 
economic evaluation of health technologies has been suggested beginning with early 
indicative studies and progressing towards more rigorous assessment as data become 
available (4,5,43). 
Sculpher et al. (4) and Fenwick et al. (82) outlined an iterative framework for economic 
appraisal and the use of models to prioritise research. They outlined an iterative process 
that starts with defining a decision problem, followed by a review of existing evidence on 
cost and effectiveness. The synthesis of evidence from the literature review leads into a 
decision model. The decision model requires input parameters that need to be carefully 
estimated in order to appropriately characterise parameter uncertainty. Probabilistic 
sensitivity analysis for exploring uncertainty in parameter estimates and the model (38), 
and the VoI analyses (8,42) are ideal tools for facilitating such an iterative process. 
The VoI statistics are the expected value of perfect information (EVPI), the expected value 
of sample information (EVSI), and the expected net benefit of sampling (ENBS). The 
expected value of information approach uses a decision analytical framework in order to 
prioritise further research through identifying those areas in which additional data 
collection and hence the reduction of uncertainty (13) would be of most value. The 
expected benefit of eliminating all parameter uncertainties, since perfect information 
would eliminate the possibility of making the wrong decision, is called EVPI. In other 
words, EVPI is the difference between the expected value of decision with and without 
perfect information (36). EVSI is the technique used to estimate the value of obtaining 
information from a study of sample size n (83). It is the difference between the expected 
value of a decision after the purposed research with sample information and the expected 
value of the decision made with current information (7). ENBS is the difference between 
EVSI with sample size n and the cost of conducting the research with sample size n 
(42,83). The data collection is only valuable though if the expected cost of the data 
collection is less than the expected value of the information it yields, i.e. if the ENBS is 
greater than zero. 
The EVPI places an upper bound on the returns to future research. The EVPI surrounding 
the decision problem can indicate whether further research is potentially worthwhile. The 
data gathered from primary research are then fed back into an updated systematic review, 
and the cycle is then repeated (42,83,84). The VoI methods play an important role within 
an iterative framework of economic evaluation as they help in identifying the focus of 
further research (research prioritisation) and the appropriate research design (82). 
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However, methodological and technical challenges such as high computation demands 
have limited the use of VoI methods in future research prioritisation (85). In addition, it is 
not clear how this iterative process has been applied in real life economic evaluation 
where decision makers (such as NICE) and research funders are separate bodies. 
The section below now provides an introduction to VBIs in physical activity promotion and 
the VBI study used as a case study in this thesis. 
 
1.6 Very brief interventions promoting physical activity 
Physical inactivity is one of the leading risk factors for global mortality, accounting for 6% 
of deaths globally (86). Incorporation of physical activity into daily life is known to lead to 
health benefits such as reduced risk of coronary heart disease (CHD), stroke, type 2 
diabetes, cancers, and premature death (87-91). In developed countries these diseases 
and conditions attributable to physical inactivity account for 1.5–3% of total direct 
healthcare costs (92). In their recent systematic review on the economic burden of 
physical inactivity in populations, Ding et al. (93) estimated that healthcare costs 
attributable to physical inactivity range from 0.3% to 4.6% of national healthcare 
expenditure. The UK Department of Health and Social Care estimated the societal cost 
related to physical inactivity in England at £8.2 billion a year (87). This estimation includes 
the direct costs of treating diseases linked to physical inactivity such as type 2 diabetes 
and cardiovascular diseases and indirect costs caused through sickness absence. 
There are a wide range of interventions to increase PA across the life course (94-96), and 
some of these interventions are considered cost-effective (97,98). In recent years, there 
has been substantial emphasis on efforts to promote PA along the continuum of individual-
level and population-based interventions (99). Recent systematic reviews and meta-
analyses of both randomised and non-randomised studies have shown that PA 
interventions such as brief exercise advice and physician counselling can significantly 
increase PA behaviour and fitness in the longer term (100-102). 
Brief intervention (BI) is a generic term used to define an intervention delivered in a 
relatively circumscribed time and is considered an important tool to prevent multiple risk 
behaviours (103). However, the nomenclature for BIs vary in the literature (104). Usually, 
they refer to simple advice, brief advice, brief counselling or minimal intervention. Brief 
interventions are well researched in substance misuse (alcohol consumption, tobacco and 
19 
other substance misuses) and provide evidence that BIs work for these conditions (103-
106) and are cost-effective (107-109). BIs range from a single session providing brief 
advice to multiple brief sessions of motivational interviewing or behaviour change 
counselling and are of short duration lasting between 5 to 30 minutes (110,111). BIs are 
typically conducted in face-to-face sessions with or without the addition of written 
materials. NICE (112) defines BIs as “those involving opportunistic advice, discussion, 
negotiation or encouragement”. 
VBIs are very short in duration taking up to five minutes although there is no clear 
definition as such. VBIs need not take extra time and can be delivered as a part of a 
routine healthcare consultation. The evidence base for BIs in PA promotion suggests that 
brief exercise advice delivered in primary care (101) setting increases physical activity. In 
their systematic review of reviews Lamming et al. (113) reported that BIs can increase 
short-term self-reported PA, but there was uncertainty about the long-term impact of BIs 
on PA level. 
Currently, in England, all adults with no diagnosis of chronic disease, i.e. those without a 
pre-existing condition of stroke, heart disease, type 2 diabetes or kidney disease, and who 
are not currently being treated for certain risk factors (114), and aged 40-74 years are 
invited to receive a free ‘health check’, referred as the NHS health check. Eligible 
participants receive a letter from their General Practitioner (GP) or local authority inviting 
them for an NHS Health Check every five years. The health check is delivered either by 
a GP, a practice nurse or an alternate provider, e.g. pharmacist (115). The NHS Health 
Check is free of charge including any follow-up tests or appointment and takes about 20 
to 30 minutes (114). 
The main aim of the Health Check is to prevent the risk of developing vascular diseases 
and raising awareness of dementia for those aged 65 to 74 (116). During the Health 
Check, healthcare professional performs basic checks by asking questions related to 
family history of illness being checked for, smoking, alcohol risk assessment, diet and 
physical activity assessment. In addition, healthcare professional measures participant’s 
body mass index (BMI), blood pressure, and takes a small sample of blood to check 
cholesterol and blood sugar levels. After the Health Check, participants are given a risk 
score, i.e. the risk of developing a heart or circulation problem over the next ten years. 
The risk score is calculated using the QRISK2 algorithm (117). 
The majority of people in the 40-74 age group do not meet the minimum recommended 
level of PA, i.e. 150 minutes of moderate intensity or 75 minutes of vigorous intensity 
activity per week (118). NHS Health Check thus provides an ideal opportunity to deliver 
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brief advice or other BIs to a larger proportion of the population. VBIs to increase PA are 
likely to be beneficial for all adults eligible for NHS Health Check in the UK (115,119). 
Although (very) BIs may have a small effect at the individual level however if a large 
population is positively affected, this could translate into a significant public health benefit 
(120). 
The VBI Programme was a five-year research programme funded through a programme 
grant from the National Institute for Health Research (NIHR). The programme aimed to 
develop and evaluate VBIs to increase PA that could be delivered by a practice nurse in 
a vascular check or other primary consultation. 
 
1.7 Statement of study problem 
Sections 1.2 to 1.5 outlined the iterative framework in decision making and section 1.6 
provided an overview of the VBIs in PA promotion. The iterative process of decision 
making provides the justification for whether future research is conducted and if so, on 
which uncertain parameters, and provides an estimate of the appropriate sample size for 
such a study. However, practical application of this in the area of VBI is limited. Although 
BIs are considered cost-effective in other domains of public health such as smoking 
cessation and alcohol misuse, there is a dearth of economic evidence in PA promotion 
(121). Compared with more complex PA interventions, VBIs can be easily integrated into 
routine healthcare consultation and are inexpensive to implement on a large scale.  
The VBI study provided an ideal opportunity to start further research by applying iterative 
decision-making theory in practice. This will allow using VoI methods to determine the 
value of future research in this area. The main aim of this thesis is to examine the 
feasibility of using an iterative framework for economic evaluation using the case of the 
VBI study. This thesis further explores the practical and methodological issues while 
applying the iterative framework in practice, merits and limitations of the framework, and 
consider potential reasons as to why it has not been widely implemented. To answer these 
questions, this thesis uses: 
a.  decision analytic modelling and PSA to assess the relative cost-effectiveness of 
promising VBIs in terms of incremental cost per QALYs gained, 
b.  expected VoI techniques to determine the value of collecting further data on input 
parameters, to help guide the design of a primary data collection exercise, and 
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c. update the decision model with the data gleaned from the VBI trial, and so update 
the policy recommendations regarding the most cost-effective VBI and the value 
of future research. 
 
1.8 Thesis overview 
This thesis is organised into six chapters. The first chapter introduces the key concepts in 
economic evaluations of health interventions including the background of an iterative 
approach in economic evaluation and brief interventions in PA promotion, the rationale of 
the study, the aim and objective and the way the thesis has been organised. Hereunder 
a brief description of the subsequent chapters is provided. 
Chapter 2 presents a background and overview of the literature regarding the cost-
effectiveness of brief PA interventions. The chapter discusses the current evidence on the 
cost-effectiveness of brief PA interventions in primary care or community setting. This 
literature review chapter summarises economic evidence – both within trial and model-
based economic evaluations – relating to BIs promoting PA. The particular issues with 
existing economic evidence are drawn out, about the long-term costs and health 
outcomes associated with such BIs. 
Chapter 3 starts expanding section 1.5 that is describing the stages of the iterative 
approach in decision making followed by a critique of such approach. The second part of 
the chapter includes a literature review on the use of VoI in an iterative framework in 
decision making to inform further research. The review aims to explore how the VoI 
methods are used within an iterative framework to inform further research. Finally, the 
chapter ends with a summary of how VoI methods are used in real life economic 
evaluations within the iterative framework. 
Chapter 4 uses the modelling approach to evaluate the cost-effectiveness of VBIs in PA 
promotion. This chapter corresponds with stages 2 and 3 of the iterative approach in 
economic evaluation, involving the development of a decision analytic model-based on 
existing evidence to undertake an economic evaluation of VBIs. This analysis determines 
whether VBIs in PA promotion are cost-effective or whether further research is needed to 
make an informed decision. This builds on the systematic review of existing evidence on 
effectiveness and cost-effectiveness of brief PA interventions presented in Chapter 2 and 
aims to estimate the cost-effectiveness of VBIs in PA promotion using a modelling 
approach based on the best available evidence. 
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Chapter 5 presents the results from a cost-effectiveness analysis of the VBI trial. This 
chapter follows on designing trials following an iterative approach and demonstrates the 
practicalities of designing clinical trials from an economic perspective. This chapter 
undertakes the re-analysis of the study from Chapter 4 (model update) in line with the 
iterative framework to compare the subsequent research priorities based on the VoI 
analysis. 
Chapter 6 presents the discussion and conclusion chapter. The chapter starts by reflecting 
on the application of the iterative framework in real life economic evaluation. Based on the 
findings of the study, the chapter provides a summary of the main findings acknowledging 
the limitations of the thesis and setting out an agenda for future work. This chapter pulls 
together the findings from Chapter 2 to Chapter 5 providing a reflection from the VBI study. 
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Chapter 2 Systematic literature review on the cost-
effectiveness of brief physical activity interventions 
 
2.1 Introduction 
Chapter 1 introduced the methods and the applied case study. This chapter develops the 
latter further by presenting a review of economic evidence for promoting physical activity 
via brief interventions. The primary motivation behind this review was to assess the 
current economic evidence on BIs promoting PA and inform the development of this thesis 
work. In turn, this chapter starts with an overview of the literature review followed by the 
methods section which describes the search strategy, study inclusion/exclusion criteria 
and methods employed to synthesise the evidence. The results section presents the 
findings of the review followed by a discussion. 
This chapter acts to provide the context for the case study to be used in the remainder of 
the thesis, showing how the work in this thesis builds upon existing literature in this clinical 
area. In other words, this chapter contributes to the research aim by answering the 
question: what is the current economic evidence for the brief physical activity interventions 
in primary care or the community setting?  
Current intervention strategies based in primary care or the community have provided 
convincing evidence that such strategies can effectively increase PA (122-124). 
Moreover, recent systematic reviews and meta-analyses of randomised and non-
randomised trials have shown that PA interventions such as brief advice, exercise on 
prescription and physician counselling significantly increase PA behaviour and fitness in 
the longer term (94,100,101) and these interventions are considered good value for 
money (97,98). Furthermore, there is growing interest in evaluating cost-effectiveness PA 
interventions as evidenced by a series of relevant systematic reviews published in the last 
few years (98,125-127). These economic reviews looked at PA interventions in general, 
for example, in their review Garrett et al. (98) looked at the cost-effectiveness of PA 
interventions among the adult population based in primary health care or community, or 
specific interventions such as exercise referral scheme. Exercise referral scheme refers 
a person from primary care to a qualified exercise professional who develops a tailored 
programme (exercise regimen) based on individual’s medical information (125). 
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Brief interventions are well researched in other domains of public health such as smoking 
cessation and alcohol misuse and are considered highly cost-effective (107-109). 
However, little economic evidence exists about their cost-effectiveness in physical activity 
(121). Although previous systematic reviews indicated that PA interventions are effective 
at increasing activity levels and are cost-effective in general, these studies are not specific 
to BIs, as they include varieties of interventions such as extended BIs. In addition, the lack 
of economic evidence for BIs in PA has been recognised (121,128). This review thus aims 
to summarise the current evidence on the cost-effectiveness of BIs in PA promotion for 
adults in primary care or community settings.  
2.2 Methodology 
2.2.1 Search strategy 
A literature search was carried out in several databases for articles published up to 31 
December 2017: Medline, Embase, PsycINFO, CINAHL, EconLit, SPORTDiscus, 
Physiotherapy Evidence Database (PEDro), the Cochrane library, the NHS Economic 
Evaluation Database and Tufts Cost-Effectiveness Analysis (CEA) Registry. The search 
consisted of keywords and medical subject heading (MeSH) terms related to physical 
activity, brief or minimal intervention, and economic or cost analysis and was limited to 
English language. The search strategy used is described in Appendix A1. References of 
retrieved articles were examined manually after reviewing the title and abstracts. A cross 
reference search was carried out using Web of Knowledge to identify any economic 
studies alongside clinical trials and other pertinent studies.  
2.2.2 Eligibility criteria  
Studies were eligible for inclusion if they met the following three criteria listed in Table 2-1. 
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Table 2-1: Criteria for study selection 
Component Inclusion criteria 
Population Inactive (i.e. not meeting the government recommended minutes of 
PA per week) adults aged 16 years or over 
Intervention The NICE definition (as described in section 1.6) was used to define 
BIs. Briefly, interventions were included if they: 
a. involved verbal advice, encouragement, negotiation or 
discussion, delivered face-to-face in a single session or 
multiple brief sessions, with or without additional non face-to-
face contacts (e.g. leaflets or phone calls) or reported as ‘brief’ 
or ‘minimal’, and  
b. aimed to increase physical activity or fitness levels (or both) at 
individual-level that is BIs delivered to individuals or groups 
Comparator Usual care or other interventions 
Outcome Information on both cost and health outcomes  
Study design chosen Economic analyses alongside RCTs or non-experimental designs, or 
modelling studies of physical activity interventions which were based 
in either primary care or the community. 
Studies focusing on specific populations or those that recruited participants on the basis 
of the pre-existing disease condition(s), such as patients with severe mental disorders or 
osteoarthritis were excluded because these populations require tailored interventions. 
Interventions were included if the primary focus of the study or one of the comparator 
intervention was physical activity as PA interventions are often used in combination with 
other types of intervention, for example, PA plus dietary advice, for its physical well-being 
benefits.  
2.2.3 Data extraction and methodological quality assessment 
The search results from electronic databases were downloaded into EndNote and 
screened by titles and abstracts against the inclusion criteria. Papers likely to fulfil 
inclusion criteria were examined and their quality assessed by two reviewers. Based on 
the Consolidated Health Economics Evaluation Reporting Standards (CHEERS) checklist 
(129), a standardised proforma (Appendix A2) was developed to extract data from full 
texts on type of economic analysis and perspective, interventions and comparison, 
participants, follow-up duration, outcome and cost-effectiveness results. Having screened 
and extracted data from included studies, a second reviewer double checked the data 
extraction table for all studies. There are a number of checklists for example (1,55,130-
132) to assess reporting and or methodological quality. In this review, Drummond’s ten-
point checklist (24) was used to guide the critical appraisal of full economic evaluation. 
The Drummond checklist includes ten questions with four possible responses: yes, no, 
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not clear and not appropriate. One point was assigned for each ‘yes’ response giving the 
lower and highest possible scores 0 and 10 respectively. Based on the checklist criteria, 
a rating of ‘high’ (9-10), ‘good’ (7-8), ‘fair’ (5-6) or ‘poor’ (1-4) was assigned. 
2.2.4 Statistical analysis methods 
To make economic results of individual studies included comparable, all costs were 
converted to 2011 UK pounds sterling (£) by applying Gross Domestic Product deflator 
index and purchasing power parity conversion rates using the CEMG-EPPI-Centre Cost 
Converter (v1.4) (133,134). The economic results of the studies were grouped into two 
categories (a) those reporting intermediate outcomes such as the incremental cost of 
moving one inactive adult to an active category; and (b) those reporting final outcomes 
such as incremental cost per incremental QALY gained, disability-adjusted life-year 
(DALY) averted or life years gained (LYG). The activity level is defined as those meeting 
the Department of Health physical activity recommendations, that is at least 150 minutes 
of moderate intensity activity per week (135). 
2.3 Results  
2.3.1 Characteristics of included studies 
Figure 2-1 presents the PRISMA flow diagram of the study selection. A total of 2,356 
records were identified through database searches and cross-referencing search, of 
which 1,731 were unique records. After excluding 1,698 records based on reading the title 
and abstract, full text of the remaining 33 studies were examined. A total of 20 studies 
were excluded because either these studies were not brief, targeted multiple behaviour, 
not delivered face-to-face, were exercise referral scheme, did not report cost or PA 
outcome. The thirteen studies included in this review described 30 intervention strategies 
or scenarios, of which 14 met the definition of BIs. The initial search included studies 
published up to August 2014 which has been updated to include studies published up to 
December 2017. The updating of the search did not result in any additional studies being 
included. 
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Figure 2-1: PRISMA flow diagram of study selection 
Table 2-2 presents the grouping of BIs along with the source of effectiveness data used 
in cost-effectiveness analysis. These BIs were typically compared with usual care or the 
current practice (n=10). 
Table 2-2: Overview of interventions 
Interventions # Short description 
Source of 
effectiveness data 
Exercise advice (136-140) 5 Brief exercise advice or counselling 
by a GP or trained health 
professionals 
CS, MA, OS, RCT 
Exercise on prescription 
(141-144) 
4 Verbal and written PA advice by GP 




4 Pedometer-based PA counselling 









Note: CS, cross-sectional population surveys; GP, General Practitioner; MA, meta-analysis 
of RCTs; OS, observational study; RCT, randomised controlled trial 
Records identified through 
database searching  
(n=2,352) 
Records after duplicates removed 
(n=1,731) 
Records excluded after 
review of title or abstract 
(n=1,698) 
Included studies (n=13) 
Full-text articles excluded 
(n=20) 
 8 not brief interventions 
 4 targeted multiple 
behaviour e.g. exercise 
and diet 
 3 not delivered face-to-
face 
 2 exercise referral 
schemes 
 2 not cost or PA 
outcome 
 1 subsidy programme  
Additional records identified 
through other sources  
(n=4) 
Full-text articles assessed for 
eligibility (n=33) 




































Of the 13 economic evaluation studies, two studies were based on quasi-experimental 
designs (137,148), four were 'piggybacked' economic evaluations conducted alongside 
clinical trial (143-145,147) and seven were model-based economic evaluations (136,138-
142,146). These modelling studies used data from a single clinical trial (139,141,142), a 
meta-analysis of RCTs (138,141,146), a systematic review of randomised and 
observational studies (136), or a cross-sectional and observational study (140) to evaluate 
the cost-effectiveness of BIs. 
Characteristics of included study are summarised in Table 2-3. Economic evaluations 
conducted alongside the clinical trial had a follow-up ranging from 3 months to 2 years. Of 
the 13 studies, only six studies reported the face-to-face duration of BIs. The duration of 
face-to-face contact lasted between 4 to 30 minutes (137,140,142-144,147). The 
measurement of PA varied between studies. Studies using a time-based outcome used a 
target of ≥150 minutes of moderate activity per week or ≥60 minutes of vigorous intensity 
activity per week. Pedometer-based studies, however, used a common threshold of 
≥10,000 steps per day while Shaw et al. (147) used a target of a weekly increase of 
≥15,000 steps. 
The economic studies either reported an intermediate outcome such as cost of moving 
one additional inactive person to active category (137,143,144,147), or a final outcome, 
i.e. cost per QALY, DALY or LYG (138,139,141,142,146), or both outcomes 
(136,140,145,148). The following sections first summarise the studies reporting 
intermediate outcomes followed by the final outcomes. 
2.3.2 Studies reporting intermediate outcomes 
Eight studies reported the cost of converting one sedentary adult to an ‘active category’, 
and the value ranged from £96 to £986 (Figure 2-2). Sims et al. (140) evaluated an 
organised approach to exercise counselling by GPs in Australia (called an ‘active script 
programme’) which was the most cost-effective intervention considered, i.e. incremental 
cost of £96 for making a person active. They compared the active script programme with 
usual care. In their study, Boehler et al. (137) reported that delivering brief exercise advice 
using disease register screening compared to opportunistic patient recruitment had the 
additional cost of £986 to convert one inactive adult to an active state. Likewise, Elley et 
al. (144) evaluated the cost-effectiveness of nurse-delivered exercise counselling and 
written prescription with telephone support (called ‘enhanced green prescription’). Their 
cost-effectiveness results showed that the cost-effectiveness of a PA intervention 
decreases over the time of follow-up (£308 at 12 months versus £630 at 24 months). 
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Figure 2-2: Incremental cost of converting one sedentary adult to an active category 
Source: Adapted from Figure 2, Gc et al. (149). Costs are 2011 equivalent £ sterling. 
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I: brief advice 
C: usual care (no active 
intervention) 
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physically inactive 
but healthy adults 
aged ≥33 years 
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MPA or 75 min 




£ 136 (brief advice 
compared with usual 
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Brief exercise comparing two 
recruitment strategies: 
I1: patients recruited 
opportunistically  
I2: patients on the hypertension 





3 months 150 minutes of 
MPA per week 
I1: 4 min 
I2: 18 min 
Total across 
intervention: 
I1: 28 min 
I2: 76 min 
£886.50 [£986] 

















I1: GP prescription – exercise 
prescription with follow-up phone 
call 
I2: GP referral for PA 
counselling to an exercise 
physiologist 
I3: mass media 
I4: TravelSmart (active 
transport) 
I5: pedometer 
I6: internet advice 
C: do nothing 
I1: 40-79 years old 
less active 
patients 
I2: 60+ years 
sedentary patients 
I3: 25-60 years 
14: 18+ years 
I5: 15+ years 
I6: 15+ years 
Modelled for 
lifetime 
150 minutes of 
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 I1: AUD 11,000 (£5,374) [£6,500] 
per DALY 
I2: AUD 75,000 (£36,638) [£44,315] 
per DALY 
I3: dominant 
I4: AUD 18,000 (£8,793) [£10,636] 
per DALY 
I5: dominant 
I6: AUD 2,000 (£977) [£1,182] per 
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over full life 
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5×30 minutes 
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 NZD 2,053 (£865) [£1,104] per 
QALY (lifetime) 
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I1: dietary advice by dieticians 
I2: exercise advice by physician 
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exercise compared to no 
intervention 
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activity, peer-mentoring, training of PA 
leaders 
inactive; 343 young 
people and 641 
adults particularly 
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I1: minimal intervention (walking 
programme and pedometer) 
I2: maximal intervention (PA 
consultation, pedometer and 
individualised walking programme) 
C: ‘usual behaviour’ 
18-65 year olds 
I1: 40 
I2: 39 
12 months weekly increase 
of ≥15,000 
steps  
30 min £92 [£99] (minimal 
versus control) 















I: active script program (ASP) – 
improving systematic PA advice by GPs 
C: routine GP care (no PA advice) 
less active adults 
aged 20-75 years, 
670 GP advising 
sedentary patients 
I: 40,258; C: 10,437 
Unclear 
time horizon 
150 minutes of 
MPA per week 
4 min GP 
consultation 
AUD 138 (£70) [£96 
per patient to become 
active 
AUD 3647 (£1,838) 
[£2,542] per DALY 
saved 
Note: BI, brief intervention; C, control group; CEA, cost effectiveness analysis; CUA, cost utility analysis; GP, general practitioner; GPRD, general practice research database; HCA, healthcare 
assistant; I, intervention group; ICER, incremental cost effectiveness ratio; METs, metabolic equivalents; MPA, moderate intensity physical activity; NHS, national health service (England); PA, 
physical activity; RCT, randomised controlled trial; S, scenario; VPA, vigorous intensity physical activity 
Source: Adapted from Table 3, Gc et al. (149) 
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2.3.3 Studies reporting final outcomes 
Three studies reported cost-effectiveness of multiple interventions, of which only a few 
were relevant (BIs) to this review. For example, Pringle et al. (148) included seven broad 
categories of community-based PA interventions, Cobiac et al. (141) compared six 
intervention strategies to promote PA, and Lindgren et al. (139) included three 
interventions of dietary and exercise advice. Figure 2-3 summarises the cost-
effectiveness results for those studies reporting QALY, DALY or LYG outcomes. 
Pedometer-based BIs, either as a motivational tool or in combination with brief exercise 
advice, were dominant, i.e. they were both cost saving and more effective when compared 
with usual care (141) or standard ‘green prescription’ (oral or written exercise advice by a 
GP or practice nurse with telephone follow-up) (145). GP advice in combination with a 
pedometer had an ICER of £8,858 per QALY when compared with current practice (146). 
 
Figure 2-3: Cost-utility (cost per DALY or QALY or LYG) for different PA interventions  
Source: Adapted from Figure 3, Gc et al. (149). All costs are 2011 equivalent £ sterling. 
The ICER for brief exercise advice or exercise on prescription compared to usual care 
ranged from £1,104 to £14,002 per QALY (136,138,142); and from £2,542 to £6,500 per 
DALY (140,141). The lowest ICER, i.e. £57 per QALY was for motivational interviews 
(148). Exercise counselling by a GP in combination with a pedometer (146) had lower 
cost-effectiveness ratio than a GP advice or counselling with written materials (138) 
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2.4.1 Principal findings 
Primary care or the community-based BIs such as exercise advice (136,140), pedometer-
based walking (147), pedometer-based exercise advice (‘green prescription’)(145), and 
motivational interviews (148) had similar cost-effectiveness ratios for converting one 
inactive person to an active state. With respect to the final outcomes, use of pedometers 
(141) pedometer in combination with written exercise advice (145), motivational interviews 
(148), exercise advice or counselling by a GP (140,142), and brief exercise advice (136) 
were cost-effective intervention strategies. The reviewed studies also showed that the 
cost-effectiveness of BIs decreases over time unless there is continued contact so that 
the activity levels are maintained over time (144). Although the ‘active script programme’ 
(140) reported lower cost per additional person active, the economic evaluation used 
rather optimistic assumptions regarding the uptake of PA. In addition, effectiveness 
evidence was derived from a pre-post study to model intervention cost-effectiveness and 
the time horizon was not clear.  
Both Leung et al. (145) and Cobiac et al. (141) reported the dominance pedometer 
intervention, but the pedometers were compared with ‘green prescription’ and usual care 
respectively. In contrast, Over et al. (146) reported a considerably higher ICER (£8,858 
per QALY) for pedometers when compared with current practice. Although both Cobiac 
et al. (141) and Over et al. (146) modelled cost-utility using intervention effectiveness data 
from a meta-analysis of 8 RCTs (151), the higher possible health gains in Cobiac et al. 
may be a consequences of much larger proportion of inactive people in the Australian 
compared to the Dutch population, and of the reported programme cost per participant 
being lower in the Australian estimates than Over et al. 
Brief exercise advice delivered by the nurse (144) had a more favourable cost-
effectiveness ratio than those delivered by a GP (143) (£308 versus £938 for converting 
one additional inactive person to an active category over a 12-month period). The nurse 
delivered ‘enhanced green prescription’ had a slightly higher proportion of participants 
who increase their PA at 12 months than the GP delivered ‘green prescription’. The nurse 
delivered intervention had extra telephone support and 6-month face-to-face contact 
which may explain the higher proportion of participants with increased activity level in 
‘enhanced green prescription’. The ICER for both QALY and DALY outcomes varied 
between studies. For example, ICER for exercise advice ranged between £1,104 and 
£14,002 per QALY. 
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Of the seven economic modelling studies, few studies adopted previously reported 
models. For example, Pringle et al.’s (148) model was informed by the NICE cost-
effectiveness model (150), while Over et al. (146) used the Chronic Disease Model (CDM) 
developed by the Dutch National Institute for Public Health and the Environment to 
estimate the long-term effects of an increase in PA. These modelling studies incorporated 
multiple chronic conditions which are known to be linked to physical inactivity except 
Lindgren et al. (139) who only included CHD conditions. 
2.4.2 Methodological issues  
There were issues where studies did not report sources of evidence used in the analysis 
and did not justify the potential exclusion of relevant costs. For example, Pringle et al. 
(148) did not include out-of-pocket expenditures which might be significant and could 
influence the intervention attendance levels apart from the cost-effectiveness of the 
intervention. The model-based economic evaluations differed mainly in terms of quality of 
evidence used, model structure and outcome measure. Only eight studies (136-
139,141,142,145,146) properly characterised decision uncertainty by performing PSA 
while the remaining studies used either scenario-based or one-way sensitivity analysis. 
Most of the studies used evidence base either from a single RCT or meta-analysed data, 
three studies (137,140,148) used evidence from non-experimental studies or theoretical 
scenarios. In addition, assumptions around the maintenance of PA levels beyond BIs were 
not clearly reported in most of the studies which could determine how cost-effect BIs are 
over the time. 
2.4.3 Comparison with previous reviews 
Previous studies (97,98,121) suggested that PA interventions are cost-effective when 
compared with usual care. The NICE review (121) of PA was limited to three studies and 
did not include other kinds of BIs promoting PA such as pedometer-based interventions. 
Garrett et al. (98) included 13 economic evaluations, of PA interventions in primary care, 
conducted alongside clinical trials and concluded that PA interventions are cost-
effectiveness in primary care especially where direct supervision or instruction was not 
required. The cost-effectiveness ratio defined as the cost of moving one inactive person 
to an active stage at 12 months varied from £262 to £3,144, and cost-utility estimated in 
nine studies varied from £276 to £68,798 per QALY gained. However, their review 
included intensive PA interventions and did not include modelling studies. Another review 
by Muller-Riemenschneide et al. (97) included eight studies (6 RCTs, 1 cross-sectional 
and 1 economic modelling) covering a broad range of interventions promoting PA 
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including workplace-based PA and environmental interventions. The cost per participant 
to achieve the recommended level of PA over a 12 months period was £662.  
These economic reviews of PA interventions either considered the cost-effectiveness of 
PA interventions in general and were not specific to BIs (97,98) or did not include other 
kinds of BIs such as pedometer-based interventions (121).  
2.4.4 Strengths and limitations 
This review includes both economic evaluations alongside clinical trials and economic 
modelling, provides a comprehensive overview of current evidence on the cost-
effectiveness of BIs in PA promotion. The included studies vary widely in terms 
methodology used, for example, the perspective used, discounting of the future value of 
cost and health outcomes. The source of evidence used to populate the model (e.g. 
intervention effectiveness) and assumptions underlying (for example, the sustainability of 
intervention effects over time) differed considerably between studies. Such 
methodological differences between the studies as well as other context characteristics, 
for example, variability in funding mechanism, health system and cost structures limit the 
generalizability of the cost-effectiveness results across different settings (152). 
Some of the studies included in this review did not provide intervention details such as 
time duration and intervention delivery method, i.e. either the intervention is delivered in 
person or in group(s). This makes it difficult to determine whether or not interventions were 
truly BIs according to the NICE definition. It is important to describe interventions in 
sufficient details (153), and this may have an impact on cost-effectiveness. For example, 
the duration of BIs has implication on resource use cost estimation. This review only 
included studies that had at least one face-to-face contact as a result PA intervention not 
delivered face-to-face such as print or telephone-based interventions were excluded. The 
latter constitutes a growing area of research and especially useful in older adults (154). In 
addition, due to the heterogeneity among studies, it was not possible to rank interventions 
based on cost-effectiveness ratios. However, when used current NICE threshold of 
£20,000 to £30,000 per QALY (2), most of these interventions are considered cost-
effective. 
2.5 Chapter summary 
This chapter has presented a review of the economic literature in relation to brief 
interventions promoting PA in primary care or community setting. In this regard, the first 
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part of the chapter provided an overview and justification why this review was conducted 
followed by the methods used and presenting review results. Overall, the reviewed 
literature offered relatively richer evidence on PA interventions based in primary care or 
the community. Results of the review showed that brief PA interventions were likely to be 
inexpensive and increase individuals’ PA at a reasonable cost however there was notable 
variation between studies. Additionally, there was limited evidence on the longer-term 
costs and consequences of these interventions. 
The review also highlighted the methodological challenges, for example, ranking and 
prioritising interventions based on the cost-effectiveness ratios was not feasible given 
variations in interventions, study participants, outcome measures and study design. 
Ideally, it would be more appropriate to compare each intervention from a list of 14 
interventions strategies included in this review in an iterative manner taking into account 
dominance and extended dominance. An intervention is considered dominated when the 
comparator intervention strategy accrues more health benefits for less cost. The 
intervention is extendedly dominated when a combination of two alternative intervention 
strategies can produce the same health benefit but at a lower cost (1,155). However, this 
was not possible as the interventions were typically compared with standard usual care, 
i.e. doing nothing. In order to make a comparison of BIs, this requires a decision analytic 
modelling framework that transforms short-term costs and health outcomes to long-term 
costs and health outcomes. This framework helps identifying which brief intervention is 
the most cost-effective intervention strategy and quantifying the associated decision 
uncertainty. This is done in Chapter 4 by developing a decision analytic model and 
evaluating three brief interventions in PA promotion. 
As this chapter gives an overview on the economic literature of brief PA interventions, the 
next chapter lays out the theoretical framework adopted in this study with the aim of 
assessing the feasibility of using the iterative framework. 
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Chapter 3 An iterative approach to economic appraisal 
 
3.1 Chapter outline 
Following the overview of the economic evaluations in healthcare and methodologies 
used in decision analytic models for economic evaluations (Chapter 1, sections 1.2 to 1.4), 
and a review of economic evidence of brief PA intervention (Chapter 2) this chapter now 
considers the iterative approach to economic appraisal as a framework for undertaking 
research in the healthcare sector. This chapter starts with an overview of the approach 
followed by a five-stage iterative framework for economic evaluation. The subsequent 
sections discuss the merits and limitations of the methods. The last section of the chapter 
explores how value of information (VoI) methods are being used in decision making to 
inform further research within an iterative process of analysis. A systematic review of 
existing VoI literature was conducted to find real life economic evaluations performed that 
follows the iterative framework to inform further research. 
3.2 Introduction 
As previously discussed in section 1.2, economic evaluations are useful in informing 
decisions about the efficiency and allocation of resources to maximise the benefit of 
healthcare spending. However, the advances in modern medicine and public health bring 
about incremental innovations (thus improved patient outcomes) that result in an evolving 
evidence base (156). As new information becomes available during the lifecycle of the 
health technology, the adoption decision is influenced and could change. Due to this 
evolving nature of health interventions or technologies, their evidence bases and the 
effects of this on healthcare decision making this suggests that an economic evaluation 
should not be a one-off activity. 
Sculpher et al. (4) and Fenwick et al. (82) suggested that economic evaluation should be 
re-performed as evidence bases develop throughout the lifecycle of the technology. This 
implies that rather than using economic evaluations as one-off analyses, it should be an 
iterative process conducted alongside all stages of healthcare research. This involves 
using decision analytic models and updating them regularly as a new evidence base 
becomes available. The five-step iterative framework (4,43) was proposed as the best 
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practice for evaluating healthcare technologies. The framework utilises the key 
methodologies for decision analytic modelling and provides a structure in which evidence 
from a range of sources can be synthesised along with Bayesian updating in order to 
answer cost-effectiveness decision problems (6). 
The process as outlined in Figure 3-1 starts with defining a decision problem, which is 
followed by a systematic review of existing evidence. The synthesis of evidence from the 
literature review leads to a decision model. The decision model requires input parameters 
that need to be carefully estimated in order to appropriately characterise parameter 
uncertainty. The next step is the adoption decision based on the availability of current 
evidence, i.e. choosing the intervention with the highest net benefit. 
 
Figure 3-1: The iterative approach to economic evaluations  
Source: Wilson and Abrams (83) 
Irrespective of the adoption decision made, the next step is to explore the value of further 
research by using VoI analysis. By using the results from the cost-effectiveness VoI 
analyses, decision makers can make a decision that is either to collect more information 
or not. The data gathered from primary research are then fed back into an updated 
systematic review, and the cycle repeated (42,83,84). 
The five stages of the iterative framework outlined by Sculpher et al. (4,43) is discussed 
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3.3 Stages of an iterative approach  
3.3.1 Identify decision problems 
The first stage of an iterative framework starts with an explanatory stage focusing on 
identifying the decision problem. This stage needs to clearly define the related aspects of 
the economic analysis such as comparators, outcome measures, disease area, patient 
population and perspective of the analysis. This stage is also similar to the first two steps 
of decision analytic modelling, i.e. ‘specifying the problem’ and ‘defining the model 
boundaries’ (section 1.4). It is essential to formulate an appropriate economic question by 
defining which patient population is being considered, the treatments or interventions that 
are currently available to the specified patient population, and the costs and benefits of 
new treatment or comparator. This involves, for example, identifying different brief 
physical activity interventions for the NHS Health Check population, their costs and 
effectiveness, i.e. are brief interventions in physical activity promotion in primary care cost-
effective compared with usual care (‘doing nothing’) from the health service perspective? 
This stage of the iterative process thus begins by exploring the literature and existing 
information to identify the decision problem. 
3.3.2 Synthesis and modelling given available evidence 
Once the decision problem has been identified, the next step (stage 2) is to explore 
existing and available information, then undertake evidence synthesis and the 
construction of a decision analytic model. It is crucial to define appropriate input 
parameters to the decision model and estimate their mean values and characterise 
uncertainty (83). The aim of the decision analytic model is to estimate the long-term costs 
and health gains of each VBI identified by a review of existing evidence: to provide an 
indication of whether VBIs are cost-effective and associated uncertainty. This involves 
developing a decision model using information synthesised from various sources, fitting 
distributions to model parameters, and undertaking probabilistic sensitivity analysis (38). 
The steps involved in developing a decision analytic model are described in section 1.4. 
Developing an early decision model can provide an indication of whether the VBIs in PA 
promotion are expected to be cost-effective and the associated uncertainty. 
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3.3.3 Setting of research priorities 
The adoption decision is determined by the available information and results from the 
decision analytic model. The intervention option with the highest incremental net benefit 
(INB) is selected. The uncertainty, i.e. standard error around INB tells us whether we 
require further information to reduce uncertainty surrounding the cost-effectiveness and 
to identify the focus of further research and appropriate research design (82). 
The VoI is based on the rationale that decisions based on existing information will be 
uncertain and given this uncertainty, there is always a chance that the wrong decision will 
be made. This will have costs in terms of health benefits forgone. Expected value of 
information (EVI) approach uses a decision analytical framework in order to prioritise 
further research through identifying those areas in which additional data collection 
(primary research) and hence the reduction of uncertainty (13) would be of most value. 
The uncertainty in parameters used in the VoI analysis determines whether new 
information has a probability of changing the adoption decision, i.e. selecting the VBI with 
highest NB. If the probability of changing the decision is zero, then no further research 
into the current decision question should be conducted. However, if  earlier, i.e. NB is 
greater than zero there is a case for conducting further research into the current decision 
question. 
The VoI statistics are Expected Value of Perfect Information (EVPI), Expected Value of 
Perfect Parameter Information (EVPPI), Expected Value of Sample Information (EVSI) 
and Expected Net Benefit of Sampling (ENBS) which are described below: 
3.3.3.1 Expected value of perfect information (EVPI) 
The EVPI represents the monetary value that can be attached to eliminating all uncertainty 
in decision making. In other words, EVPI calculates the opportunity cost of making the 
wrong decision. It does this by calculating how the costs and consequences of a decision 
made with current evidence differ from those made with perfect evidence. Thus, the 
expected cost of uncertainty is determined by the probability of making the wrong decision 
multiplied by the consequences of a wrong decision. If the EVPI exceeds the expected 
cost of additional research (EVPI > 0), then it is potentially worthwhile undertaking further 
research to gather more information. However this is necessary, but not a sufficient, 
condition (157,158). 
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The process of calculating the EVPI follows on from calculating the cost-effectiveness 
acceptability curve (CEAC) using the results from a PSA. In determining the CEAC from 
the PSA results, the net benefits can be calculated for each comparator for the number of 
iterations (n) of the Monte Carlo simulation. The average of these is taken in order to 
determine the optimal intervention. The optimal intervention is the intervention which has 
the highest expected net benefit across the n Monte Carlo simulations. 
The EVPI is estimated using the expected costs (C), effects (E) and cost-effectiveness 
parameters from the decision model and PSA. The NB for intervention j with the ceiling 
ration λ can be calculated as follows (35): 
Assuming, j alternative interventions, θ input parameters to the model and given current 
information, the adoption decision is made based on the intervention with the maximum 
expected NB over n iterations of the Monte Carlo simulation: 
If there was perfect information, the value of θ would be known, and the value of the 
optimal decision at these known values of θ could be obtained by maximising the NB, 
 𝑚𝑎𝑥𝑗 𝑁𝐵(𝑗, 𝜃). However, it is not known where the uncertainty around θ will resolve. Thus, 
the expected value of decision made with perfect information is estimated by averaging 
the maximum NB in each iteration: 
The EVPI for an individual patient (158) is simply the difference between the expected net 
benefit with perfect information (equation 3-3) and that with current information (equation 
3-2), as detailed in equation (1-1).  
After calculating the EVPI per patient, it is important to account for the relevant population 
who may benefit from the additional research over the expected lifetime of the technology. 
The population EVPI is calculated using the estimates of current and future patient 
number (I), over the lifetime of the new technology or intervention (T) in each time period 
(t) discounted at a discount rate (r) as follows (36): 
𝑁𝐵𝑗 = 𝐸𝑗 𝜆 − 𝐶𝑗 (3-1) 
𝑚𝑎𝑥𝑗 𝐸𝜃 𝑁𝐵(𝑗, 𝜃) (3-2) 
𝐸𝜃  𝑚𝑎𝑥𝑗 𝑁𝐵(𝑗, 𝜃) (3-3) 
𝐸𝑉𝑃𝐼 = 𝐸𝜃  𝑚𝑎𝑥𝑗 𝑁𝐵(𝑗, 𝜃) −  𝑚𝑎𝑥𝑗 𝐸𝜃 𝑁𝐵(𝑗, 𝜃) (3-4) 
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Determining the estimates of the potential patient who might benefit and the lifetime of the 
new technology or intervention requires some assumption to be made. It should consider 
far enough into the future to reflect important differences between alternative 
interventions, the duration of treatment and the duration of the treatment effect. 
The per person EVPI and population EVPI indicate whether further research is potentially 
worthwhile by providing an upper bound on the value of conducting further research. 
However, as perfect information is not achievable, EVPI alone is not sufficient to 
determine the potential for conducting future research. Thus, it is a necessary but not a 
sufficient condition (157,158). 
3.3.3.2 EVPI for parameters (EVPPI) 
After the calculation of EVPI and investigating if future research is worthwhile using EVPI, 
the next question comes about the optimal design for collecting further evidence. One 
consideration is to establish on which parameter(s) further information will be of most 
value. The expected benefit of reducing uncertainties surrounding a particular parameter 
or a subset of model parameters is called the EVPPI. Those parameter(s) with a higher 
EVPPI value are likely to be more uncertain, and thus further research to get a more 
precise estimate of its value is likely to be of value. 
EVPPI is simply the difference between the expected value of a decision made with 
perfect and current information about parameter(s) (83,158,159). It provides an upper 
bound to research expenditure with respect to a particular parameter or set of parameters. 
In a decision model with uncertain parameters θ, the value of perfect information about 
the parameter or a subset of parameters (ϕ) are of interest. If there was perfect 
information, it would be known which value ϕ will take. Then the alternative with the 
maximum ENB would be chosen by averaging the ENB over the remaining uncertain 
parameters (ψ), where 𝜑 ∪ 𝜓 =  𝜃. In other words, by taking the value of ϕ and calculating 
ENB over the remaining uncertain parameters (ψ) the alternative with maximum ENB (j) 
is selected (equation 3-6): 
 𝑚𝑎𝑥𝑗 𝐸𝜓|𝜑𝑁𝐵(𝑗, 𝜑, 𝜓 ) (3-6) 








However, the true value of ϕ is unknown. Therefore the expected value of a decision with 
perfect parameter information is found by averaging the maximum ENBs over the 
distribution of ϕ (equation 3-7): 
𝐸𝜑  𝑚𝑎𝑥𝑗 𝐸𝜓|𝜑𝑁𝐵(𝑗, 𝜑, 𝜓 ) (3-7) 
The expected value with current information is the same as EVPI because 𝜑 ∪ 𝜓 =  𝜃. So 
the EVPPI for the parameters (ϕ) is the difference between the expected value of the 
decision made with perfect information on ϕ and the decision made with current 
information. (159) as given in equation 3-8: 
𝐸𝑉𝑃𝑃𝐼𝜑 = 𝐸𝜑  [𝑚𝑎𝑥𝑗 (𝐸𝜓|𝜑𝑁𝐵(𝑗, 𝜑, 𝜓 ))] − 𝑚𝑎𝑥𝑗 [𝐸𝜃  𝑁𝐵(𝑗, 𝜃)] (3-8) 
Similar to calculating EVPI, the results from the decision model and PSA are used to 
calculate EVPPI. While calculating EVPPI, the simulation needs to run for the 
parameters 𝜓 with each value 𝜑. Values for the parameter 𝜑 are selected using an outer 
loop. The simulation is then run for each value of 𝜑 to generate the expected costs and 
QALYs which are used to estimate ENB. This step is repeated until there is sufficient 
sampling from the distribution of 𝜑. 
To compute EVPPI as outlined in equation 3-8, it involves various steps which are 
described below (159) in Box 3-1. 
 
Box 3-1: Monte-Carlo algorithm for calculation of EVPPI 
Preliminary steps (adoption decision) 
1) The first step, Set up a decision model comparing different brief PA intervention 
strategies and set up a decision rule, for example, ICER ≤ 𝜆 (where 𝜆 is the society’s 
willingness to pay threshold)  
2) Characterise the uncertain parameters with probability distributions. For example, 
normal(𝜃, 𝜎2), beta (a, b), gamma (a, b), triangular (a, b, c), . . ., etc. 
3) Simulate 𝐿 iterations (e.g. 𝐿 = 10,000) sample sets of uncertain parameter values 
using Monte Carlo simulation. 
4) Work out the baseline adoption decision given current information, that is, the brief 
intervention giving the highest estimated expected net benefit over 𝐿 simulations. 
Partial EVPI for a Parameter Subset of Interest 
The algorithm has 2 nested loops. 
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5) Obtain a sample value for the parameter of interest, say intervention effect (ϕ) from 
its prior distribution, given by 𝜑𝑘. This step corresponds to the outer level simulation. 
The intervention effectiveness parameter (ϕ) is a subset of the entire set of 
parameters (𝜑 ∪ 𝜓 =  𝜃). 
6) Run the Monte Carlo simulation which was set up in the preliminary steps to estimate 
ENB of the intervention given perfect information on ϕ, which is fixed at the sampled 
value 𝜑𝑘 obtained in the outer loop. 
 In running this simulation, all remaining uncertain parameters (𝜓) are simulated over 
say, 𝑗 = 10,000 times, allowing them to vary according to their conditional probability 
distribution (conditional on the parameter subset of interest at its sampled value 𝜑𝑘). 
This corresponds to the inner-level simulation. 
7) Calculate the conditional ENB of each intervention strategy given perfect information 
about the treatment effect (ϕ). The brief PA intervention strategy chosen is the one 
with the highest estimated ENB for the sampled value of 𝜑 (𝐸𝜑|𝜓[𝑁𝐵(𝑗, 𝜑, 𝜓)]). 
8) Loop back to step 5 and repeat steps 5-7 (say, j =10, 000 times) and then calculate 
the average net benefit of the revised adoption decisions given perfect information on 
treatment effect parameters (𝜑). 
9) Calculate and record the average net benefit of each brief PA intervention strategy 
across all the inner loop iterations and then calculate the maximum of those average 
net benefits.  
10) Across all L outer loop iterations, calculate the average of the average net benefit for 
each brief PA intervention strategy and the average of the maximum net benefits.  
11) The partial EVPI for the parameter subset of interest (treatment effect, 𝜑) across the 
intervention strategies is estimated by getting the difference between the average 
maximum net benefit and the maximum average net benefit of each intervention 
strategy in step 7. 
Source: Adapted from Brennan et al. (159) 
The EVPPI can be run for a single parameter as well as for groups of parameters where 
a specified group of parameters such as treatment effects are held constant rather than a 
single parameter. Additional parameter information is only valuable for those parameter(s) 
for which additional information would change the adoption decisions. Parameters with 
more uncertainty will have a higher VoI attached to them. It is important to note that the 
EVPPI for individual parameters does not sum to the overall EVPI, and likewise, the 
EVPPI for groups of parameters is not the sum of the EVPPI for individual parameters 
(36). 
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The EVPPI measures the sensitivity of the decision problem to uncertainty in particular or 
a group of parameters. The population EVPPI can be estimated by multiplying the EVPPI 
value with ‘effective population’. The effective population can be determined in the same 
way as described above for EVPI (section 3.3.3.1). 
The EVPI and EVPPI give an upper bound of the expected benefit of doing more research 
by calculating the improvement in net benefit expected from eliminating uncertainty in all 
parameters or a subset of parameters respectively. The next step is to determine if further 
research is worthwhile and identify an efficient research design. 
3.3.3.3 Expected value of sample information (EVSI) 
Whilst EVPI and EVPPI place an upper bound on the potential value of further research, 
they provide a necessary but not sufficient condition for acquiring further information 
(42,160). The VoI framework can be extended to establish the expected value of sample 
information for a sample of n participants for particular research designs (160). It is the 
societal benefit of acquiring additional evidence from a sample to inform a decision. This 
allows the marginal benefit of additional sample information for a patient population and 
the marginal cost of sampling to be examined. The Expected Value of Sample Information 
(EVSI) is the technique used to assess the value of sample information acquired after the 
proposed research and the expected value of the decision given current information (75). 
The EVSI is estimated using a similar process used to estimate EVPI and EVPPI. 
However, in estimating EVSI a sample is drawn rather than assuming perfect information 
about parameter(s). EVSI for a parameter or a subset of parameter 𝜑 can be estimated 
over the remaining parameters 𝜓. 
If 𝜑 and 𝜓 are independent then a sample of 𝑛 on 𝜑 provides the sample result D. If D 
were known, the ENB could be averaged over the prior distribution of 𝜓 and the posterior 
distribution of treatment effect (𝜑) given D: 
 𝑚𝑎𝑥𝑗 𝐸𝜓,𝜃|𝐷𝑁𝐵(𝑗, 𝜑, 𝜓 ) (3-9) 
As D is unknown, so the expectation of the maximum ENB over the predictive distribution 
of D conditional on 𝜑 is taken and averaged over the prior distribution of treatment effect 
𝜑: 
 𝐸𝐷𝑚𝑎𝑥𝑗 𝐸𝜓,𝜃|𝐷𝑁𝐵(𝑗, 𝜑, 𝜓 ) (3-10) 
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As above, the EVSI is the difference between the expected value of a decision with sample 
information and that with current information (160): 
 𝐸𝑉𝑆𝐼 =  𝐸𝐷𝑚𝑎𝑥𝑗 𝐸𝜓,𝜃|𝐷𝑁𝐵(𝑗, 𝜑, 𝜓 ) − 𝑚𝑎𝑥𝑗 𝐸𝜃𝑁𝐵(𝑗, 𝜃 ) (3-11) 
The various steps for the EVSI estimation (7,71,160,161) are provided below: 
 
Box 3-2: Monte-Carlo algorithm for calculation of EVSI 
1) For an assumed new sample size (n), the initial step involves setting up a decision 
model with parameters 𝜃 (𝜑 ∪ 𝜓 = 𝜃) and setting up a decision rule, for example, 
ICER ≤ 𝜆. The first step is to draw sample value(s) from a prior distribution of 
treatment effect (𝜑). 
2) Draw, a random sample to simulate the true event given sample size (n) and the 
estimate of treatment effect parameter, 𝜑. Using this draw and the prior mean for the 
treatment effect parameter, 𝜑, calculate a posterior estimate.  
4) Sample value from pre-posterior distribution of 𝜑 and from distribution of remaining 
parameters,𝜓, place back into the model and recalculate the NB for each intervention 
i.e. 𝑁𝐵(𝑗, 𝜑, 𝜓)  
5) The NB for each intervention is calculated and stored, identifying the intervention with 
the highest NB.  
6) This process is repeated again (steps 1-5), using the second iteration of prior means 
from the Monte Carlo simulation and continually repeated for all of the posterior 
estimates. The NB for each intervention is recorded and the intervention that gives 
the maximum ENB for each is identified  
7) Once the process has been repeated for all of the prior iterations in the Monte Carlo 
simulation, the stored NBs and maximum intervention identities are used to calculate 
the ENB for each iteration. The intervention with the highest ENB is the expected 
value of a decision based on current information. 
8) Calculate the expected maximum NB (averaging the maximum NBs). This is the 
expected value of a decision based on sample information for the selected sample 
size (n). 
9) The ENB of a decision under current information is subtracted from the ENB of a 
decision based on sample information to give the EVSI. 
Source: Adapted from Ades et al. (7), Brennan et al. (161) and Wilson (71) 
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The EVSI calculated is the value per decision. Thus, the population EVSI can be 
calculated using the same approach used to determine EVPI and EVPPI (equation 3-12).  
The calculation of population EVSI should define the eligible population who can benefit 
from the results of research. Population EVSI value depends on the definition of eligible 
population, disease incidence and prevalence (𝐼), and the time horizon (𝑡) over which the 
additional information is expected to be useful. Thus, the EVSI associated with future 
patients should be discounted appropriately and the discount rate (𝑟) stated. The 
calculation of population EVSI assumes that the intervention shown to be cost-effective 
with sample information for a sample of n will be implemented instantly to the entirety of 
eligible population. However, this assumption is generally unrealistic especially in the 
healthcare setting (162). Adoption of a new intervention strategy requires time and such 
strategies do not immediately get implemented perfectly into practice. For example, 
implementation of new intervention strategies may require new skills which may lead into 
less perfect or phased implementation of such intervention strategies. 
3.3.3.4 Expected net benefit from sampling (ENBS) 
With respect to the sample size, the greater 𝑛 is the less uncertainty around the 
parameter(s) of interest. However, as 𝑛 increases so does the cost of the study. Therefore, 
the optimal sample size can only be determined by comparing the EVSI with the expected 
cost of sampling (new research). The costs of sampling are defined in terms of financial 
resource (fixed and variable) costs and the opportunity cost. The expected net benefit of 
sampling (ENBS) is the EVSI less the cost of conducting a research with sample size 𝑛. 
The ENBS reaches the maximum at the optimal sample size. If the maximum ENBS is 
greater than the fixed cost of conducting the research, then additional research is 
warranted (42,160,163). The ENBS of sample size (n) can be calculated given the 
population EVSI for that sample size and the cost of additional research at that sample 
size (𝐶𝑛): 
 







𝐸𝑁𝐵𝑆𝑛 = 𝑝𝐸𝑉𝑆𝐼𝑛 − 𝐶𝑛 (3-13) 
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3.3.4 Primary research 
Based on outcomes of the decision model in stage 2 (section 3.3.2) and the research 
priorities established in stage 3 (section 3.3.3) using VoI analyses, the next stage is to 
design and conduct primary studies to detect a difference in the key parameters driving 
the primary research. For example, if the research priorities identified in stage 3 indicated 
insufficient data surrounding the treatment effect, then the study should be conducted to 
detect a difference in effectiveness (6). If an economic evaluation is commissioned 
alongside a clinical trial, attempts should be made to adhere to the gold standard 
characteristics (use of appropriate comparator, endpoints, adequate length of follow-up to 
assess the full impact of treatment etc.) for economic evaluation within clinical trials (27). 
Use of gold standard economic evaluation within a clinical trial (section 1.3) will strengthen 
the design of research and improve the quality of economic evaluation. 
3.3.5 Synthesis and modelling with updated evidence 
In this stage of the iterative approach, new evidence is incorporated into the information 
set used within the decision model, and any other evidence published during the interim. 
Having synthesised the primary research outcome with any other relevant information in 
stage 5, the iterative process then loops back to stage 2 again. This updating of existing 
evidence or knowledge about each parameter in the model with new information as it 
becomes available is known as a Bayesian process (164). 
Having described the key steps of an iterative approach to economic evaluation, the 
following section examines its merit and limitations/challenges. 
3.4 Merits and criticism of using an iterative approach 
The iterative economic framework has been suggested throughout the lifecycle of a health 
technology assessment as it incorporates new evidence when such information becomes 
available and is recognised by some funding and decision making bodies such as NICE 
in the UK (5,6,10). This also, in overall, supports a process of gathering information and 
reducing uncertainty in order to improve decision making. The iterative approach to 
economic evaluation provides a framework in which evidence from a range of sources 
can be synthesised, and the information is continually updated using Bayesian process. 
The framework is based on a stepwise approach. In other words, each stage of the 
research process feeds information into the next stage in order to reduce uncertainty and 
aid decision making throughout. This involves various stages to improve information 
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regarding the important parameters of interest, for example, treatment effect, the 
comparator in the model, and uncertainty surrounding the cost-effectiveness results. 
Given the iterative nature of the framework, the use of a single one-off trial is inadequate 
as a sole input for economic appraisal. The iterative process evolves alongside all stages 
of healthcare research (as illustrated in Figure 3-1) instead using one-off analysis by 
providing a structure to answer a given decision problem and improves decision making 
by reducing uncertainty. The main objective of such a process is to answer the cost-
effectiveness decision problem (6). 
The use of an early stage probabilistic decision analytic model can help set search 
priorities and inform if additional research is required (6). If additional research such as 
an RCT is undertaken, this will provide information on costs, effects and other important 
parameters. This updated information is then used to update the model. By re-running the 
model and performing VoI, this process allows to explore if there is any scope to acquire 
further information to reduce uncertainty. If there is potential for additional research, the 
decision model can again help to inform the design of the future research. For example, 
if the VoI analysis suggested that it would be of most value to gather further information 
on the quality of life or cost, an RCT is not the optimal research design. Instead, 
observational studies would be more appropriate to collect such information than 
conducting a large-scale RCT. 
The iterative framework supports healthcare research bodies to prioritise between several 
competing and possibly cost-effective alternatives. The iterative approach allows decision 
making bodies such as NICE in the UK to assess the potential cost-effectiveness of 
alternative interventions and helps to identify evidence gaps and set research priorities. 
This will enable efficient allocation of limited resources.  
Though the iterative framework improves the overall decision making as mentioned 
above, it has practical and methodological limitations. First, such a process requires time 
and is resource intensive. The VoI results assist decision makers in research prioritisation 
decisions, and they are described as a best practice for handling decision uncertainty (39). 
However, VoI analysis can be time and resource intensive to develop a de novo decision 
model and conduct literature searches for model inputs. Even though researchers have 
good knowledge and access to a programming language as well as familiarity with the 
VoI methodology and process, it requires considerable time to develop a decision model, 
undertake probabilistic analysis followed by EVPI analysis and finally undertaking EVSI 
calculation for a wide range of sample sizes (6). Calculation for EVPPI and EVSI for non-
linear models requires sophisticated computations along with advanced expertise in 
economic evaluation and simulation techniques (73). The use of two-level Monte Carlo 
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simulation although seems straightforward, particularly in models that require individual-
level simulations, this approach is computationally expensive (10). Nonetheless, in recent 
years, there have been advances in VoI methodology and computing tools to reduce 
computational challenges (165-167). 
The most recent approaches offer computationally efficient procedures for estimating 
EVPPI and EVSI. For example, Strong et al. (168) provide an efficient method for 
estimating EVPPI. Their nonparametric regression-based method requires only the 
probabilistic sensitivity analysis sample rather than estimating EVPPI via a two-level 
Monte Carlo procedure. In their applied example, Tuffaha et al. (165) used the 
nonparametric regression approach to estimate EVPPI and EVSI calculations. They 
reported that the nonparametric regression method estimated EVPPI and EVSI values in 
less than a minute. In contrast, the Monte-Carlo simulation took around 4 hours for every 
EVPPI estimate and around 8 hours for every EVSI value for a given sample size. 
Recently Heath et al. (169) proposed a novel approximation method for the EVSI 
calculation using the moment matching methodology. 
Second, the VoI analysis not only uses current information but also requires future patient 
population estimates over an ‘appropriate’ time horizon. A future population that could be 
benefitted from the information is calculated as the sum of the discounted incidence of 
disease. It may be appropriate to estimate future incidence and prevalence of the disease 
depending on the nature of disease and treatment, but it is very difficult to define an 
appropriate time horizon, and VoI is extremely sensitive to the time horizon selected 
(170,171). In addition, it is hard to estimate the effective lifetime of an intervention or a 
health technology given dynamic and complex nature of innovation of new therapy or 
technology. Ideally, the time horizon should reflect the time over which the decision 
question remains relevant as when new technologies and treatments become available 
the current decision question becomes irrelevant. A systematic assessment of the 
potential impact of new and emerging technologies in the early stage of technology 
development provides a means to estimate appropriate time horizon (172). 
Third, the validity of the VoI approach within the iterative framework in economic 
evaluations rests on the assumption that the model structure on which the analysis is 
based on is correct and that uncertainty in model input parameters is appropriately 
characterised. Structural uncertainty arises because of uncertainty about the true 
structural relationship between model outputs and a set of quantities which form the model 
output (173). The assessment of the structural uncertainty is usually limited to running a 
range of scenario analyses (68) and model averaging is an alternative approach (174). 
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Model averaging involves averaging all the possible combinations of predictors when 
inferences are made about quantities of interest (175). 
Following the iterative framework with earlier modelling at stage 2 of the iterative 
framework could reduce the cost related to the subsequent evaluation of health 
technology or intervention and further research. Conducting RCTs is often infeasible 
particularly for less prevalent diseases and can be an arduous process. For example, in 
rare diseases, international research projects could be desirable. Over the years, there 
have been international networks that support research into the rare disease which may 
enable more informative registries. However, many authorities require local information 
which could not be easily available such as resource use or quality of life (QoL) (176). 
Quality of life is a ubiquitous concept that encompasses a number of different dimensions 
and has different philosophical, political and health-related definitions (177). The 
dimensions generally cover physical, psychological, social and spiritual wellbeing (178). 
The subjective perception one has about different aspects of life depends significantly on 
individuals’ priorities and needs. Health-related QoL (HR-QoL) is a patient-reported 
outcome which is usually measured with validated instruments such as questionnaires 
and semi-structured interview schedules. It includes the physical, functional, social and 
emotional well-being of an individual. The measurement of QoL is basically done using 
three approaches (179): using generic instruments that provide a summary HRQoL (e.g. 
health profiles), specific instruments (e.g. disease specific, population specific, function 
specific) and preference-based measures such as health state utility. Preferences for the 
same health state (for example type 2 diabetes, being physically active) could be quite 
different in different countries. Such variation in preferences can vary, among others, by 
cultural belief, availability of health care and social institutions (20). Likewise, differences 
in methods may obscure true differences in values between countries (180). These 
differences can have a significant impact on the valuation of health states and the resulting 
cost-effectiveness of interventions (181,182). 
3.5 A review on the use of iterative framework in decision making 
As discussed in Chapter 1 and earlier sections of this chapter, economic evaluations are 
helpful in informing decision making process as they adopt a systematic approach to 
compare alternative options (health interventions) in terms of costs and associated health 
benefits. Several decision making and funding bodies such as NICE in the UK, 
Pharmaceutical Benefits Advisory Committee in Australia (57) use methods of economic 
evaluation in particular decision analytic models to inform reimbursement, and allocate 
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finite and constrained health care resource. Decision analytic models have become an 
integral part of such process (183) as it allows synthesis of all available evidence in order 
to identify the incremental costs and health benefits of new intervention/technology 
compared with current practice (section 1.4). An essential component of such model-
based economic evaluation includes adequately characterising uncertainty associated 
with the model structure, identification of model inputs and choices or assumptions made 
within the analysis (38,68,183). The typical method of quantifying the level of confidence 
in the output of the cost-effectiveness analysis in relation to uncertainty in the model inputs 
is PSA (37,63). PSA have become the norm in many health economic evaluations and is 
recommended by HTA bodies such as NICE in the UK (63). VoI was proposed to 
characterise uncertainty in cost-effectiveness analyses (85) and is the notion that 
information is valuable because it reduces the uncertainty surrounding decisions. The 
analysis of VoI is an increasingly popular method to conduct PSA in health economic 
evaluations (5,66,164). 
VoI methods have been proposed as a systematic decision analytic approach to 
understanding the need for further research, appropriate research design and set 
research priorities (82,163). In recent years, there have been methodological 
development and application of VoI methods in several healthcare fields. Recent 
systematic reviews of VoI methods in health technology assessment provided insight on 
evolving methods and application (73,166), how the VoI statistics interpreted (184) and 
used in research prioritisation (85,185). These reviews also highlighted methodological 
and technical challenges, for example, such as high computational demand that has 
limited the use of VoI methods in future research prioritisation. 
An iterative framework to the economic evaluation of health technologies was suggested 
beginning with early indicative studies and progressing towards more rigorous 
assessment as data become available (4,5,43). However, it is not clear how this iterative 
process has been applied in real life economic evaluation. Thus, a systematic review is 
conducted with an aim to identify literature on how VoI method is used in decision making 
to inform further research within an iterative process of analysis. 
The sections below describe the methodology used to review the evidence and results. 
3.5.1 Literature review methods 
As the focus of this literature review was on the application of VoI methods within the 
iterative framework in decision making to inform further research, it provides synthesised 
information such as where such studies fit within the framework, type of decision informed 
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by the VoI methods. An initial scoping search was conducted on PubMed using search 
term (health-care decision making AND cost-effective AND (iterative approach OR value 
of information[ti])) which resulted in 13 hits. Then a structured search strategy was 
developed by elaborating the key search words in PubMed search. Search strategies 
used to identify relevant published economic evaluations, listed in Appendix B1, consisted 
of a combination of keywords and MeSH terms. Searches were conducted in MEDLINE, 
Embase, CINAHL, EconLit, Cochrane library, Scopus and NIHR databases to include 
studies published up to 31 December 2017. In addition, citation search of Claxton et al. 
(72), Fenwick et al. (5), and Sculpher et al. (4,43) were done as these studies described 
or used VoI methods in the iterative framework. Reference list of included studies was 
checked in order to locate any relevant publication from the same or related study. 
Studies were included if they were published economic evaluations in healthcare, were in 
English-language and used VoI methods within the iterative framework. Studies were 
excluded if they were a systematic review, the VoI methods were applied in areas other 
than healthcare research or were concerned with methodological research as the focus 
of the review was on the application of VoI methods.  
Following de-duplication of database search results, articles were screened by applying 
the inclusion criteria on titles and abstracts of each identified article. Full-text data 
extraction of selected studies was performed using a standardised proforma (Appendix 
B2) which was developed using the CHEERS checklist (129) and ISPOR-SMDM guidance 
on good practice for economic modelling in health care (57). 
3.5.2 Results 
The search of electronic databases identified 2,078 potentially relevant articles including 
389 articles identified through other sources and cross-referencing. Following de-
duplication and abstract screening, 184 articles were selected for full-text screening. Of 
those, 89 studies met the inclusion criteria and included in this review. The remaining 95 
were excluded because either they reported methodological studies (n=46), reported 
systematic review or were editorial or conference abstracts (n=24), did not report VoI 
results (n=22) or were study protocol or published as a part of full HTA report (n=3). Figure 
3-2 summarises the study selection process. 
On the basis of this literature, the remainder of this chapter describes the characteristics 
of included studies, maps with the iterative framework and discusses the main aspects of 
processes and approaches used in evidence gathering and or priority setting for research. 
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Figure 3-2: PRISMA flow diagram of study selection 
3.5.2.1 Characteristics of included studies 
Almost half (n=45) studies were conducted in the UK (Table 3-1.) Remaining studies were 
conducted in Europe (n=20), North America (n=20), Australia (n=3) or Thailand (n=1). 
Included studies evaluated medicines, health interventions, diagnostics and medical 
devices for a range of different conditions and study populations. The type of decision 
models used were either decision trees (n=19) (5,76,78,80,84,186-199), Markov models 
(n=45) (75,200-243), a combination of a decision tree and Markov models (n=12) (81,244-
254), or individual patient data / discrete event simulation / microsimulation (n=4) (77,255-
257), or simple linear regression (n=2) (258,259). Seven studies did not report model type, 
or the description was not clear (260-266). In terms of the type of VoI analysis, 82 of the 
included articles (92%) reported EVPI estimation, 48 (54%) reported EVPPI, 15 (17%) 
reported EVSI, 7 (8%) reported ENBS, and one (1%) reported ENG. These studies used 
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VoI to inform decisions (i.e. whether additional research was worthwhile), inform research 
focus and/or trial design by determining optimal sample size, or inform research priorities. 
3.5.2.2 Mapping with the iterative framework 
The included studies are mapped (Figure 3-3) with the ‘five steps’ of the iterative 
framework as described in section 3.3. Majority of the studies (n=72, 81%) started with 
evidence synthesis and decision analytical modelling whereas the remaining 17 studies 
started with conducting the economic evaluation (prospectively or retrospectively) 
alongside the clinical trial. Thirty-one studies reported funding from the NIHR or UK 
Medical Research Council and 27 of which reported only mapped with the first 3 steps of 
the iterative framework. Of these 31 studies, only two (230,267) studies did not 
recommend additional data collection. These studies are summarised below according to 
which steps in the  iterative framework they pertained to: 
Stages: I–III (N=68) 
Sixty-eight (76%) studies described the first 3 steps of the iterative framework, i.e. 
identified decision problem, synthesised available evidence and populated the decision 
model, and performed VoI analysis for research priority setting. Usually, a single 
publication reported the results from the economic model and VoI analysis. However, in 
some cases, for example, Jutkowitz et al. study (243,268) they initially performed cost-
effectiveness analysis to evaluate the cost-effectiveness of urate-lowering treatment 
strategies (allopurinol and febuxostat) for the management of gout (268). In a subsequent 
publication, Jutkowitz et al. (243) used the same Markov model and incorporated VoI 
analysis to quantify decision uncertainty regarding the cost-effectiveness of allopurinol 
and febuxostat in the management of gout, and concluded that there is value in conducting 
additional research on the effectiveness of allopurinol dose escalation and febuxostat 
dose escalation. 
Stages: I–V (n=2) 
Two studies (206,269) sequentially followed all the five steps. Oostenbrink et al. (269) first 
developed a Markov model to assess the cost-effectiveness of bronchodilator therapy in 
chronic obstructive pulmonary disease (COPD). Their VoI analysis showed that the utility 
parameter had the highest EVPPI, i.e. contributed most to the overall uncertainty as to 
which bronchiolitis treatment to adopt given the current information. Then additional utility 
research was performed in a sample of 1,234 COPD patients who completed the EQ-5D 
questionnaire at baseline. 
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The newly collected information on utility was combined with the prior information (222) 
and the total EVPI per patient for the updated model was substantially reduce (from €1985 
to €1037). Burr et al. (267) in their glaucoma screening study first evaluated the cost-
effectiveness of glaucoma screening. The analysis suggested a feasibility study to 
improve detection, refinement of model parameters and an RCT of an intervention to 
improve uptake of glaucoma testing. They used a mixed method approach to inform the 
optimal design for a trial using a Delphi survey (270) and views of NHS providers (271). 
Their updated model (206) was informed by feasibility study suggested that glaucoma 
screening trial in the UK is unlikely to be the best use of research resource. 
Stages: I, II & V, III (n=2) 
Two studies (211,215) first used a decision model to estimate the cost-effectiveness of 
health technology. Favato et al. first developed a model (272) to evaluate the cost-
effectiveness of a vaccination strategy to prevent HPV related diseases. Later they 
extended their model to include herd immunity, made it a dynamic model and assessed 
the cost-effectiveness of a quadrivalent-based HPV vaccination strategy within a 
Bayesian framework. Hall et al. (215) first developed a decision model to assess the cost-
effectiveness of trastuzumab for HER2-positive overexpressing early breast cancer. They 
re-evaluated the cost-effectiveness of trastuzumab using data from a clinical trial with 
longer follow-up. Their VoI analysis placed the highest value on research into the duration 
of treatment benefit. 
Stages: IV, V, III (n=13) 
Thirteen studies (5,80,191,199,200,202,203,216,223,228,240,251,262) first performed 
economic analysis alongside the trial then updated the evidence, developed a model to 
assess long-term cost-effectiveness including VoI analysis. For example, in their study 
Boyd et al. (203) first undertook economic evaluation alongside a clinical trial, then used 
a model to synthesise evidence from the trial and published sources. EVPI results 
suggested that additional research is potentially worthwhile. 
Stages: IV, III (n=3) 
Only three studies (258,259,265) first performed economic evaluation alongside the 
clinical trial then VoI analysis in order to quantify decision uncertainty. 
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Table 3-1: Summary of systematic review findings 








Stage of iterative 
evaluation 
included* 





Haemophilia A children with severe haemophilia A not 
reported 
EVSI, ENG I, II, III Canadian Blood Services, Bayer 







Adult patients with stress, urgency 
or mixed UI 
not 
reported 
EVPI IV, III The Netherlands Organisation 
for Health Research and Development  
Ashby 2014 
(200) 
UK venous leg ulcer Adults aged ≥18 years with a 
venous leg ulcer 
Markov EVPI IV, V, III NIHR HTA programme 
Bansback 2009 
(201) 
USA CHD Female patients with Rheumatoid 
arthritis 
Markov EVPPI I, II, III None 
Bartha 2013 
(202) 
Sweden hip-fracture Patients aged >70 years, weight 
≥40 kg scheduled for hip-fracture 
surgery during operating hours 




UK psychosis People with a current diagnosis of 








UK Smoking cessation Pregnant smoker (women) in 
Glasgow 




UK Breast cancer 
screening 
Women registered with a GP 
practice 
Markov EVPI I, II, III MRC UK 
Bruce 2015 
(186) 
UK Otitis media with 
effusion (OME) 
Children with cleft palate under the 
age of 12 years 
Decision 
tree 




UK Primary rectal cancer Patients aged ≥50 years, 
undergoing pre-operative staging 
prior to curative surgery 
Markov EVPI I, II, III NIHR HTA programme 
Burr 2011 (206) UK Open acute 
glaucoma 
A cohort of 40-year old males Markov EVPI, EVPPI I, II, III, IV, V MRC UK 
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Table 3-1 (continued) 
Author, year Country Disease or 
condition 




Stage of iterative 
evaluation 
included* 





A cohort of patients with ischemic 
cardiomyopathy 
Markov EVPI I, II, III NIHR HTA programme 
Carlton 2008 
(208) 
UK Amblyopia Children aged up to 7 years Markov EVPI I, II, III NIHR HTA programme 
Castelnuovo 2006 
(244) 
UK Hepatitis C infection Former injecting drug users aged 




EVPI, EVPPI I, II, III NIHR HTA programme 
Claxton 2001 
(209) 
USA Alzheimer’s disease People with mild to moderate 
Alzheimer’s disease 
Markov EVPI, EVPPI I, II, III Commonwealth Fund 
Colbourn 2007 
(187) 
UK Group B 
Streptococcal and 
bacterial infection 
Women giving birth Decision 
tree 
EVPI I, II, III NIHR HTA programme 
Collins 2007 
(210) 
UK Prostate cancer Men with metastatic hormone-
refractory prostate cancer 
(mHRPC). 
Markov EVPI I, II, III NIHR HTA programme 
Favato 2012 
(211) 
Italy Human Papilloma 
Virus (HPV) 
Girls aged 12-25 years Markov EVPI I, II, III & V Sanofi Pasteur MSD, Italy and UK NIHR 
Fenwick 2006 (5) UK Elective procedure High-risk patients undergoing 
major elective surgery 
Decision 
tree 
EVPI, EVPPI IV, V, III Bayesian Initiative 
Fox 2007 (212) UK Heart failure People with HF due to LV systolic 
dysfunction 
Markov EVPI, EVPPI I, II, III NIHR HTA programme 
Gajic-Veljanoski 
2012 (255) 
Canada Fractures 50-year old postmenopausal 
women without osteoporosis 
Microsimul
ation 
EVPI I, II, III Canadian Institutes of Health Research 
(CIHR) 
Galani 2008 (213) Switzerland Obesity Obese and overweight people Markov EVPI, EVPPI I, II, III Swiss Federal Office of Health 
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Table 3-1 (continued) 
Author, year Country Disease or 
condition 




Stage of iterative 
evaluation included* 







Patients with chest pain Decision 
tree,  
Markov 
EVPI I, II, III Netherlands Organisation for Health 
Research and Development, and the 
Erasmus University Medical Centre 
Ginnelly 2005 
(214) 
UK recurrent UTI Children Markov EVPI I, II, III NIHR HTA programme 
Gurusamy 2012 
(188) 
UK Gallbladder Patients with gallbladder and 
common bile duct stones 
Decision 
Tree 
EVPI, EVPPI I, II, III No funding received 
Guzauskas 
2017 (246) 
USA Ischemic stroke Patients with mild stroke Decision 
tree, 
Markov 
EVSI IV, V Genentech, Inc. 
Hall 2011 (215) UK Breast cancer Women with HER2-positive early 
breast cancer 
Markov EVPI, EVPPI I-II, V NIHR HTA Programme 
Hall 2017 (216); 
Stein 2016 
(273) 
UK Breast cancer Women with surgically treated 
breast cancer 
Markov EVPI, EVPPI 
and EVSI 
IV, V NIHR HTA Programme 
Hassan 2009 
(217) 
USA Colorectal cancer Adults aged 50-year olds in the 
US 
Markov EVPI, EVPPI I, II, III Not reported 
Hassan 2010 
(189) 
USA Colorectal cancer Adults aged 60 years following 
complete endoscopic resection of 
an LR malignant polyp 
Decision 
tree 
EVPI, EVPPI I, II, III Not reported 
Haukaas 2017 
(247) 
Norway Latent tuberculosis Immigrants <35 years of age from 





EVPI, EVPPI I, II, III No funding received 
Havrilesky 2013 
(248) 
USA Endometrial cancer Women with grade 3 or grades 2-




EVPI, EVPPI I, II, III No funding received 
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Table 3-1 (continued) 
Author, year Country Disease or 
condition 




Stage of iterative 
evaluation included* 
Source of funding 
Henriksson 
2006 (218) 
Sweden Abdominal aortic 
aneurysm (AAA) 
Men aged 65 years Markov EVPI, EVPPI I, II, III Health Council of Ostergotland, 
Sweden, and the National Pharmacy 
Corporation’s fund for research and 








EVPI, EVPPI I, II, III NIHR 
Iglesias 2006 
(219) 
UK Venous leg ulcers Individuals aged 66 years Markov EVPI, EVPPI I, II, III pump priming research grant from the 





AS patients requiring daily or 
routine (≥25 days per month) 
NSAID intake 




USA Gout Hypothetical gout patient Markov EVPI, EVPPI, 
EVSI, ENBS 





Acute Knee Trauma Patients with acute knee trauma not clear EVPI, EVPPI, 
EVSI, ENBS 










EVPI, EVSI IV and III The Netherlands organization for 





Adult patients with newly 
diagnosed GBM 




UK Aphasia Patients with aphasia Markov EVPI, EVPPI IV & V NIHR RfPB, CLAHRC 
Leaviss 2014 
(235) 
UK Smoking cessation adult smokers Markov EVPI, EVPPI I, II, III NIHR HTA programme 
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Table 3-1 (continued) 
Author, year Country Disease or 
condition 




Stage of iterative 
evaluation included* 
Source of funding 
Leelahavarong 
2011 (232) 
Thailand HIV  general population aged 18 to 30 years 
old, FSW, IDU, MSM, and military 
conscripts 
Markov EVPI, EVPPI I, II, III Health System Research 
Institute (HSRI) 
Lewis 2016 (191) UK Chronic pelvic pain women aged 18-50 years who suffered 
from pelvic pain for >6 months 
Decision 
tree 
EVPI, EVPPI IV, V Chief Scientist Office, Scottish 
Government 
Loon 2010 (234) The 
Netherlands 
Non-small cell lung 
cancer 





 Patients with glioblastoma multiforme Markov EVPI I, II, III Schering-Plough, Finland Oy 
McCullagh 2012 
(252) 





EVPI, EVPPI I, II, III No funding received 
McKenna 2009 
(221) 
UK Angina adults with chronic stable angina Markov EVPI, EVPPI, 
EVSI, ENBS 
I, II, III NIHR HTA Programme 
McKenna 2010 
(230) 
UK Post-MI heart failure patients with 
post-MI HF 
Markov EVPI, EVPPI I, II, III NIHR HTA Programme 
Micieli 2014 (256) Canada Atrial fibrillation Patients with AF at risk of stroke Microsimul
ation 
EVPI, EVPPI I, II, III Heart & Stroke Foundation of 
Canada & University of Toronto 
Miners 2014 
(236) 





Breast Cancer Cohort of 40-year old women with triple-
negative breast cancer 

















Depression Patients with minor depression Markov EVPI, EVPPI I, II & II, III Dutch Ministry of Health, RIVM 
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Table 3-1 (continued) 
Author, year Country Disease or 
condition 




Stage of iterative 
evaluation included* 
Source of funding 
Morliere, 2015(239) France Complete Spinal cord 
injury 
Patients with a complete spinal 
cord lesion and a neurogenic 
bladder 
Markov EVPI, EVPPI I, II, III Not clear 
Ney, 2014(264); 
Chi, 2014(276) 
USA Primary molar 
sealant 
children under age 12 months Not clear EVPI I, II & II, III National Institute of Dental and 







COPD patients with moderate to very 
severe COPD 
Markov EVPI, EVPPI I, II & II, III & IV & V Boehringer Ingelheim 
International and Pfizer Global 
Pharmaceuticals 
Palmer, 2016(240) UK Joint hypermobility 
syndrome 
People with JHS Markov EVPI IV, V NIHR HTA Programme 
Pandor 2011 (197) UK Minor Health Injury Patients with MHI Decision 
tree 
EVPI I, II, III NIHR HTA Programme 
Pei 2015 (237) USA HIV Patients initiating ART Markov EVPI I, II, III National Institute of Allergy and 
Infectious Diseases of the 
National Institutes of Health, 
NIH 
Petrou 2015 (227) Cyprus Renal Cell 
Carcinoma (RCC) 
People with RCC who have been 
previously treated with Sunitinib 
or cytokines 
Markov EVPI I, II, III Not mentioned 
Philips 2006 (249) UK NSTEACS Patients at high risk of NSTEACS Decision 
tree; 
Markov 
EVPI, EVPPI I, II, III & III NIHR HTA Programme 
Purmonen 2011 
(223) 
Finland Breast cancer HER2 positive patients aged 50 
years 
Markov EVPI, EVPPI IV, V, III Yrjö Jahnsson Foundation and 
Pharma Industry 




EVPI I, II, III Elision Health Ltd. 
67 
Table 3-1 (continued) 
Author, year Country Disease or 
condition 
Study population Model type VoI analysis 
type 
Stage of iterative 
evaluation included* 





Head and neck 
cancer 
Patients with advanced head and neck 
cancer 
Markov EVPI I, II, III No funding received 
Robinson 2005 
(250) 
UK NSTEACS patients with non-ST elevation ACS over 
a period of 50 years 
Decision tree, 
Markov 
EVPI I, II, III NIHR HTA Programme 
Rodgers 2008 
(253) 
UK AF refractory Adults with AF refractory Decision tree, 
Markov 
EVPI, EVPPI I, II, III NIHR HTA Programme 
Rogowski 2009 
(254) 
UK NSTEACS Patients with NSTEACS Decision tree, 
Markov 
EVPI I, II, III NIHR HTA Programme 
Simpson 2014 
(77) 
UK Peripheral arterial 
occlusive disease 
(PAD) 
Patients with symptomatic PAD suitable 
for endovascular treatment for disease 
distal to the inguinal ligament. 
Discrete event 
simulation 
EVPI I, II, III NIHR HTA programme 
Singh 2008 (84) Canada Chest pain Patients presenting to emergency 
departments with chest discomfort. 
Decision tree EVPI I, II, III Funding not received 
Soares 2012 
(81) 




EVPI I, II, III NIHR HTA Programme 
Soeteman 2017 
(242) 
USA Stroke Patients suffering from stroke aged ≥45 
years 
Markov EVPI, EVPPI, 
EVSI, ENBS 
I, II & II, III American Heart Association 
Speight 2006 
(241) 
UK Oral cancer hypothetical population over the age of 
40 years 





UK Fractures Cohort of osteoporotic women Individual 
patient model 





Table 3-1 (continued) 
Author, year Country Disease or 
condition 




Stage of iterative 
evaluation included* 
Source of funding 
Stevenson 2009 
(263) 
UK Osteoporosis Osteoporotic women Not clear EVSI I, II, III the UK National Coordinating Centre 





UK Postnatal depression Women with postnatal depression Not clear EVPI, EVPPI I, II, III NIHR 
Tappenden 2004 
(75) 
UK Multiple Sclerosis 
(MS) 
Patients with MS Markov EVPI I, II, III HTA programme 
Thariani 2013 
(261) 
USA Breast cancer Women undergoing surveillance 
after completion of primary breast 
cancer therapy for early-stage 
breast cancer 
Not clear EVSI I, II, III Centre for Comparative Effectiveness 
Research in Cancer Genomics, NIH 
Ting 2015 (225) USA Non-small cell lung 
cancer 
Patients with advanced EGFR 
mutation-positive NSCLC 
Markov EVPI, EVPPI I, II, III No funding received 
Tuffaha 2014 (80) Australia Peripheral arterial 
catheter 
Adult surgical patients admitted to 
post-operatively to the ICU who 






IV, V National Health and Medical 
Research Council, Australia 
Tuffaha 2015 
(193) 
Australia Elective caesarean 
section 






I, II, III National Health and Medical 
Research Council, Australia 
Tuffaha 2015 (78) Australia pressure ulcers Hospitalised patients who are at 
risk of pressure ulcer and 





I, II, III National Health and Medical 
Research Council, Australia 




EVPI I, II, III HTA Programme 




Pregnancy Women with 33 weeks gestation Decision 
tree 
EVPI I, II, III Dutch Association for Acupuncture 
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Table 3-1 (continued) 
Author, year Country Disease or 
condition 




Stage of iterative 
evaluation 
included* 
Source of funding 
Wailoo 2008 
(196) 
UK Influenza Healthy patients with influenza Decision 
Tree 
EVPI, EVPPI I, II, III NICE and the NHS HTA Programme 
Wallner 2016 
(226) 
Canada Type 1 diabetes Cohort of T1DM patients who met 
the transplantation criteria 
Markov EVPI, EVPPI I, II, III Stem Cell Network grant, a 
Collaborative Research and Innovation 
Opportunities grant by Alberta 
Innovates Health Solutions and salary 
support: Capital Health Endowed Chair 
in Emergency Medicine Research and 
the Faculty of Medicine & Dentistry 
from the University of Alberta (CM). 




EVPI, EVPPI I, II, III Not reported 
Wilson 2013 
(251) 
UK Pigmented skin 
lesions 
45-year-old patient with one 




EVPI, EVPPI IV, V, III NIHR School of Primary care Research 





EVSI IV, V, III Centre for Comparative Effectiveness 
Research in Cancer Genomics 
(CANCERGEN) 
Note: 





The majority of studies identified in this review reported VoI as a measure of quantifying 
decision uncertainty and to inform future research priorities or design an optimal trial. The 
most common types of VoI methods used were EVPI and EVPPI (n=74) and only 15 (17%) 
studies used EVSI. When mapped within the five steps of the iterative framework in 
economic evaluation, only two studies followed all the five steps in sequential order. From 
the analysis, it still appears that the wide adoption and application of VoI approach in 
healthcare is still limited as most of the studies do not proceed further after identifying 
future research priorities. More than half of the included studies (n=46) used VoI to inform 
future research focus by using EVPPI. 
For those studies (n=68) that reported the first 3 steps of the iterative framework (i.e. pre-
trial economic model) and set research priorities, the citation search was not able to 
capture follow-up studies. It may be possible that these studies received further funding 
to carry out primary research, but the results are not published yet. For example, Lewis et 
al. (191) performed an economic evaluation alongside a pilot trial evaluating gabapentin 
in chronic pelvic pain management (GaPP1). They used a decision tree to combine trial 
data with evidence from published sources and performed VoI analysis. The VoI 
suggested the feasibility of a future large multicentre RCT to determine the efficacy of 
gabapentin in the management of chronic pelvic pain in women. Subsequently, the 
investigators secured funding to perform a large multicentre, double-blind RCT, but the 
results are not available yet (279). For other studies, it could be that they were not 
successful in securing funds because such funding and research prioritisation decision, 
in general, are often based on the opinions, judgements and consensus of experts on 
research panels evaluating the scientific merit and relevance of research proposals 
(85,280). 
The 15 studies that reported EVSI were published after 2007 with the majority (n=10, 
66%) published after 2011 reflects the advances in computing and VoI methods in recent 
years (281). Most of the studies started with early indicative studies (pre-trial economic 
model) and suggested that there is value in collecting additional data to reduce decision 
uncertainty. However, it was difficult to locate follow-up publications because such studies 
may result in more than one publications. It is possible that not all VoI analyses were 
identified because of restrictions in search criteria, i.e. published, full-text, English-
language articles. Although reference list of included studies was scanned to identify prior 
study and citation search was done to identify any follow-up studies especially when the 
study recommended future research, it was not easy to locate such studies. Web of 
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Science citation report was used to identify follow-up publications, but the database has 
its own limitation as it doesn’t include all records and often excludes papers that are 
published online ahead of print. Furthermore, this review did not attempt to assess the 
quality of included studies as there are not any validated tools to value studies of research 
prioritisation methods (185). 
This review tried to fill the research gap in verifying how the research priorities identified 
using VoI analysis are being implemented within the iterative framework of economic 
evaluation. Although the iterative framework supports a process of information gathering 
and reducing uncertainty in decision making, from the reviewed studies, it seems that the 
use of this approach in healthcare, in general, is still limited. 
3.6 Chapter summary 
This chapter introduced the iterative framework in the context of economic appraisal. This 
framework incorporates decision analytical modelling, probabilistic and VoI analyses to 
inform the adoption and research priority setting decision on an iterative basis. The review 
on the use of VoI methods within the iterative framework provided an insight on how the 
method has been used in real life economic evaluations. The remainder of the thesis 
presents an application of the proposed iterative framework for the case study considering 
the cost-effectiveness of BIs to promote physical activity. Chapter 4 presents the decision 
analytic model and evidence synthesis and estimates the cost-effectiveness and VoI 
analysis of BIs given current information. Chapter 5 considers the designing of the VBI 
study following an iterative approach, reconsiders the cost-effectiveness of VBIs as the 
evidence base evolves following the publication of the first trial data. Chapter 6 presents 
a reflection relating to the application of iterative framework and concludes by discussing 




Chapter 4 Estimating the cost-effectiveness of brief 
physical activity interventions 
4.1 Introduction 
The purpose of this chapter is to outline the modelling approach to establish a link between 
physical activity (PA), health consequences/effectiveness, and cost-effectiveness of brief 
interventions in PA promotion. This chapter corresponds with stages 2 and 3 of the 
iterative approach (as described in Chapter 3, section 3.3) in economic evaluation, 
involving the development of a decision analytic model-based on existing evidence to 
undertake an economic evaluation of (very) brief physical activity interventions. This will 
determine whether the very brief interventions in PA promotion are cost-effective, or 
whether further research is needed to make a more informed decision. It builds on the 
systematic review of existing evidence on effectiveness and cost-effectiveness of brief PA 
interventions presented in Chapter 2 and aims to estimate the cost-effectiveness of VBIs 
in PA promotion using a modelling approach based on the best available evidence. 
The first section describes the decision problem followed by several sections describing 
the methodological development of the model. This includes decisions regarding specific 
model structure, modelling techniques, type of model inputs including baseline population. 
This is followed by the methods used to calibrate the decision model and finally presents 
the results from the first iteration of the model. This chapter provides the theoretical 
framework for the remaining chapters of this thesis. 
4.2 The decision problem 
Physical inactivity is the fourth leading cause of mortality worldwide (282). It leads to an 
increased risk of developing over twenty health conditions including coronary heart 
disease (CHD), cancer, stroke and type 2 diabetes (87,89,90,283,284). Physical inactivity 
is also associated with a considerable economic burden, which accounts for 1.5% to 3% 
of total direct healthcare costs in developed countries (92). In 2006-07, the direct cost to 
the UK National Health Service (NHS) for treating the consequences of physical inactivity 
was estimated at £0.9 billion (285). When other costs such as the value of 
morbidity/premature mortality-related lost productivity are included, the annual cost of 
physical inactivity in England is estimated at £8.2 billion, with an additional £2.5 billion for 
the contribution of physical inactivity to obesity (87). 
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Physical activity interventions delivered in a primary care setting are effective in increasing 
activity levels (94,101) and are considered cost-effective (97,98). A recent systematic 
review of evidence on the effectiveness of brief advice in PA indicated that such 
interventions are effective in improving PA participation compared with usual care (100). 
Although brief interventions are considered highly cost-effective in other domains of public 
health, such as smoking cessation and alcohol misuse (107-109), little economic evidence 
exists about their cost-effectiveness in physical activity (121,149). 
The NHS health check (114) provides an ideal opportunity to deliver brief advice or other 
brief interventions to a larger proportion of the population. Very brief interventions to 
increase physical activity are likely to be beneficial for all adults aged 40-74, the target 
age group for the NHS health check in England (115,119). The latest Health Survey for 
England (118) indicated that the majority of 40-74 year olds do not meet the new 
guidelines for aerobic activity (at least 150 minutes per week of moderate PA, 75 minutes 
per week of vigorous PA or an equivalent combination of the two, in bouts of 10 minutes 
or more). Moreover, the proportion of people meeting these guidelines decreases with 
age. Compared with more complex PA interventions, VBIs could be easily integrated into 
the routine health check and are inexpensive to implement on a large scale. While (very) 
brief interventions may have a small effect, over a large population, this could translate 
into a significant public health benefit. 
This study aims to investigate whether there is evidence for cost-effectiveness for VBIs in 
PA promotion in the primary care in the UK. 
4.2.1 Interventions and comparators 
The three classes of BIs were identified from the review of effectiveness evidence 
(Chapter 2). They are: 
a) Use of pedometers: Pedometer as a motivational tool, goal setting (e.g. walking 10,000 
steps/day for five times a week), in some cases participants received individual 
exercise feedback (walking plus feedback) 
b) Advice or counselling: Brief advice or counselling on PA delivered by health 
professionals, face to face or by phone or both 
c) Action planning interventions: Participants formulate their action plan in the format of 
what, when and where (time, place and number of minutes), record their intention on 
PA in the logbook or calendar 
74 
All three interventions were compared against usual care, i.e. no additional intervention. 
These BIs aim to increase individual’s activity level by increased participation in PA. 
4.2.2 Population 
The study population included the NHS health check population, i.e. all people aged 
between 40 and 74 years in England, who have not been previously diagnosed with 
diabetes, hypertension, chronic heart or kidney disease (114). 
4.2.3 Perspective 
The costs and benefits (quality-adjusted life-years gained) of each VBI were assessed 
from the perspective of the UK NHS. The NHS and Personal Social Services (PSS) 
perspective was chosen because the study was conducted in the NHS context (primary 
care setting) and the NICE recommends in adopting a healthcare perspective (2). 
4.3 Use of modelling techniques in the economic evaluation 
Physical activity interventions have a range of both short (e.g. improvements in the mood) 
and long-term health benefits (51). It may be difficult to measure long-term benefits of PA 
from a single study (i.e. prospective study). To make an informed decision to adopt a given 
very brief PA intervention, a long-term assessment of costs and health effects must be 
made to capture all relevant differences in costs and health effects. RCTs usually have 
too short follow-up to measure this, and this often requires a modelling component to 
estimate the overall change in health-related quality and quantity of life as a result of a 
change in activity level. 
Decision analytic models synthesise relevant data available from a variety of sources and 
facilitate in evaluating complex processes associated with the implementation of health 
interventions (286). They are useful to extrapolate primary data beyond the short-term 
endpoint of a trial (46), inform research planning and design, characterising and 
presenting decision uncertainty given existing information (287). Decision analytic models 
in cost-effectiveness analysis establish the most cost-effective interventions in the context 
of uncertainty about the future states of the world (59). It provides an analytical framework 
that represents a decision problem explicitly, combines evidence from a range of sources 
and facilitates the extrapolation of cost and health effects over time and between patient 
groups and clinical settings (288). The process of developing a decision model is more of 
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an iterative process which starts with developing a conceptual model, followed by 
synthesis of available evidence to populate the model then revision of the model. 
4.4 Model design and development 
The two sections above described the decision problem and the use of modelling 
techniques in the economic evaluation of brief PA interventions. This section describes 
the review of existing evidence to inform and structure the model, selection of diseases 
(model boundary) and the type of model used. 
4.4.1 Informing and structuring the decision model 
4.4.1.1 Review of evidence concerning physical activity and health  
A literature search was carried out in order to synthesise the evidence available 
concerning PA and health. A search on PubMed was carried out using keywords and 
MeSH terms covering the literature published up to January 2015. The search combined 
physical activity with chronic conditions namely cardiovascular, cancers, mental health as 
well as with musculoskeletal conditions. These disease conditions included in this search 
were identified from the model-based economic evaluations (Chapter 2) that modelled the 
impact of PA on chronic conditions, and the Department of Health report examining the 
impact of PA and its relationship with health (87). The search results were limited to 
English language publications. The search identified existing systematic reviews, and only 
reviews were included using the review filter under ‘Article types’. These were systematic 
reviews and meta-analyses of both prospective and controlled studies examining the 
effects of PA on health. Once the systematic reviews and meta-analysis examining the 
link between PA and many chronic conditions were identified, another literature search 
was performed using the same method to investigate the association between PA and 
risk factors. For this, keywords related to chronic conditions were replaced by risk factors 
namely cholesterol level, blood pressure, and glycated haemoglobin. In particular, the 
interest was on the, if PA influences risk factor values, how the intensity, duration and 
energy expenditure of exercise may or may not influence these risk factors (biomarkers).  
The pooled evidence from meta-analyses of well-designed RCTs as well as prospective 
studies is summarised in Table 4-1. 
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Table 4-1: Health benefits of PA in adults 
Measures Study details Physical activity Impact of PA on measures Source 
All-cause 
mortality 
Systematic review and meta-analysis of 80 cohort studies 
with 1,338,143 participants (118,121 deaths) examining 
the association of domain-specific PA with all-cause 
mortality 
Higher vs lower 
activity level 
RR of 0.74 for leisure activity, RR for 1-hr 
increment per week for vigorous and 
moderate activity were 0.91 and 0.96 
respectively 
Samitz et al. 
(289) 
Total cholesterol Meta-analysis of studies examining the effect of exercise 
on lipids and lipoproteins in adults aged ≥50 years, mean 
age 63 years,  
Aerobic exercise 
(walking, jogging)  
Decrease in total cholesterol by 3.3 (-6.5 to 
-0.02) mg/dL i.e.  
Kelly et al. (290) 
HDL cholesterol Meta-analysis of 25 RCTs examining the effect of PA on 
HDL-C level, mean aged varied between 23 and 75 years 
Aerobic exercise Mean net change (increase) by 2.53 (1.36–
3.7) mg/dL  
Kodama et al. 
(291) 
HbA1c Systematic review and meta-analysis of 47 RCTs 
assessing PA on HbA1c in diabetic patients 
Structured exercise 
(≥150 min/wk) vs 
no exercise (usual 
care) 
Decline in HbA1c level by 0.67% (-1.26% to 
-0.51%) 






Meta-analysis of 54 RCTs with 2,419 participants, mean 
age between 21 and 79 years, the sample included both 
normotensive and hypertensive patients 
Aerobic exercise Decrease in SBP by 3.84 (-4.97 to -2.72) 
mmHg; -4.94 and -4.04 mmHg in 
hypertensive and normotensive samples 
respectively  
Whelton et al. 
(293) 
CHD Meta-analysis, nine prospective cohort studies had 
quantitative estimates and included in the dose-response 
analysis, average age ranged from 43 to 67 years 
150 min/week of 
moderate-intensity 
PA vs no PA 




Table 4-1 (continued) 
Measures Study details Physical activity Impact of PA on measures Source 
Stroke Meta-analysis of 23 prospective studies examining the 
association between PA and stroke incidence or mortality 
High activity vs 
low activity or 
sedentary 
27% lower risk of stroke incidence or 
mortality (RR of 0.73 (0.67 to 0.79) 
Lee et al. (295) 
Type 2 diabetes Meta-analysis of 9 prospective cohort studies, average 
age ranged from 35 to 75 
Moderate 
intensity PA (~11 
MET h/week) vs 
no PA 
17% lower risk (RR: 0.83, 0.76 to 0.90) Jeon et al. (296) 
Cancers     
Breast cancer 
(female) 
Meta-analysis of prospective cohort studies with average 
follow-up of 5 to 20 years, participant aged ≥30 years 
Most active vs 
least active 
13-17% lower risk; 3% decrease in breast 
cancer risk for every 10 MET-h/week 
increment; 6% lower risk for each additional 
hour of PA 
Monninkhof et 
al. (297), Wu et 
al. (298) 
Colon cancer Meta-analysis of 28 cohort studies, 30-50 year olds Most active vs 
least active 
RR of 0.83 (0.78 to 0.88) Wolin et al. 
(299) 
Lung cancer Meta-analysis of prospective cohort studies Moderate PA vs 
sedentary or no 
activity 
18% (13 to 23%) lower risk Buffart et al. 
(300) 
Renal cancer Meta-analysis of 14 cohort studies,  Moderate to 
vigorous PA vs no 
or sedentary 
activity 




Table 4-1 (continued) 
Measures Study details Physical activity Impact of PA on measures Source 
Mental health 
Dementia Systematic review and meta-analysis of 11 cohort studies, 
≥30 years 
Highest PA category 
vs lowest category 
RR of 0.72 (0.60 to 0.86) Hamer & Chida 
(302) 
Depression A meta-analysis that converted the overall effect sizes of 3 
meta-analyses (37 studies) on the effect of PA on 
depression to binomial effect size  
Running and walking 
or other aerobic 
activity 
Increased success rate to 67-74% 
reduction in depressive symptoms 
Craft & Perna 
(303) 
Musculoskeletal 
Osteoporosis Meta-analysis of 13 prospective cohort studies Moderate to vigorous 
PA 
Hip fracture reduction of 45% (31-56%) and 
38% (31-44%) in men and women 
respectively 
Moayyeri (304) 
Osteoarthritis Meta-analysis of 13 RCTs examining the efficacy of 
aerobic walking and home based quadriceps 
strengthening exercise in patients with knee arthritis, 




Pooled effect (mean difference of score) 
sizes for pain were between 0.39 to 0.52, 
and self-reported disability ranged from 
0.32 to 0.46 




Systematic review and meta-analysis of 14 RCTs 
including 1,040 patients, mean age ranged between 44 to 
68 years,  
Aerobic exercise vs 
usual care 
Improved function: SMD of 0.24 (assessed 
by the health assessment questionnaire) 
and SMD for pain on VAS was 0.31 




Meta-analysis of 13 RCTs examining the effect of exercise 
on fall prevention in older adults aged ≥60 years 
Exercise (walking, 
cycling or other 
endurance 
exercises) 
Beneficial effect on the risk of falling, 
adjusted RR of 0.86 (0.75–0.99), the 
number needed to treat 16 




Meta-analysis of RCTs evaluating exercise therapy in a 
population with chronic (>12 weeks duration) low back 
pain 
Exercise therapy Improved pain and function, measured on a 
scale of 100 points, were 5.4 and 0.7 
respectively 
Hayden et al. 
(308) 
Note: RR: relative risk, SMD: standardised mean difference, VAS: visual analogue scale 
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The current evidence suggests a significant beneficial effect of PA on different measures 
on cardiovascular, metabolic, mental illness, cancer and musculoskeletal system 
diseases. Also, these meta-analyses provide dose-response evidence between PA and 
risk factors namely systolic blood pressure, total and HDL cholesterol, and HbA1c. Based 
on the available evidence, a schematic diagram showing the relationship between PA, 
risk factors and chronic diseases was developed. The diagram below (Figure 4-1) depicts 
the relationship between different factors. For example, increased physical inactivity 
increases systolic blood pressure that will result in an increased risk of cardiovascular 
disease. An increase in CVD events leads to an increase in costs and a decrease in quality 
of life. 
 







(osteoporosis, low back 
pain, arthritis etc.) 






BMI Cholesterol levels HbA1c 
Direct link between PA 
and diseases 
Link between different 
factors 
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4.4.1.2 Selection of co-morbidities 
Previous section and Table 4-1 summarised systematic reviews and meta-analyses of 
epidemiological studies of PA which suggested a reduced risk of cardiovascular disease 
(including hypertension, coronary heart disease and stroke), type 2 diabetes, some form 
of cancers, osteoporosis, obesity, falls and fractures, and some mental health problems 
(51,283,284,309). Some of these disease conditions were also included in the model-
based economic evaluation of brief PA interventions as described in Chapter 2. 
Furthermore, Guh et al. (310) provided an estimate of the incidence of each co-morbidity 
related to obesity and being overweight. Their systematic review and meta-analysis 
included prospective cohort studies of the general population in Western countries. 
These studies provided a list of chronic conditions and comorbidities attributable to 
physical inactivity. Regular PA could prevent the occurrences of these chronic conditions, 
i.e. has a beneficial effect. Risk factors such as blood pressure were the key component 
of the causal diagram (Figure 4-1) linking the physical activity and chronic conditions. 
These casual pathways were not available for all the conditions, for example, mental 
health. In addition, how the intensity, duration and energy expenditure of exercise may or 
may not influence these. 
In the ideal, all diseases that are attributable to physical inactivity would be incorporated 
into the model. Including all diseases in a single model requires far greater time to develop 
and evaluate the model. In addition, there need to be a lot of structural assumptions and 
increasing complexity that makes the model unmanageable. From the review of existing 
evidence of physical activity on health, diseases attributable to physical inactivity namely 
coronary heart disease, stroke, type 2 diabetes, and cancers (colorectal, breast, lung and 
kidney) are selected (Table 4-2). 
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Reason for inclusion/exclusion 
Risk factors Include A key component of the casual diagram 
Mental health (anxiety, 
depression)  
exclude The current evidence suggests a beneficial effect 
of PA on mental illness (observational studies). 
However, the relationship between PA and mental 
illness is complex, and the current data are 
insufficient to provide dose-response relationship 
CVD (hypertension, 
ischaemic heart disease, 
myocardial infarction, stroke, 
congestive heart failure) 
Include There is a clear dose-response link between 
physical activity, risk factors and CVD events. 
Also, it has a substantial impact on the costs and 
effects. 
Type II diabetes Include Has substantial impact upon the cost and effects 
Neuropathy Include Key outcomes associated with type II diabetes 
Retinopathy Include Key outcomes associated with type II diabetes 
Nephropathy Include Key outcomes associated with type II diabetes 
Cancers (colorectal, breast, 
lung and kidney) 
Include There are clear links showing the beneficial effect 
of PA on cancers. However, the dose-response 
relationship is not clear for all cancers. Other risk 
factors such as BMI have also impact upon the 
model outcomes, e.g. higher risk of colorectal 
cancer in obese participants.  
Musculoskeletal 
(osteoarthritis, osteoporosis, 
low back pain, rheumatoid 
arthritis, fall prevention) 
Exclude Not possible to quantify dose-response relation 
 
The selection of diseases was based on the data available from previous systematic 
reviews and meta-analyses including the dose-response evidence between PA and risk 
factors (Table 4-3). The incidence of chronic diseases attributable to physical inactivity in 
the UK was also considered. For example, 10.5% of CHD, 13% of type 2 diabetes, 17.9% 
of breast cancer and 18.7% of colon cancer cases are attributable to physical inactivity in 
the UK (284). In addition, the selected chronic diseases had the greatest impact on health 
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4.4.1.3 Review of existing cost-effectiveness models 
A review of existing epidemiological and cost-effectiveness models related to physical 
activity and obesity was undertaken to help inform the model structure. This provided a 
list of disease conditions that had an established dose-response link with PA. The primary 
objective of the review was to evaluate published decision-analytic models in the area of 
physical activity and/or obesity to identify structural assumptions and data sources (inputs 
to the model) potentially relevant to this study. It is also expected that the review would 
highlight key areas of uncertainty and potential data gaps, and identify key input 
parameters requiring additional systematic reviews and/or analysis of primary data. 
Reviewing methods 
A systematic literature search was conducted to identify economic or epidemiologic 
studies or models on comorbidities related to physical activity and obesity. The search 
was performed in Medline (OvidSP), CENTRAL and NHS EED (Cochrane library) 
covering the period until January 2015. In addition, a free text search was performed using 
Google scholar. Web of Knowledge was used for a cross-reference search. The retrieved 
articles were limited to the English language. 
 
Table 4-4: Inclusion criteria for the systematic review 
Criteria Inclusion criteria 
Type of study Modelling with an economic evaluation/pharmaco-economic 
component, or epidemiological models of chronic diseases that have 
established link to physical (in)activity 
Population Adults with or without chronic diseases and conditions (type 2 
diabetes, heart disease, stroke, breast cancer, colorectal cancer, lung 
cancer and kidney cancer) 
Intervention Any physical activity or other interventions for chronic disease 
Outcome of interest All information on the model structure, data inputs, key economic 
evaluation methodology and results, any reported strengths and 
limitations of models used 
The search terms for economic evaluation were adopted from the NHS Economic 
Evaluation Database Handbook (314) and modified to include epidemiological models as 
well. Search terms for diseases were adopted from the specialised register (electronic 
searches) of respective Cochrane group, where available. Details of search terms are 
available in Appendix C1. 
84 
Review results 
In total, 2298 title and abstract records were identified. After screening titles and abstracts, 
38 published papers relating to economic and/or epidemiological models on physical 
activity and obesity co-morbidities were included in the review (Figure 4-2). Table 4-5 
summarises the chronic diseases and complications covered in the models. A summary 
table of the study description, modelling method used, population and setting, type of 
intervention, complications modelled, time horizon and primary outcome measure is 
presented in Appendix C3. 
 
Figure 4-2: Electronic database search results 
Of 38 modelling studies included, 16 were related to type 2 diabetes progression and 
complications (315-330), six circulatory disease (331-336), five PA or lifestyle 
interventions (141,337-340), five breast cancer (341-345), three colorectal cancer (346-
348), two lung cancer (349,350), and one kidney cancer (351). The main data source used 
in these micro-simulation (141,316,318,319,321,324,325,328,329,339), Markov 
(315,317,320,322,323,326,327,330,337,340) and decision tree (338,352) models were 
from the UK Prospective Diabetes Study (UKPDS) (315-319,321,323,325-328), the 
# of records identified 
through database 
searching = 2,298 
# of records after duplicate 
removed = 1,806 
# of potential relevant 
records after abstract 
shifting = 31 
# of records after review by 
title = 117 
# of full-text articles 
available = 24 
# of grey literature, 
citation search papers 
= 14 
# of total articles reviewed = 38 
# of records excluded 
due to irrelevant full 
text = 7 
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Surveillance, Epidemiology, and End Results (SEER) (341-345,349,350), Framingham 
Heart Study (316,327,329), WESDR (320,325,330), CORE-2 (315,323), Finnish Diabetes 
Prevalence study (337,340), cross-sectional surveys in Australia (141), Canadian 
population health survey (339), Health Survey for England (338), KORA study in Germany 
(352), and West of Scotland Coronary Prevention study (WOSCOPS) (321). A summary 
of the main data sources used is presented in Table 4-6. 
Of six circulatory disease models, three were economic models (331-333), two models 
predicted future morbidity, mortality and cost (334,336), and the remaining one (335), an 
epidemiological model investigated the routine use of low dose aspirin. Breast cancer 
cost-effectiveness (341,342) or epidemiological models (343-345) used data from SEER 
programme to either develop or validate their model. Chien et al. (351) reported an 
epidemiological model to estimate chronic kidney disease risk in Chinese population. This 
model, a clinical point base, uses clinical variables and biochemical measures to predict 
the incidence of the disease. Colorectal cancer models enrolled patients over 40 years of 
age. Allen et al. (346) compared four screening strategies, Ladabaum et al. (347) 
compared three, and Loeve et al. (348) compared two screening strategies for colorectal 
cancer. In addition to the 38 modelling studies identified from the database and cross-
referencing search, there were two reviews on economic models in type 2 diabetes(353) 
and simulation models of obesity (354). The commonly reported health and economic 
outcome were life expectancy, long-term costs and QALYs gained, and the incidence of 
chronic conditions. 
The type II diabetes complication models mainly use three complication pathways for 
micro-vascular complications namely retinopathy, neuropathy and nephropathy. The 
structure of the CDC/RTI type II diabetes complication model (317) was based on previous 
models namely UKPDS and the Eastman model (320). Another model used by Chen et 
al. (318) has the same basic structure as the CDC model. 
In these models, the risk of cardiovascular events in the general population is predicted 
using the risk prediction equations based on the Framingham Heart Study. Whereas the 
prediction of cardiovascular events in patients with type 2 diabetes was mainly based on 
the UKPDS risk equations (319). Among the reviewed models of colorectal cancer, 
Frazier’s model (355) appeared to be comprehensive and robust regarding the model 
structure and natural history of disease progression. The breast cancer model by 
Johnston (356) provided a detailed structure of the breast cancer model including 
transitional probabilities of different stages of breast cancer. The data used in this model 
was based on a database from the Professorial Unit of Surgery at the City Hospital, 
Nottingham, UK (357). 
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Table 4-5: Summary of chronic diseases and complications covered 








Cobiac 2009 (141)  x   x   
Galani 2007 (337)  x   x   
Matrix 2006 (338)  x   x   
Nadeau 2011 (339), 
Zucchelli 2010 (358) 
 x    x  
Avenell 2004 (340) x x      
Bagust 2001 (315) x x x     
Brown 2000 (316) x x x x x x x 
CDC /RTI Model (317) x x x x   x 
Chen 2008 (318) x x x x x  x 
Clarke 2004 (319) x x x x x  x 
Eastman 1997 (320,359) x x     x 
Eddy 2003 (321,360)  x x   x  
Habacher 2007 (322)        
Lamotte 2002 (323) x x x  x  x 
McPherson 2007 (324) x x   x   
Muller 2006 (325) x x x x x x x 
Ortegon 2004 (326)        
Palmer 2004 (327) x x x x x x x 
Waugh 2007 (328) x x x  x  x 
Wilson 2005 (329)  x x  x x  
Zhou 2005 (330)  x   x  x 
Icks 2007 (352)        
Barton 2011 (331)  x      
Clegg 2005 (332) x   x    
Hayashino 2007 (333) x x x  x   
Jacobs-van der Bruggen 
2007 (334) 
 x  x    
Nelson 2005 (335)  x   x   
Weinstein 1987 (336)  x x     
Anderson et al. 2006(341)        
Chen 2010 (342)        
Fryback 2006 (343)        
Hanin 2006 (344)        
Noah-Vanhouck 2011 (345)        
Chien 2010 (351) x    x   
Das 2006 (349)        
Marshall 2001 (350)        
Allen 2005 (346)        
Ladabaum 2010 (347)        
Loeve 2000 (348)        
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Table 4-5 (continued) 












Cobiac 2009 (141)        
Galani 2007 (337)        
Matrix 2006 (338)        
Nadeau 2011 (339), 
Zucchelli 2010 (358) 
       
Avenell 2004 (340)        
Bagust 2001 (315) x x x x x x  
Brown 2000 (316) x x  x x x  
CDC /RTI Model (317) x x   x x  
Chen 2008 (318) x   x x   
Clarke 2004 (319) x x x x x x  
Eastman 1997 (320,359) x x  x x x  
Eddy 2003 (321,360)  x   x   
Habacher 2007 (322)   x     
Lamotte 2002 (323)        
McPherson 2007 (324)        
Muller 2006 (325) x x x  x x  
Ortegon 2004 (326)   x x  x  
Palmer 2004 (327) x x x x x x  
Waugh 2007 (328)  x      
Wilson 2005 (329)        
Zhou 2005 (330)  x   x x  
Icks 2007 (352)        
Barton 2011 (331)        
Clegg 2005 (332)        
Hayashino 2007 (333)        
Jacobs-van der Bruggen 
2007 (334) 
      x 
Nelson 2005 (335)        
Weinstein 1987 (336)        
Anderson et al. 2006(341)        
Chen 2010 (342)        
Fryback 2006 (343)        
Hanin 2006 (344)        
Noah-Vanhouck 2011 
(345) 
       
Chien 2010 (351)        
Das 2006 (349)        
Marshall 2001 (350)        
Allen 2005 (346)        
Ladabaum 2010 (347)        
Loeve 2000 (348)        
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Table 4-5 (continued) 













Cobiac 2009 (141) x x    x x 
Galani 2007 (337)      x  
Matrix 2006 (338)  x    x  
Nadeau 2011 (339), 
Zucchelli 2010 (358) 
x x    x x 
Avenell 2004 (340)      x  
Bagust 2001 (315)      x  
Brown 2000 (316)      x  
CDC /RTI Model (317)      x  
Chen 2008 (318)        
Clarke 2004 (319)      x  
Eastman 1997 (320,359)        
Eddy 2003 (321,360)        
Habacher 2007 (322)        
Lamotte 2002 (323)      x  
McPherson 2007 (324) x x x   x x 
Muller 2006 (325)      x  
Ortegon 2004 (326)        
Palmer 2004 (327)      x  
Waugh 2007 (328)      x  
Wilson 2005 (329)       x 
Zhou 2005 (330)        
Icks 2007 (352)      x  
Barton 2011 (331)        
Clegg 2005 (332)      x  
Hayashino 2007 (333)      x  
Jacobs-van der Bruggen 
2007 (334) 
x x x x  x x 
Nelson 2005 (335)        
Weinstein 1987 (336)        
Anderson et al. 2006(341) x      x 
Chen 2010 (342) x      x 
Fryback 2006 (343) x      x 
Hanin 2006 (344) x      x 
Noah-Vanhouck 2011 (345) x      x 
Chien 2010 (351)   x   x  
Das 2006 (349)     x   
Marshall 2001 (350)     x   
Allen 2005 (346)  x      
Ladabaum 2010 (347)  x      
Loeve 2000 (348)  x      
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Table 4-5 (continued) 












Cobiac 2009 (141)  x x x  
Galani 2007 (337)  x    
Matrix 2006 (338)  x x x  
Nadeau 2011 (339), 
Zucchelli 2010 (358) 
x x x   
Avenell 2004 (340) x x x   
Bagust 2001 (315) x x x x x 
Brown 2000 (316) x x x   
CDC /RTI Model (317) x x x x x 
Chen 2008 (318)   x x  
Clarke 2004 (319) x  x x  
Eastman 1997 (320,359) x  x x x 
Eddy 2003 (321,360)  x x x x 
Habacher 2007 (322)    x x 
Lamotte 2002 (323)  x x  x 
McPherson 2007 (324)  x x x  
Muller 2006 (325) x x x x x 
Ortegon 2004 (326)    x x 
Palmer 2004 (327) x x x x x 
Waugh 2007 (328)      
Wilson 2005 (329) x x x   
Zhou 2005 (330) x x x x x 
Icks 2007 (352)      
Barton 2011 (331)  x    
Clegg 2005 (332) x    x 
Hayashino 2007 (333) x x x   
Jacobs-van der Bruggen 
2007 (334) 
x x x x  
Nelson 2005 (335) x x  x x 
Weinstein 1987 (336) x x  x  
Anderson et al. 
2006(341) 
x    x 
Chen 2010 (342) x   x  
Fryback 2006 (343) x   x x 
Hanin 2006 (344) x    x 
Noah-Vanhouck 2011 
(345) 
x   x x 
Chien 2010 (351) x     
Das 2006 (349) x     
Marshall 2001 (350) x     
Allen 2005 (346) x     
Ladabaum 2010 (347) x     
Loeve 2000 (348) x     
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Table 4-6: Summary of main data sources used (available) in the models 
Data Population Follow up Outputs Source 
Cost of diabetes Type II 
in Europe (CODE 2 
study) 
More than 7000 peoples with type 2 diabetes in 8 
European countries, mean age 65.9 years,  
6 months cross-
sectional 
Total medical cost of T2DM (323,340) 
Diabetes Control and 
Complications Trial 
(DCCT) 
1441 Insulin Dependent Diabetes Miletus (IDDM) 
patients recruited at 29 centres from 1983 to 1993, 
age 13-39 years 
Average follow up 
of 6.5 years 






A 5-year prospective double-blinded RCT, 215 
patients from two sites 
5 years Development of diabetes, development 
and/or progression of diabetes-associated 
micro- and macro-vascular complications 
(328) 
Health Survey for 
England (HSE) 
Cross-sectional survey (annual) to measure health 
and health-related behaviours in adults and children 
in England 
- Cardiovascular disease, physical activity, 
accidents, lung function measurement 





Finnish participants aged 40-65 years, BMI 25 or 
higher; Intensive lifestyle intervention 
1993-2013 Type 2 diabetes and cardiovascular risk (340) 
Framingham cohort 
study 
Original cohort of 5,209 respondents of a random 
sample of 2/3 of the adult population of Framingham, 
Massachusetts, 30-62 years of age in 1948 
10 years risk  Risk engines for various cardiovascular 
disease outcomes in different time 





Helsinki Heart Study Middle-aged men (40-55 years) with primary 
dyslipidaemia, 2030 and 2051 (placebo versus 
Gemfiborzil) 
5 years MI (321,323) 
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Table 4-6 (continued) 
Data Population Follow up Outputs Source 
Hoorn study  
The Netherlands 
Initiated in 1989 to study the prevalence and determinants 
of T2DM in general population in the Netherlands. Original 
cohort of 2484 subjects aged 50-75 years old. New Hoorn 
study began in 2006 with 2700 men and women aged 40-
65 years old – younger than the original cohort. 
10 year follow up; 
new follow up 
underway 
Prevalence and risk factors 
of diabetes and 




KORA 4 large studies investigating cardiovascular disease since 
1984, first 3 were part of the MONICA project, since 1996 
the research is continued under the name of KORA. 
Longitudinal and cross-sectional study; inhabitants of 
Augsburg and surrounding counties, age 25-74 (n = 
400,000). 
7 years follow up Prevalence of risk factors 
for cardiovascular and 
other chronic diseases 
(328,352) 
Long-Term Intervention with 
Pravastatin in Ischaemic 
Disease (LIPID) study 
9,014 post-MI or unstable angina patients, the primary 
endpoint of CHD, randomised to pravastatin 40mg or 
placebo, 31-75 years old 
Mean follow up 6.1 
years 
CHD death, fatal or non-
fatal MI, Ischemic stroke 
(321) 
PROCAM (Prospective 
Cardiovascular Munster Heart 
Study) 
More than 30,000 participants aged between 16-65 years 
in Munster and the northern Ruhr area, Germany 
Fixed follow-up 
periods of 8 years; 
multicentre 
Coronary events (non-fatal 
cerebrovascular events and 





and End Results (SEER) 
Programme 
A database that collects complete and accurate data on 
all cancers diagnosed among residents of geographic 
areas covered by SEER cancer registries in the US. Data 
collection began in 1973. Requires SEER*Stat software to 
retrieve/analyse data from the registry 
Regularly updated All Cancers (341-346,348-
350) 
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Table 4-6 (continued) 
Data Population Follow up Outputs Source 
UKPDS Hypertensive patients with type 2 diabetes, 758 / 390 
(studied vs. control) 
8.4 years (median) 
Multicentre 
Stroke, MI, microvascular 
events, retinopathy, vision loss, 





West of Scotland Coronary 
Prevention Study (WOSCOPS) 
Men aged 45-64 yr. with no history of MI and with 




Coronary events (CHD death, 
MI) 
(321) 
WHO Multinational MONItoring 
of trends and determinants in 
CArdiovascular disease 
(MONICA) project 
Established to determine how trends in events for CHD 
and optionally stroke were related to trends in classic 
coronary risk factors. Risk factors monitored across 38 
populations from 21 countries. Total of 69,251 men 
and 69,187 females aged 35-64 years 
10 years (1979-
1996), multicentre 
CHD risk factors – smoking 
status, SBP, TC, BMI 
(335,337) 
Wisconsin Epidemiologic 
Study of Diabetic Retinopathy 
(WESDR) 
Younger-onset T1D (996 people) and older-onset 
persons mostly with T2DM (1370 people) who were 
first examined from 1980 to 1982 in southern 
Wisconsin 
5 follow up 
examination of 
cohort in 1984-86, 
1990-92, 1995-96, 
2000-01, 2006-07 
Complications associated with 
diabetes. Eye complications – 
diabetic retinopathy and visual 
loss, kidney complications – 




Wisconsin Cancer Reporting 
System (WCRS) 
Cancer incidence and mortality in Wisconsin 1995-2008 Cancers (343) 
WHO (CHOosing Interventions 
that are Cost-Effective) 
CHOICE 
Reports the costs and effects of a wide range of health 
interventions in the 14 epidemiological sub-regions  





The reviewed models differed according to the extent and type of interventions they 
evaluated, co-morbidities included and adverse events captured. Most had the same 
fundamental structure, used similar micro-simulation techniques and were based on key 
data sources. Some of the studies included in this review lack transparency around 
assumptions, equations and algorithms used to predict disease incidence, data used to 
calibrate or estimate model parameters, the goodness of fit measures used to calibrate 
data and validate results. Similar types of problems were also reported in other reviews 
(354). 
4.4.1.4 Selection of the type of decision analytic model 
Different types of models can be used in economic evaluation to combine information 
already available and to assess the policy implications for decision making. The 
availability of data plays a greater role in determining a model’s structure (55,56). Brennan 
et al. (56) suggested that in addition to the availability of data, the background skill of the 
researcher and the type of software available also have a considerable role in determining 
the model structure. There are several guidelines for good research practices in modelling 
(55,57-61), and these guidelines focus mainly on transparent structure, appropriate and 
systematic use of evidence, and handling uncertainty. 
The selection of the particular type of model structure and complexity is always a trade-
off between descriptive realism and computational burden and data requirement (63). The 
economic models use two common approaches – aggregate or ‘cohort’ models and 
individual-level models also called patient-level simulation or microsimulation – to 
estimate the expected costs and outcomes (56,58). Microsimulation models use 
mathematical equations to simulate the behaviour of an individual taking into account the 
heterogeneous composition of the target population without focusing on a representative 
or average individual. In other words, the cost and health outcomes are modelled for 
individual patients. 
While in a cohort-level simulation, decision trees or Markov models are frequently used 
(described in section 1.4.3), and the health and cost outcomes are modelled for the cohort 
as a whole. Decision trees are although simpler and useful for short-term analyses; they 
lack an explicit time variable. As the time horizon of the analysis increases, they have 
limited use for modelling complicated disease conditions involving a longer time period 
(61). Markov model overcome with this issue and can deal with the pattern of recurring 
disease over time. They involve a transition between various health states and outcomes 
over time (53). The main limitation with this approach is that they do not account for the 
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history of progression in the model. Markov models could be extended to include the 
history of disease progression, but this requires a load of tunnel states. Furthermore, this 
does not consider the outcomes for individual patients within that cohort. The patient-level 
simulation accounts for variability in all included parameters which can be characterised 
with empirical distribution. The models often used in the economic evaluation are the 
former cohort models. 
From the review of existing chronic disease epidemiological and PA cost-effectiveness 
models, it appeared that a microsimulation approach is feasible and can be considered to 
model the effect of VBIs. The models need to incorporate longer-term consequences of 
VBIs which could be unmanageable in a decision tree. Although cohort Markov model 
would require less computation power, it would not have been possible to include a large 
number of health states and capture individual variability. The advantage of using a 
microsimulation approach is that it facilitates modelling of the behaviour of individuals in 
a complex system (36) and allows individual characteristics to be modelled as continuous 
variables. Although this approach requires significant computational power, this can be 
easily addressed using the R programming language. R is a free and powerful software 
environment for statistical computing and graphics (361). It is known for efficiency in 
coding and memory management that allows flexibility and complex models to be coded. 
In addition, ‘R’ supports parallel computing and the models coded in ‘R’ are more 
transparent because it is script based. 
4.4.2 The model structure 
This section builds on the review of the evidence as outlined in previous sections (4.4.1). 
The identification of the decision problem and the conceptualisation of the decision 
analytic model were informed by reviewing the relationship between PA and health (Table 
4-1). The initial starting point of this process was the review of the obesity cost-
effectiveness model developed by Wilson & Fordham (329). This model simulates a 
cohort of 2,500 patients and estimates the health impact and cost of obesity in Norfolk, 
England over a ten year period and was developed in Microsoft Excel. The effect of a 
(hypothetical) intervention was mediated through the effect on BMI levels. After a review 
of this model, other modelling approaches including a selection of co-morbidities were 
considered because this model considered the effect of intervention only on BMI levels 
and excluded other relevant measures. 
Figure 4-1 outlines the conceptual structure of the model. The simplified schematic of the 
model is depicted in Figure 4-3. As mentioned in the earlier section, a probabilistic model 
using a simulation approach is adopted to model the effect of VBIs in PA promotion. The 
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current model incorporates health benefits of increased physical activity by changes in 
risk factors values. The change in activity level due to VBIs modifies the risk factor values 
such as reduced blood pressure, total cholesterol and HbA1c. Changes in these risk 
factors have implications for diseases and comorbidities. For example, increased physical 
activity lowers systolic blood pressure that will result in a reduced risk of cardiovascular 
disease. 
 
Figure 4-3: A schematic of the physical activity cost-effectiveness model 
In the initial cycle, the model generates a cohort of 10,000 individuals, loads in patient 
cohort, intervention effect (MET-hour increase in PA) and cost of the intervention. The 
simulation estimates yearly changes in metabolic risk factors based on the individual’s 
baseline characteristics and MET-hour increase in PA. Within each annual cycle, 
participants included in the model may develop one of the disease states of interest 
(Figure 4-4). Baseline characteristics and risk factors determine the individual’s probability 
of disease events including cardiovascular disease, type II diabetes, colorectal cancer, 
breast cancer, lung cancer or kidney cancer. For cardiovascular and diabetes, the dose 
response-link between risk factors and disease event is clear (quantifiable). However, it 
was not clear for cancers thus the RR estimates for developing cancers are adjusted for 
the increase in PA (MET-hour). For example, the risk of breast cancer is reduced by 3% 
for every 10 MET-hour increments in PA (298). 
96 
 
Figure 4-4: The simulation process 
In subsequent cycles, the risk factor values were updated based on the values of the 
previous year (t-1), and the future outcomes (morbidity, mortality) including costs and 
QALYs are estimated. 
Table 4-7 compares the VBI model with selected obesity and physical activity models that 
are relevant or applicable to the current decision problem. The VBI model is 
comprehensive in terms of the inclusion of known risk factors and comorbidities related to 
physical inactivity. Previous models (141,150,362,363) used physical activity categories 
(inactive, moderately active, and active) to model the effect of interventions. The current 
model measures PA changes in intensity, duration and frequency, i.e. the metabolic 
equivalent of task (MET). One MET represents the metabolic rate equivalent to consuming 
3.5 millilitres of oxygen per kilogram of body weight per minute and is equivalent to a 
resting metabolic rate (364). For example, moderate intensity activity such as brisk 
walking elicits an intensity of 3 – 6 METs depending on how brisk the walk is. The model 
incorporates METs using a dose-response function as detailed in Table 4-3. The model 
is designed in a modular framework using ‘R’ (361) such that the model can be easily 
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BMI: body mass index; PA: physical activity; HBP: high blood pressure, CHD: coronary heart disease; T2DM: type 2 diabetes mellitus; CVD: cardiovascular disease; IHD: ischemic heart 
disease; MSD: musculosketal disorder; CHF: congestive heart failure; MI: myocardial infraction; HSE: health survey for England; ONS: office for National Statistics UK; BHF: British 
Heart Foundation; YHPHO: Yorkshire and Humber Public Health Observatory; UKPDS: UK perspective diabetes study; FHS: Framingham heart study; TfL: transport for London; CRUK: 
cancer research UK; WESDR: Wisconsin epidemiologic study of diabetic retinopathy; SEER: Surveillance, epidemiologic and end results 
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4.4.2.1 Model parametrisation  
The model requires a cohort of patients to be modelled through the cycles and a set of 
data inputs such as transitional probabilities between health states, morbidity and 
mortality rates, disease costs and utility weights for the health states. The following section 
describes the process used to generate a hypothetical cohort of patients followed by the 
data sources used to estimate disease incidence, mortality, costs and health states utility 
weights. 
Cohort generation 
A cohort of 10,000 patients was generated at random using the UK population distribution 
of parameters (366,367). Firstly, the demographic characteristics of individual participants 
(age, gender, ethnicity) were estimated using data from the Office of National Statistic 
figures for 2011 (366,367). The risk factor profile (systolic blood pressure, total 
cholesterol, HDL cholesterol, BMI, HbA1c and smoking status) and prevalence of type 2 
diabetes and cardiovascular events (IHD, MI, stroke and HF) for individual participants in 
the cohort was generated using data from the Health Survey for England 2011 (368). The 
data sources used in initial cohort generation and covariates and sources for annual 




Table 4-8: Cohort variables  
Parameter Description Source for initial 
cohort generation  
Covariates & sources for annual 
progression / risk equation 
Age, gender 
and ethnicity 
Patient age, gender 
and ethnicity 
ONS (366,367) n/a 
SBP Systolic blood 
pressure 
HSE (368) Age, gender, BMI, smoking, 
T2DM, TC, SBP, MI history, 
physical activity (293,319,369) 
BMI Body mass index HSE (368) Age, gender, BMI (368) 




HSE (368) Age, gender, HDL-C, physical 
activity (291,368) 
TCHDL TC/HDL ratio HSE (368) TC, HDL,TCHDL, T2DM (319) 
HbA1c Glycated 
haemoglobin A1c 
HSE (368) Gender, HbA1c, T2DM, physical 
activity (292,319) 
Smoking Smoking status HSE (368) Age, gender, T2DM,Smoking, 
duration of T2DM (319) 
Antihypertensive Antihypertensive drug 
treatment 
HSE (368) Age, gender, SBP 
AF Atrial fibrillation  Majeed et al (370) 
& NICE (371) 
Age, gender, BMI, SBP, 
Antihypertensive, HF (372) 
IHD Ischaemic heart 
disease 
HSE (368) Age, gender, HbA1c, TCHDL, 
SBP, T2DM, duration of T2DM 
(319) 
MI Myocardial infarction HSE (368) Age, gender, ethnicity, SBP, 
TCHDL, HbA1c, smoking, IHD, 
T2DM, duration of T2DM 
(319,373) 
Stroke Stroke HSE (368) Age, gender, SBP, 
Antihypertensive, T2DM, 
smoking, AF, HF, MI, TCHDL, 
HbA1c, duration of T2DM 
(319,374) 
HF Congestive heart 
failure 
HSE (368) Age, gender, BMI, HbA1c, SBP, 
T2DM, duration of T2DM 
(319,375) 
T2DM Type 2 diabetes HSE (368) BMI, age, gender, physical 
activity (296,329,376,377) 
Retinopathy Diabetic retinopathy WESDR (320) T2DM, duration of diabetes (320) 
Neuropathy Diabetic neuropathy WESDR (320) T2DM, duration of diabetes (320) 
Nephropathy Diabetic nephropathy UKPDS T2DM, duration of diabetes (378) 
Colorectal 
cancer 
Colorectal cancer CRUK (379) Age, polyp size, physical activity 
(312,355,380) 
Breast cancer Female breast cancer Maddams et al. 
(381) 
Age, gender, prognostic groups, 
physical activity (298,356) 
Lung cancer Lung cancer CRUK (379) Age, gender, smoking, physical 
activity (313,382,383) 
Kidney cancer Kidney cancer CRUK (379) Age, gender, T2DM, physical 
activity (296,379,384) 
Note:  
CRUK, Cancer Research UK; HbA1c, glycated haemoglobin A1c; HDL-C, high density lipoprotein 
cholesterol; HSE, Health Survey for England; IHD, ischaemic heart disease; MI, myocardial 
infarction; ONS, office for national statistics; SBP, systolic blood pressure; T2DM, type 2 diabetes; 
TC, total cholesterol; UKPDS, the UK prospective diabetes study; WESDR, Wisconsin 
Epidemiologic Study of Diabetic Retinopathy. 
Source: Adapted from Gc et al. (385) 
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One of the limitations of the baseline cohort is that individual parameter values are 
determined mostly by age and gender that means it does not allow interdependencies. 
For example, obese and older people are more likely to have raised systolic blood 
pressure which the current cohort does not take into account. It would have been more 
appropriate to use data from cohort or cross-sectional studies that would allow 
interdependencies, i.e. considering individual dynamics while generating the starting 
population. An attempt was made to get patient-level data from the EPIC Norfolk study 
investigators so that the data would allow us to generate a baseline cohort taking into 
account the correlation between input parameters. However, the request was not 
successful thus as an alternative source, the HSE data tables, are used to generate the 
baseline cohort. Sensitivity analysis and cross tabulation are done to check if the cohort 
characteristics match with HSE data, and the values appeared to be within the range. 
The following section deals with the data sources used to estimate longitudinal trajectories 
of metabolic risk factors, the probability of disease event and mortality rates. 
Risk factors progression 
Six risk factors – systolic blood pressure, total cholesterol, HDL-cholesterol, BMI (obesity), 
blood glucose (HbA1c) and smoking status are modelled. These risk factors were chosen 
due to their role of being an important cause of chronic conditions of interest. The 
progression of risk factor values in diabetic patients were updated using UKPDS risk factor 
equations (319). Systolic blood pressure values for individuals without a diagnosis of type 
2 diabetes was updated using the regression equation from the Baltimore Longitudinal 
Study of Ageing (369). The annual proportional change in the mean values of the 
remaining risk factors was estimated using HSE data from 2000 to 2011. 
Systolic blood pressure 
A linear-mixed effects model from the Baltimore Longitudinal Study on Ageing (369) was 
used to estimate the changes in SBP in the non-diabetic population whereas the UKPDS 
SBP progression equation was used for the diabetic population. Table 4-9 provides the 





Table 4-9: Coefficient estimates for systolic blood pressure from BLSA 
 Parameter description Mean Standard error 
β1 Constant or average 121.000 0.8599 
β2 Age at first examination 0.398 0.0320 
β3 (age at first examination)2 0.005 0.0016 
β4 Time 0.228 0.0561 
β5 Time2 0.021 0.0053 
β6 Binary variable for CHD event 6.578 1.1290 
β7 Binary variable for BMI (<20) 2.268 1.6510 
β8 Binary variable for BMI (25-29.9) 2.559 0.5785 
β9 Binary variable for BMI (≥30) 0.037 1.2803 
β10 Binary variable for current smoking -0.263 0.6701 
β11 Binary variable for cholesterol (200-239.9 mg/dL) 1.647 0.5024 
β12 Binary variable for cholesterol (≥240 mg/dL) 4.511 0.8058 
β13 Age at first examination × time 0.022 0.0033 
β14 (cholesterol ≥240) × time 0.376 0.1053 
β15 (cholesterol >240) × time2 -0.029 0.0120 
 
The function form of the SBP prediction equation used in non-diabetic population is: 
𝑆𝐵𝑃𝑏𝑙𝑠𝑎 =  𝛽1 + 𝛽2𝑇𝑖𝑚𝑒 + 𝛽3𝑇𝑖𝑚𝑒
2 + 𝛽4𝐹𝐴𝑔𝑒 + 𝛽5𝐹𝐴𝑔𝑒
2 + 𝛽6𝐶𝐻𝐷 + 𝛽7𝐵𝑀𝐼<20
+ 𝛽8𝐵𝑀𝐼25−29.9 + 𝛽9𝐵𝑀𝐼≥30 + 𝛽10𝑠𝑚𝑜𝑘𝑒 + 𝛽11𝑇𝐶200−239.9 + 𝛽12𝑇𝐶≥240
+ (𝛽13𝐹𝐴𝑔𝑒 + 𝛽14𝑇𝐶>240)𝑇𝑖𝑚𝑒 + 𝛽15𝑇𝐶>240 × 𝑇𝑖𝑚𝑒
2 
 
The coefficients used in UKPDS outcome model (319) to predict the changes in SBP 
values in a diabetic population is presented below in Table 4-10. 
Table 4-10: Coefficient estimates for SBP estimated from UKPDS data (319) 
 Parameter description Mean  Standard error 
β16 Intercept 0.03 0.014 
β17 Log transformation of year since diagnosis 0.039 0.008 
β18 SBP score in last period 0.717 0.004 
β19 SBP score at diagnosis 0.127 0.004 










Glycated haemoglobin levels (HbA1c) 
The annual change in HbA1c in the model is estimated using data from HSE. The UKPDS 
HbA1c progression equation (319) was used for the diabetic population (Table 4-11). 
 
Table 4-11: Coefficient estimates for HbA1c from UKPDS data 
 Parameter description Mean  Standard error 
β23 Intercept -0.024 0.017 
β24 Log transformation of year since diagnosis 0.144 0.009 
β25 Binary variable for year after diagnosis -0.333 0.05 
β26 HbA1c score in last period 0.759 0.004 
β27 HbA1c score at diagnosis 0.085 0.004 
𝐻𝑏𝐴1𝑐𝑢𝑘𝑝𝑑𝑠 =  𝐻𝑏𝐴1𝑐𝑡−1 + 𝛽23 + 𝛽24 log(𝑑𝑖𝑎𝑏 𝑦𝑒𝑎𝑟) + 𝛽25𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛𝑦𝑒𝑎𝑟=2
+ 𝛽26(𝐻𝑏𝐴1𝑐𝑡−1 − 7.09) + 𝛽27(𝐻𝑏𝐴1𝑐𝑎𝑡 𝑑𝑥 − 7.09) 
𝐻𝑏𝐴1𝑐𝑡 = 𝑖𝑓 𝑑𝑖𝑎𝑏𝑒𝑡𝑖𝑐 (𝐻𝑏𝐴1𝑐𝑢𝑘𝑝𝑑𝑠) 𝑒𝑙𝑠𝑒 (𝐻𝑏𝐴1𝑐ℎ𝑠𝑒) 
 
Smoking 
The coefficient estimates for smoking status were estimated from the UKPDS data (319). 
Table 4-12: Coefficient estimates for smoking estimated from UKPDS data 
 Parameter description Mean Standard error 
β28 Intercept -4.02 0.236 
β29 year since diagnosis -0.203 0.024 
β30 Age  -0.027 0.008 
β31 Binary variable for female -0.489 0.154 
β32 Binary variable for smoking in last year 1.878 0.211 
β33 Binary variable for smoking at diagnosis 4.879 0.494 
𝑆𝑚𝑜𝑘𝑒𝑡 =  𝛽28 + 𝛽29 × 𝑑𝑢𝑟𝑎𝑡𝑖𝑜𝑛 + 𝛽30(𝑎𝑔𝑒 − 52.59) + 𝛽31 × 𝑓𝑒𝑚𝑎𝑙𝑒 + 𝛽32 × 𝑠𝑚𝑜𝑘𝑒𝑡−1
+ 𝛽33 × 𝑠𝑚𝑜𝑘𝑒𝑎𝑡 𝑑𝑥 
Cardiovascular events 
The Framingham risk equations were used to predict the cardiovascular events in the 
general population (373-375,386). These risk predictions are based on longitudinal follow-
up of CVD events in the US population. There is a CVD risk prediction equation specifically 
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developed for the UK population (the QRISK2) (117) however the QRISK model includes 
patient variables that were not available for the current cohort such as rheumatic arthritis, 
chronic kidney disease and deprivation score. 
Risk factors included in the equations from the Framingham Heart Study such as PR 
interval, prevalence of heart murmur, valve disease and congenital heart disease were 
not simulated in this model; therefore they could not be included in the model to predict 
AF and HF risk. Baseline odds of AF was adjusted to reflect the expected prevalence of 
these risk factors in a UK population. In line with the results from the Whitehall II cohort 
study, PR interval was assumed to be 170ms (387). Based on HSE data, prevalence of 
heart murmur was assumed to be 3.3% (388). The prevalence of valve disease was 
estimated from a population based study in England (389). The prevalence of congenital 
heart disease was estimated from BHF 2003 report (390). Predicted probability of AF was 
calculated using Cox proportional hazards regression coefficients reported in Table 4-13. 
 
Table 4-13: Regression coefficients for the AF risk equation 
Parameter description Mean Standard error 
Age 0.15052 0.05767 
Age² -0.00038 0.00041 
Male sex 1.99406 0.39326 
Body-mass index 0.0193 0.01111 
Systolic blood pressure 0.00615 0.00225 
Treatment for hypertension 0.4241 0.10104 
Heart failure 9.42833 2.26981 
10-year baseline survival 0.96337  
The probability of type 2 diabetes was estimated as a function of age and BMI using a 
regression equation based on the Health Survey for England data (329). The 
macrovascular complications of diabetes namely ischaemic heart disease (IHD), stroke, 
myocardial infarction (MI) and heart failure (HF) were modelled using the UKPDS risk 
equations (319). Details of the risk equation used within the IHD, stroke, MI, heart failure 




Table 4-14: Risk equations coefficients used to estimate the risk of cardiovascular events 
in the general population 
Disease condition Risk equation 
IHD (386) L_chol = β1*Age + β2*TC1+ β3*TC2 + β4*TC3 + β5*TC4 + β6*TC5 + 
β7*HDL1 + β8*HDL2 +β9*HDL3 + β10*HDL4 + β11*HDL5 + β12*SBP1 + 
β13*SBP2 + β14*SBP3 + β15*SBP4 + β16*SBP5 + β17*DIAB + 
β18*SMOK 
A = L_chol – (3.00069 for men; 9.9914136 for women) 
B = e^A 
IHD risk = 1 – [s(t)]^B where s(t) = 0.90015 for men; 0.96246 for women 
Stroke (374) L= β1*Age + β2*SBP+ β3*NEWHRXSBP + β4*MIHx + β5*LVH + 
β6*SMOKE + β7*AF + β8*DIAB 
A = L – (5.6770 for male; 7.6074 for female) 
B = e^A 
Stroke risk = 1 –[S(t)]^B 
MI (373) mu.hat = 11.4712 +10.5109*female - 0.7965*log(age) – 5.4216 
*log(age)*female + 0.7101*log(age)^2*female – 0.6623*log(SBP) – 0.2675 
* smoke – 0.4277 *log(TC/HDL) – 0.1534*diab – 0.1165*diab*female – 
0.1588 *LVH*male 
sigma.hat = e^(3.4064 – 0.8584 * mu.hat) 
v.hat = e^((log(1) - mu.hat)/sigma.hat) 
Mi risk = 1 – e^(-v.hat) 
Heart failure (375) x = α + β1*Age/10 + β2*SBP/20 + β3*Diabetes +β4*BMI  
heart failure risk = 1/ (1 + exp(-x)) 
 
Table 4-15 presents the parameter coefficients used in IHD risk equation (386). 
Table 4-15: Covariates used in IHD risk equation 
Abbvr Parameter Variable Men Women 




TC1 β2 <160 -0.65945 -0.26138 
TC2 β3 160-199 Ref Ref 
TC3 β4 200-239 0.17692 0.20771 
TC4 β5 240-279 0.50539 0.24385 




HDL1 β7 <35 0.49744 0.84312 
HDL2 β8 35-44 0.2431 0.37796 
HDL3 β9 45-49 Ref 0.19785 
HDL4 β10 50-59 -0.05107 Ref 
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Table 4-15 (continued) 
Abbvr Parameter Variable Men Women 




SBP1 β12 Optimal -0.00226 -0.53363 
SBP2 β13 Normal Ref Ref 
SBP3 β14 High normal 0.2832 -0.06773 
SBP4 β15 Stage I hypertension 0.52168 0.26288 
SBP5 β16 Stage II-IV hypertension 0.61859 0.46573 
 
β17 Diabetes 0.42839 0.59626 
 
β18 Smoker 0.52337 0.29246 
  
Baseline survival [s(10)] 0.90015 0.96246 
 
Table 4-16 reports the coefficient estimates for risk of stroke from Framingham Heart 
Study (374). The probability of an event was calculated from the survival function at one 
year raised to the power of B where B is the exponential of sum product of coefficients 
(Table 4-16) multiplied by the individuals’ characteristics. One year survival probability 
[S(t)] for male and female are 0.9948 and 0.9977 and mean values (M) for men and 
women are 5.6770 and 7.6074 respectively. 
The equation for the probability of stroke event in year t is calculated as 𝑝 = 1 − 𝑆(𝑡)𝐵, 
𝐵 = ∑ 𝛽𝑋 
Table 4-16: Coefficient estimates for risk of stroke by gender 








Age 0.0488 0.0103 0.0699 0.0089 
Systolic blood pressure 0.0152 0.0031 0.0161 0.0024 
newHRxSBP 0.00019 0.0001 0.00026 0.00007 
Prev diagnosed CHD, CF or 
intermittent claudication 
0.546 0.0151 0.4404 0.1462 
Binary variable for left 
ventricular hypertrophy 
0.7864 0.2846 0.8055 0.2429 
Binary variable for cigarette 
smoking 
0.5224 0.1429 0.5419 0.1453 
Binary variable for atrial 
fibrillation 
0.5998 0.3011 1.1173 0.2302 
Binary variable for diabetes 
mellitus 
0.3429 0.1894 0.5604 0.1706 
newHRxSBP = HRx (dummy variable defined as one if the individual is on 
antihypertensive medication and 0 if not) × (SBP – 100) × (SBP – 200). 
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The risk of heart failure in the general population was calculated using regression 
coefficients reported in Table 4-17 as 𝑝 = 1/(1 + exp(−𝑋𝑏𝑒𝑡𝑎)) where Xbeta is the sum 
of intercept and sum product of regression coefficients reported in Table 4-17 multiplied 
by the individual’s characteristics (i.e. value of risk factor). 
Table 4-17: Regression coefficients estimates for HF risk prediction in general population 




Intercept -9.07269629 -10.6277 
Age 0.0412 (0.072) 0.0503 (0.078) 
Systolic blood pressure 0.00804 (0.061) 0.00337 (0.057) 
Diabetes 0.2244 (0.0174) 1.3857 (0.185) 
BMI  0.0578 (0.014) 
Table 4-18 lists the risk equations used along with coefficients used to estimate the risk 
of type 2 diabetes and complications mainly IHD, MI CHF and stroke. 
 
Table 4-18: Risk equations coefficients used to estimate the risk of type 2 diabetes and 
risk and cardiovascular events in the diabetic patient 
Disease Risk equation 
Diabetes (329) Risk of type 2 diabetes = (-853.08 + 1.415 * age + 36.616 * 
bmi)/100,000 for male; (-997.312 + 0.279 * age + 43.868 * 
bmi)/100,000 for female 
IHD (319) β = -5.31 + 0.031 * (age at diagnosis - 52.59) - 0.471 * sex + 0.125 
* (HbA1ct - 7.09) + 0.098 * ((SBPt - 135.09) / 10) + 1.498 * (ln (tcHDLt 
) - ln (5.23)) 
 
IHD risk = e^β * year^1.150 * BMI Risk Factor * CV Risk Factor } 
MI (319) β = -4.977 + 0.055 * (age at diagnosis - 52.59) - 0.826 * sex - 1.312 
* ethnicity + 0.346 * smoking + 0.118 * (HbA1ct - 7.09) + 0.101 * 
((SBPt - 135.09) / 10) + 1.190 * (ln (tcHDLt ) - ln (5.23)) + 0.914 t t t 
1.257 * IHD Event Occurred + 1.558 * CHF Event Occurred  
 
MI risk = e^β * year^1.257 * BMI Risk Factor * CV Risk Factor  
CHF (319) β = -8.018 + 0.093 * (age at diagnosis - 52.59) + 0.066 * (BMIt - 
27.77) + 0.157 * (HbA1ct - 7.09) 0.114 * ((SBPt - 135.09) / 10)  
 
CHF risk = eβ * year1.711 * BMI Risk Factor * CV Risk Factor  
Stroke (319) β = -7.163 + 0.085 * (age at diagnosis - 52.59) - 0.516 * sex + 0.355 
* smoking + 0.128 * (HbA1ct - 7.09) + 0.276 * ((SBPt - 135.09) / 10) 
+ 0.113 * (ln (tcHDLt ) - ln (5.23)) + 1.428 * AF + 1.742 * CHF Event 
occurred 
Stroke risk = eβ * year1.497 * BMI Risk Factor * CV Risk Factor Risk  
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Microvascular complications of type 2 diabetes 
The model structure for microvascular complications of diabetes was informed by the CDC 
and Eastman models (320). If diabetes is not treated, it can lead to an increased risk of 
developing a number of different health problems. Sustained high glucose levels are 
associated with damage to blood vessels, nerves and organs. These microvascular 
complications were chosen because they are the key outcomes of type 2 diabetes (as 
described in section 4.4.1.2). This section describes the three sub-modules of type 2 
diabetes complications, i.e. diabetic nephropathy, retinopathy and neuropathy. 
Transitional probabilities and hazard rates were taken from Eastman et al. (320,391) to 
model the natural history of diabetic retinopathy and neuropathy. 
Diabetic retinopathy 
Based on the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR), it is 
assumed that twenty per cent patients with type 2 diabetes have background retinopathy 
(BDR) at the time of the first diagnosis of diabetes.(392) The retinopathy model includes 
five health states – no retinopathy, non-proliferative retinopathy (BDR), proliferative 
Retinopathy (PDR), significant macular oedema (ME), and blindness. 
 
Figure 4-5: Diabetic retinopathy health states 
Progression to a health state within retinopathy module is dependent on the current health 
state and duration of diabetes. Annual transitional rates for the different stages of 
retinopathy (378) were taken from the WESDR study (Table 4-19). 
Diabetic neuropathy 
Diabetic neuropathy is the damage to peripheral nerves in the body that is associated with 
sustained high blood sugar levels from diabetes. The natural history model includes 
normal (no neuropathy), symptomatic neuropathy, first lower-extremity amputation (LEA), 







Figure 4-6: Diabetic neuropathy health states 
The hazard rates of diabetic neuropathy depend on the duration of diabetes were taken 
from Eastman et al. (320) (Table 4-19). 
 
Table 4-19: Annual transitional rates through the different stages of retinopathy and 
neuropathy 
Characteristics Duration of diabetes Hazard rate (per year) 










Proliferative diabetic retinopathy 





Condition Hazard rate (per year) 




Progression of ME to blindness Untreated 0.05 
Treated 0.033 
Diabetic neuropathy   
Progression to diabetic neuropathy All durations 0.0144 
Progression to first lower-extremity 
amputation (LEA) 
1–8 0.028 
 9—13 0.0350 
 14—19 0.0467 
 20+ 0.14 
 12—20 0.0385 
 21+ 0.074 
Second LEA subsequent to the first 
LEA 













The prevalence data for diabetic nephropathy, i.e. development of microalbuminuria were 
based on the UKPDS data (Table 4-20) and include pre-specified renal outcomes in newly 
diagnosed diabetes (378). 
 
Figure 4-7: States and transition probabilities in diabetic nephropathy 
The health states modelled for diabetic neuropathy include micro-albuminuria, macro-
albuminuria, and end-stage renal disease (ESRD). The values presented in Table 4-20 
are annual transition rates and 95% CI levels. 
 













































The breast cancer model starts by estimating the number of women aged 50 years and 
above. From this group, a proportion of women receive a diagnosis of breast cancer. For 
those with breast cancer, disease severity is classified according to the Nottingham 
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good, moderate and poor.(393) The annual transition probabilities by different prognostic 
groups and recurrences and death (Table 4-21) were adopted from Johnston (356). 
 
Figure 4-8: Health states for breast cancer 
 
Table 4-21: Annual transition probabilities of breast cancer differing by prognostic group 
Transition/Prognostic 
groups 
DCIS Excellent Good Moderate Poor 
Annual transition probabilities by prognostic groups 
BCD to LR 0.0044 0.0015 0.0069 0.0110 0.0279 
BCD to RR 0.0054 0.0045 0.0080 0.0155 0.0257 
BCD to DR 0 0 0.0074 0.0155 0.0764 
BCD to dead (breast cancer) – age-specific 
50 – 59 years 0 0.0039 0.0097 0.0602 0.2770 
60 – 69 years 0 0.0051 0.0100 0.0837 - 
70 – 79 years 0 0.0061 0.0112  - 
80 – 89 years 0 0.0069 0.0121 - - 
90 – 99 years 0 0.0073 0.0132 - - 








Local recurrence - 0.400 0.2258 0.2152  
Regional recurrence - - 0.2258 0.2438  
Distal recurrence - - - 0.7450  
Note:  
BCD, breast cancer diagnosed; LR, local recurrence; RR, regional recurrence; DR, distal 
recurrence; DCIS, ductal carcinoma in situ 














Colorectal cancer (CRC) is the fourth most common form of cancer in the UK, where 
approximately 41,700 new cases of CRC diagnosed each year, resulting in around 16,000 
CRC-related deaths annually (379) and the risk depends on increasing age. The baseline 
parameter values were derived from Frazier et al. (355) and applied to the baseline 
population to generate prevalence of CRC. The model simulates the evolution of cancer 
from normal epithelium to adenomatous polyp to cancer. Person representative of the 50-
year-old are placed into health states defined by the presence of polyp (380) or cancer 
(Table 4-22). 
 
Table 4-22: Baseline parameter values and transitional probabilities for colorectal cancer 
Variables Value (range) 
Baseline data  
Normal epithelium 0.78875 
Prevalence of polyps at age 50 (low risk) 0.206 
High-risk polyps 0.004 
Colorectal cancer – localised (early) 0.001 
Colorectal cancer – regional (regional) 0.0002 
Colorectal cancer – distant (advanced) 0.00005 
Prevalence of polyps at age 50 years, % 21 (11-42) 
Proportion of polyps at age 50 years that are of high risk % 2 (1-10) 
Annual transition probabilities  
Normal epithelium to low-risk polyp  
50 – 54 years 0.005 
55 – 59 years 0.0065 
60 – 64 years 0.008 
Over 65 years 0.0095 
Low-risk polyp to high risk polyp 0.02 (0.01-0.04) 
High risk polyp to localised cancer 0.05 (0.2-0.10) 
Localised cancer to regional cancer 0.28 (0.10-0.50) 
Regional cancer to distant cancer 0.63 (0.32-0.80) 
Annual CRC specific mortality rates  
Localised cancer 0.002  
Regional cancer 0.032  




Lung cancer is one of the most deadly cancers, and it is the second most common cancer 
diagnosed in the UK after breast cancer (379). Non-small cell lung cancer accounts for 
78% of lung cancer in England and Wales (379). Age and sex specified incidence rates 
of developing lung cancer in the general population are based on the estimates from the 
Cancer Research UK data (383). The risk in non-smokers is estimated by adjusting the 
general population estimates using the equation from Godfrey et al. (382).The relative risk 
in current smokers (Male 9.87 [6.85-14.24] and Female 7.58 [5.36-10.73]) was taken from 
a meta-analysis of observational studies published between 1961 and 2003 (394). The 
probability of developing lung cancer based on age, sex and smoking status (382,394) is 
presented in Table 4-23. 
 
Table 4-23: Probability of developing lung cancer by age, sex and smoking status 
Age group Men Women 
Non-smokers Smokers Non-smokers Smokers 
35–39 0.00% 0.01% 0.00% 0.01% 
40–44 0.00% 0.01% 0.00% 0.02% 
45–49 0.00% 0.04% 0.01% 0.04% 
50–54 0.01% 0.11% 0.01% 0.09% 
55–59 0.02% 0.23% 0.03% 0.19% 
60–64 0.04% 0.42% 0.04% 0.32% 
65–69 0.07% 0.71% 0.07% 0.52% 
70–74 0.10% 0.95% 0.08% 0.64% 
75–79 0.15% 1.47% 0.12% 0.93% 
80–84 0.18% 1.78% 0.14% 1.03% 
85+ 0.17% 1.63% 0.11% 0.80% 
 
Kidney cancer 
Kidney cancer is the eighth most common cancer in the UK, accounting for 3% of all new 
cases. Of those new kidney cancer diagnosed in 2004, 85-90% were renal cell 
carcinomas (379). The major risk factors for kidney cancer include age, sex, obesity, 
smoking, and some genetic and medical conditions such as hypertension. Renal cell 
carcinoma is nearly twice as common in men as in women, and most commonly affects 
adults aged 50-80 years. Approximately 25% of kidney cancer patients represent with 
advanced and/or metastatic disease (stage III or IV). An estimated 50% of patients who 
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have curative resection for earlier stages will develop recurrent and/or metastatic disease. 
Without the treatment, median survival is only 6-12 months, and the two-year survival rate 
is 10-20% (395). 
The age and sex-specific incidence rates for kidney cancer were obtained from the Cancer 
Research UK statistics for 2010 (379) and were adjusted for diabetes (384) to estimate 
the risk of kidney cancer. 
 
Table 4-24: Annual probability of developing kidney cancer by age, sex and diabetes 
status 
Age Range Men Women 
Diabetic Non-diabetic Diabetic Non-diabetic 
15 to 19 0.000001 0.00000 0.00000 0.00000 
20 to 24 0.000003 0.00000 0.00000 0.00001 
25 to 29 0.000005 0.00001 0.00001 0.00001 
30 to 34 0.000014 0.00001 0.00002 0.00002 
35 to 39 0.000039 0.00002 0.00005 0.00004 
40 to 44 0.000072 0.00004 0.00009 0.00006 
45 to 49 0.000109 0.00006 0.00014 0.00009 
50 to 54 0.000195 0.000107 0.000246 0.000182 
55 to 59 0.000302 0.00017 0.000381 0.000289 
60 to 64 0.000444 0.000229 0.000559 0.000389 
65 to 69 0.000563 0.000292 0.000709 0.000496 
70 to 74 0.000782 0.000396 0.000985 0.000673 
75 to 79 0.000924 0.000478 0.001164 0.000813 
80 to 84 0.001003 0.000505 0.001264 0.000859 
85+ 0.000981 0.000474 0.001236 0.000806 
It would be appropriate to model different stages of lung and kidney cancers. From the 
epidemiological studies, only the stage-specific mortality rates were available, and 
transition rate information was missing. Thus, only three health states are considered for 
lung and kidney cancers – progression-free, progressive and dead. To capture the 
disease progression in cancer, it requires a more complex model structure to estimate 
additional parameter values, such as missing transition rate information (396). 
Mortality risks 
Background mortality rates were taken from life tables for the English population (397). 
Death rates for cardiovascular (MI and stroke) and cancers were excluded from all-cause 
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mortality to estimate other cause mortality rates. These rates adjust age-specific UK 
annual incidence of mortality. Annual transitional probabilities for breast cancer 
recurrence to death were taken from Johnston (356). The rates are assumed to be the 
same for prognostic groups. Mortality estimates for colorectal cancer by stages were 
based on Frazier et al. (355). These rates vary by cancer stages. Lung cancer mortality 
estimates were obtained from a comparative study of lung cancer survival in six developed 
countries (398). The mortality rate for lung cancer was calculated as one minus one-year 
net survival rate: 28.8% (28.3 – 29.4) in the UK. Mortality rates for kidney cancer were 
estimated using UK survival rates for kidney cancer (379). It was assumed that mortality 
rates associated with disease conditions that were not explicitly modelled remain stable 
at the rates recorded in the relevant population. To avoid double counting, deaths from 
type 2 diabetes were not modelled as adults with diabetes are more likely to die from 
cardiovascular conditions. 
Costs 
Health care resource use was estimated for each health state. The annual costs 
associated with each state were estimated by multiplying the healthcare utilisation 
associated with the state by the costs of each unit of health care and inflated to 2011 UK 
£ sterling using inflation indices from the Hospital and Community Health Services 
(HCHS) index (28). Previous economic models, HTA reports, RCTs and cost-of illness 
studies were searched to obtain the most recent and appropriate evidence to populate 
costs. The costs associated with the model and associated parameters and ranges for the 
probabilistic analysis are reported in Table 4-25. These costs were considered from the 
UK NHS perspective where possible. Gamma distributions are assumed to sample costs 
because costs are constrained to be either zero or positive (positively skewed) (36). 
 
Table 4-25: Costs of health states in the cost-effectiveness model 




Hypertension by age – male (399)    
35-54 £30.06 2009/10 £30.89 
55-64 £28.76 2009/10 £29.55 
65-74 £31.74 2009/10 £32.61 
75+ £32.56 2009/10 £33.46 
Hypertension by age – female (399)    
35-54 £29.20 2009/10 £30.00 
55-64 £30.06 2009/10 £30.89 
65-74 £31.20 2009/10 £32.06 
75+ £33.64 2009/10 £34.57 
LVH (329) £898.21 2004 £1,067 
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Table 4-25 (continued) 




Type 2 diabetes (400) £653 2005 £724 
Ischaemic heart disease (IHD)  (401) £3,880 2009 £4,010 
IHD (history) (402) £171 2004 £203 
Myocardial infraction (first) (402,403) £4,448  2004 £5,284.75  
MI (subsequent) (402) £171  2004 £203.17  
MI (fatal) (404) £1,166  2004 £1,825.96  
Stroke (first) (402) £8,046.00 2004 £9,559.60 
Stroke (subsequent) (402) £2,163.00 2004 £2,569.90 
Stroke (fatal) (402) £7,041.00 2004 £8,365.54 
CHF (404) £2,221  2004 £3,478.09  
CHF (history) (404) £631  2004 £988.15  
Dilated eye examination for diabetic 
retinopathy (28) 
£24.98 2010/11 £24.98 
Cataract extraction (404) £1,553 2004 £2,432.00  
Blindness (404) £872 2004 £1,365.55  
Blindness (history) (404) £281 2004 £440 
Micro- albuminuria (405) £104 2001 £146  
Overt nephropathy (proteinuria) (405) £6,084 2001 £8,545  
End Stage Renal Disease (ESRD) (405) £27,924 2001 £39,221  
Amputation (404) £8,459 2004 £13,247 
Amputation (history) (404) £300 2004 £470 
Lung cancer initial treatment (382) £12,902  2009 £13,336.90  
Annual cost (382) £5,611 2009 £5,800 
Kidney cancer (406) £26,653  2007/08 £28,527 
Localised (407) £10,370  2004/05 £12,352.43  
Regional (407) £19,077  2004/05 £22,723.11  
Metastatic (407) £11,946  2004/05 £14,229.00  
Breast cancer – DCIS (356) £2699 1998/99 £4,139.76 
Breast cancer – Excellent (356) £2700 1998/99 £4,141.30 
Breast cancer – Good (356) £2,935 1998/99 £4,501.74 
Breast cancer – Moderate (356) £3,156 1998/99 £4,840.72 
Breast cancer – Poor (356) £3,262 1998/99 £5,003.30 
Follow-up after primary treatment (356) £71 1998/99 £108.90 
Breast cancer - local recurrence (356) £2,502 1998/99 £3,837.60 
Breast cancer - regional recurrence (356) £3,327 1998/99 £5,103.00 
Breast cancer - distal recurrence (356) £5,249 1998/99 £8,050.99 
Breast cancer - follow-up after local and 
regional recurrence (356) 
£163 1998/99 £250.01 
Breast cancer - follow-up after distal 
recurrence (356) 
£4,336 1998/99 £6,650.62 




Treatment costs for hypertension were taken from National Clinical Guidelines Centre 
2011 (399) that undertook an updated review of the costs for hypertension. These costs 
include annual check-up and cost of the hypertensive drug. 
Diabetes and complications 
The cost of type 2 diabetes without complications is taken from Ara & Brennan (400). This 
cost includes GP and nurse visits, lab tests and drug costs. Costs of diabetic retinopathy 
and neuropathy were taken from the UKPDS study (404). The cost of amputation in the 
first year of surgery and subsequent years were extracted and inflated to 2011/12 prices. 
Costs of diabetic nephropathy were taken from a cost of illness study by Gordois et al. 
(405). These costs are based on the health care cost estimation of diabetic nephropathy 
in the UK and include the costs of outpatient clinics, treatment and drug costs. 
Cardiovascular events 
Treatment costs for cardiovascular events were taken from Ward et al. (402). The cost of 
angina pectoris was used as a proxy for ischaemic heart disease (402). This includes the 
cost of GP contact plus medication costs. 
Cost of non-fatal MI in the first year was taken from Palmer et al. (403) and Ward et al. 
(402). The cost was based on the Nottingham heart attack register study. As this cost 
does not include primary care costs, primary care and medication costs were assumed to 
be the same as angina. Cost of MI in subsequent year was based on the assumption that 
all the patients receive primary care support. Cost of fatal MI and CHF were taken from 
the UKPDS study (404). The cost of CHF was based on the UKPDS study, i.e. for diabetic 
patients thus costs for CHF events may be higher than the cost of CHF for the non-diabetic 
population. 
Cost of stroke was taken from an HTA report by Ward et al. (402). The cost is based on 
the Nottingham Heart Attack Register (NHAR) study and includes the cost of inpatient 
stay, GP visits, outpatient, readmission, respite care and day hospital care (408). The 
estimated cost of non-fatal and subsequent stroke is based on the cost of acute events 




Breast cancer treatments costs (356) include costs for primary treatment, recurrences and 
follow-up. The initial treatment and annual costs of lung cancer are taken from Godfrey et 
al. (382). These costs include lung cancer-related costs for the NHS. Costs related to 
kidney cancer treatment are taken from the PenTAG model (406). Kidney cancer 
treatment costs include GP consultations, blood tests, CT scans, drug administration 
(Sunitinib) and pain medication. 
Health state utility values 
The primary outcome of the model is expressed in terms of QALYs using estimates of 
survival and quality of life attributable to each health state. The utility values represent the 
strength of an individual’s preferences for specific health-related outcomes. They are 
measured in an interval scale of zero reflecting states equivalent to death and one 
reflecting perfect health (1,409). Utility values associated with each health state depend 
on the presence or absence of a particular health state. 
The CEA registry (410) was searched to identify utility estimates for inclusion in the model. 
The original source papers were scanned to extract data on disease, country, year, time 
horizon, perspectives used, participants, sample size, response rate, reference 
estimation, the method used to value, and quality score (if available). To obtain health 
state utilities, a choice based technique (e.g. standard gamble or time trade-off) or a 
generic instrument (e.g. EQ-5D) was used, where available. Table 4-26 indicates the 
condition-specific utility values used in the model. The beta distribution was used to 
sample utility values. 
Most of the utility values for health states in the model were taken from Sullivan et al. 
(411). Sullivan and colleagues applied community-based UK preferences to EQ-5D 
descriptive questionnaire responses in the US-based medical expenditure panel survey. 
Utility values for type 2 diabetes, amputation and blindness were taken from the UKPDS 
study (412). Clarke et al. estimated the impact of diabetes complications on quality of life 
using EQ-5D questionnaires. Utility values for diabetic nephropathy and foot ulcer were 
from Coffey et al. (413). Their study included 2,048 patients with type 1 and type 2 
diabetes and used self-administered quality of well-being index to calculate a health utility 
score. Utility values for background and proliferative diabetic retinopathy were taken from 
a prospective observational study of diabetes care in the US (414). This study included 
7,327 individuals with type 2 diabetes and measured the quality of life using EQ-5D. Utility 
values for breast cancer recurrences were taken from Lidgren et al. (415). In their study, 
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Lidgren et al. included 361 breast cancer patients and estimated the impact of breast 
cancer on quality of life using the EQ-5D questionnaire. Utility values for health states 
related to colorectal cancer were taken from Ness et al. (416,417). 
 





Health states Value Standard error Source 
Healthy 1.00   
Hypertension 0.72 0.0035 (411) 
IHD 0.65 0.0203 (411) 
Acute MI 0.60 0.022 (411) 
Stroke 0.52 0.0192 (411) 
Congestive heart failure 0.49 0.0194 (411) 
Left ventricular hypertrophy 0.62 0.0087 (411) 
Atrial fibrillation 0.69 0.0095 (411) 
Type 2 diabetes 0.785 0.0530 (412) 
Diabetic retinopathy    
Background diabetic retinopathy 0.78 0.005 (414) 
Proliferative retinopathy 0.76 0.008 (414) 
Blindness or vision loss 0.711 0.018 (412) 
Diabetic neuropathy    
Foot ulcer 0.60 0.009 (413) 
Amputation  0.56 0.056 (412) 
Diabetic nephropathy    
Micro/macro albuminuria 0.678 0.009 (413) 
Renal failure 0.611 0.026 (413) 
Lung cancer 0.56 0.0433 (411) 
Breast cancer 0.76 0.0133 (411) 
Local/regional recurrence 0.78 0.0373 (415) 
Distal recurrence 0.69 0.0293 (415) 
Colorectal cancer    
Localised cancer 0.74 0.023 (417) 
Regional cancer 0.67 0.026 (417) 
Distal cancer 0.25 0.028 (417) 
Kidney cancer 0.66 0.0729 (411) 
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4.4.3 Time horizon 
The National Institute for Health and Care Excellence (NICE) recommends a lifetime time 
horizon for chronic disease interventions (2). The effectiveness evidence of VBIs in 
physical activity is based on studies with up to 2 years of follow-up data. For this model, 
a 10-year time horizon is chosen. This is based on the estimates that the long-term effects 
of PA would be 55% of the effect after one year of intervention (334). The shorter time 
horizon may underestimate the long-term benefits of increasing physical activity, but a 
longer time horizon would need larger assumptions about the uptake of physical activity, 
study population demographics, disease incidence, mortality rates and costs. Sensitivity 
analyses were performed with varying decay rates between 0% (lifelong behaviour 
change) and 100% (behaviour change reversed after the first year post-intervention).  
4.4.4 Discounting 
Cost-effectiveness analysis is based on intervention in the first year, with all health 
outcomes and costs measured over the 10-year period. In health economic evaluations, 
it is the standard practice to adjust costs and health outcomes for differential timing by 
applying a rate of discount. This allows comparison of costs and health outcomes in terms 
of net present value. All future costs and health outcomes are discounted at 3.5% per 






Where V0 is the current value, 𝑉𝑡  is the value at time 𝑡 and 𝑟 is the rate of discount. 
4.4.5 Cycle length 
The model uses one-year cycle length. This is based on the availability of data. Previous 
models of PA (141,337,339) used a similar approach in terms of cycle length. Use of a 
monthly cycle would increase the processing time because it would result in a 12-fold 
increase in evaluation time over a year. 
4.5 Model calibration 
The above section detailed the development of the model and how it was parametrised, 
this section now describes the model calibration. As the model included more than ten co-
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morbidities and as varied sources were used to inform model parameters, it was essential 
to assess the accuracy of the model’s predictions (418). This section describes the model 
calibration process including calibration endpoints and assessment of goodness-of-fit. 
Model calibration is the process of identification of a set of inputs that generates model 
outputs that best predict observed data (418). It seeks to explicitly modify model input 
coefficients such that simulated values of parameters match as closely as possible to the 
observed. This is an essential and often under-appreciated part of the model development 
process and seeks to check that the model predictions are consistent with the other data 
sources describing the model output (419,420). The accuracy of the model predictions 
depends on the structural assumptions of the model and the quality of key input 
parameters (421). 
The effect of increased physical activity in the model on disease events is mediated 
through the risk factors, and there exists direct evidence on the link between increased 
physical activity and risk of a disease event. The risk equations used to predict 
cardiovascular outcomes in non-diabetic patients were from the Framingham Heart Study. 
Cardiovascular events contribute largely in terms of healthcare costs and quality of life. 
To overcome with such issues, it is necessary to calibrate the model using these targets, 
i.e. using the direct link between physical activity and risk of disease event (relative risks) 
and incidence/prevalence of diseases in the UK. 
4.5.1 Model calibration endpoints and model parameters 
Seven endpoints were selected as calibration targets due to their likely influence on the 
cost-effectiveness of interventions as well as the availability of data examining the direct 
effect of physical activity on disease events (Table 4-27). The endpoints relate to relative 
risks (of all-cause mortality, stroke and CHD) with various levels of physical activity, 
disease incidence (MI and stroke) and prevalence (of CHD and diabetes). The evidence 
for these endpoints was derived from meta-analyses of observational studies, cross-






Table 4-27: Model calibration endpoints 




MI incidence per year per 100,000 (424) 13.58 0.09 
Prevalence of CHD (424) 5.3 % 0.07 
Stroke incidence per year per 100,000 (424) 14.89 0.09 
Prevalence of Diabetes (425) 5.5 % 0.07 
Relative risk of CHD (0 vs 11.3 METs) (294) 0.86 0.12 
Relative risk of stroke (0 vs 11.5 METs) (423) 0.89 0.18 
Relative risk of all-cause mortality (0 vs 11 METs) (422) 0.81 0.37 
 
4.5.2 Assessing the goodness-of-fit of calibration results 
Goodness-of-fit metric measures the accuracy of the calibrated input in replicating the 
target endpoints (426). As the model has multiple endpoints, we combined the measure 
of goodness-of-fit across all calibration targets using the absolute weighted mean 
deviation (WMD). The WMD is calculated as the weighted sum across all the seven 
endpoints of the proportional difference between the predicted and observed values of a 
given parameter (Equation 4-2). 







Where 𝑛 = number of endpoints, 𝑝𝑟𝑒𝑑𝑖 = model-based estimates of the 𝑖
𝑡ℎ end point, 𝑜𝑏𝑠𝑖 
= data-based target value of the 𝑖𝑡ℎ end point, and 𝑤𝑖= weight of the 𝑖
𝑡ℎ endpoint 
Weights were assigned to each endpoint based on the relative importance of the 
estimates in the cost-effectiveness analysis (Table 4-27). In order of importance, from 
most important to least important, these were: relative risk (RR) of all-cause mortality, RR 
of stroke, RR of CHD, disease incidence (stroke and MI) and prevalence (CHD and 
diabetes). The weights were then assigned as 1/order of importance and normalised by 
dividing the raw weights of each endpoint over the sum of the weights for all endpoints 
(Equation 4-3) (427). As a result, RR of all-cause mortality had higher weights and 









Where 𝑟𝑖is the rank of the 𝑖
th end point, 𝑘 is the total number of end points 
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4.5.3 Parameter search algorithm 
Different parameter search strategies have been described in the literature to calibrate 
models in economic evaluation, for example, grid search, generalised reduced gradient, 
simulated annealing and mixed approaches (418,419,421,426,428). There is no single 
approach that would be suitable for all models (429). In theory, all algorithms should 
ultimately produce model outputs that match the specified calibration target most closely. 
Therefore, the choice of algorithm is ultimately a pragmatic decision based on 
computational efficiency, as all algorithms should converge on the optimal solution, given 
sufficient searches. We chose the Nelder-Mead search algorithm(430) as our preferred 
method, implemented using the ‘neldermead’ package in R (431). This method has 
previously been used to calibrate cost-effectiveness models and was found to be efficient 
(428,432,433). Others have suggested that the Nelder-Mead method performs best with 
a relatively smaller number of variables (434). We identified the top ten most influential 
coefficients in the model by performing one-way sensitivity analyses, evaluating the WMD 
of the model outputs with each coefficient at its lower and upper 95% confidence interval 
(CI) values, respectively. The ten coefficients yielding the biggest variation in WMD were 
selected for calibration using the Nelder-Mead function. 
The Nelder-Mead algorithm converged but not a true minimum after 703 iterations, i.e. the 
value of the objective function (weighted mean deviation) did not reduce further. As a 
result, we chose the typically less efficient but widely used method in health economics, 
the directed random search method (429). This was done in two stages. First, 100,000 
sets of all model parameter values (coefficients) were generated by sampling randomly 
from the mean +/- two standard errors with a uniform distribution. Second, the set yielding 
the lowest WMD was used as the starting point for a further 100,000 sets of sampled 
coefficients +/- one standard error. The set yielding the lowest WMD was chosen as the 
optimal set. 
4.5.4 Model calibration results 
Before calibration, the value of the objective function (WMD) was 43%. The best-fitting 
parameter set from the random search method had a WMD of 12%. Figure 4-9 shows the 
percentage deviation from the aggregated target for each calibration endpoint. The model 
predicted endpoints from the random search calibration deviated from the target endpoints 




Figure 4-9: Comparison of aggregated endpoints by the calibration method 
In our case, the Nelder-Mead method could not further minimise the goodness-of-fit value 
after 703 iterations with a weighted mean deviation of 18%. It is possible that the 
optimisation problem may have multiple local minima, i.e. the smallest value that a 
function can take in a region of its domain. The Nelder-Mead method is known to work 
reasonably well for problems that do not have multiple local minima (435). 
Although the random search method was less efficient, it resulted in a better goodness-
of-fit. Parameter values used in the random search method were restricted to a plausible 
range within the parameter space. This required longer processing time to search for the 
largest or the smallest value on the entire range of the function (global extremum), and it 
took approximately 80 processor-days to run 100,000 iterations. The weighted mean 
deviation was chosen as a measure of goodness of fit because it combines measures of 
goodness-of-fit across all calibration targets. However, the weights assigned for multiple 
endpoints remain arbitrary. 
4.6 Intervention effectiveness and costs input to the model 
Having described the development of the model and how the model was calibrated, this 
section now first details the brief interventions and reports the results for each brief 
intervention considered reporting incremental cost per QALY gained. This section also 
describes the approach used to harmonise the PA outcome measures reported in studies 
included in the meta-analyses and estimating cost of delivering BIs. 
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4.6.1 Brief interventions 
A literature search was performed in PubMed and found four recent high-quality reviews 
(meta-analyses of RCTs) of BIs that could be delivered in primary care/community setting. 
They include advice or counselling on PA in primary care (101), use of pedometers as a 
motivational tool to promote PA (151,436) and action planning interventions (437). These 
meta-analyses summarised effectiveness evidence as continuous outcomes in either 
mean difference or standardised mean difference (SMD). Kang and colleague (436) 
included 32 studies in their meta-analysis of pedometer-based physical activity 
interventions compared to 8 studies in Bravata and colleagues (151) and reported a 
pooled SMD of 0.68 (95% CI: 0.55 – 0.81). They included all study designs in their meta-
analysis. In contrast, Bravata and colleagues (151) included 8 RCTs and 18 observational 
studies in their meta-analysis. Their analysis reported estimated intervention effects 
separately for RCTs and observational studies, and the effect size was measured in terms 
of increases in steps per day which facilitates clinical interpretation. Thus, effectiveness 
evidence from the Bravata review was included in this analysis. 
The model includes changes associated with activity level over time with varying decay 
rates of VBIs. The follow-up period of the studies included in the meta-analysis of BIs was 
short; only a few studies had >12 months follow-up. As there were no other estimates on 
how effects of PA interventions decay over time, Over et al. (146,334) provided estimates 
on a decay rate of 55%. We used this rate of decay after one year of intervention. 
4.6.2 Physical activity outcome translation 
Although mean difference and SMD are commonly used summary statistics for meta-
analysis of continuous data (438), choosing a common exposure metric measure such as 
intervention changes in intensity, duration, and or frequency of physical activity (METs) 
allows direct comparison of results. It is possible to convert steps per day figures directly 
to MET hour per day using the formula for physical activity outcome translation (Table 
4-28) presented by Wu et al.(439) However, it is not possible to translate SMD values 





Table 4-28: Formula for physical activity outcome translation 





Steps/day on walking MET-hour=(steps/10,000)×4.25×(1/3)×3 MET 
30-minute blocks in physical activity per 
day 
MET-hour=[(30-minute block)/4]×MET assigned 
Minutes/day on physical activity MET-hour=[(minutes/day)×MET assigned]/60 
% people meeting guideline MET-hour=(% people)×(1.5 MET-hour for adults)  
MET minutes/week MET-hour=(MET minutes/week)/60/7 
Active days (at least 3 MET-hour) per week MET-hour=(active days)×(3.0 MET-hour)/7 
Source: Wu et al. (439) 
For this, firstly the exposure measure (PA outcome) from individual studies included in the 
original meta-analysis were extracted. Then these values were converted into MET-hours 
of activity per day by selecting the estimate from the 2011 compendium of physical activity 
(364). Finally, the meta-analysis was re-run with translated values (MET-hours). Table 
4-29 provides the summary of interventions included and their effectiveness. 
When the activity levels were not described in terms of METs, moderate-intensity physical 
activity was assigned to 3.0 METs, moderate-to-vigorous physical activity 4.5 METs and 
vigorous physical activity 6.0 METs (309). Once the physical activity outcomes of 
individual studies included in these meta-analyses were translated into MET-hours, the 
meta-analysis was updated using the translated values (MET-hours). As in the original 
meta-analyses, a random-effects model was used to estimate the pooled effect, 
expressed as a difference in means. 
4.6.3 Short-term effectiveness of BIs 
Table 4-29 provides a brief description of BIs included in the meta-analyses along with 
the reported changes in PA (outcome) reporting both original figures reported in the meta-
analyses and translated MET-hour values. Converting step counts per day into MET-hour 
per day was straightforward following the PA outcome translation formula (Table 4-28) 
because all 8 RCTs included in the meta-analysis measured PA outcome in terms of step 
counts per day. However, it was not possible to translate the reported outcome from some 
of the studies included in these meta-analyses into MET-hours. This was mainly the case 
for five of the nineteen RCTs included in the meta-analysis of action planning interventions 
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(437). These five studies either did not provide details on changes in intensity, duration 
and/or frequency of activity required for MET-hours translation, or the outcome was 
expressed in composite units (e.g. a sum of scores where responses were rated on a 
scale). Thus, these five studies were excluded while re-running the meta-analysis with 
MET-hour values. 
 
Table 4-29: Description of brief interventions and their effectiveness 
Intervention No of 
studies 
Intervention description Changes in PA, 
original and translated 




8 RCTs Pedometer as a motivational tool, 
goal setting (e.g. walking 10,000 
steps/day for 5 times a week), in 
some cases participants received 
individual exercise feedback (walking 
plus feedback) 
Increase in steps per 
day: 2491 (711)  
MET-hr per day = 1.06 
(0.30) 
Advice/counse




Brief advice or counselling on PA 
delivered by health professionals, 
face to face or by phone or both 
SMD = 0.25 (0.07) 








Participant formulate their action plan 
in the format of what, when and 
where (time, place and number of 
minutes), record their intention on PA 
in the logbook or calendar, 
intervention delivery time 5-20 
minutes 
SMD = 0.24 
MET-hr per week = 
0.035 (0.01) 
There were some practical issues while converting the exposure to MET hours. For 
example, moderate intensity activity such as walking is generally considered to be 3 to 6 
METs. While converting such exposure, mid-point of moderate intensity was taken at 4.5 
METs. Woodcock et al. (422) also used a similar approach for exposure translation in their 
meta-analysis of non-vigorous physical activity and all-cause mortality.  
4.6.4 Intervention costs 
As the included studies in the meta-analyses did not report the cost of the intervention, 
we first extracted resource use data based on the intervention description provided for 
individual studies in the meta-analyses. Then each intervention was costed based on the 





Table 4-30: Unit costs of health care utilisation  
Cost item Unit cost Source 
Primary care consultation 
£36 per 
consultation 
PSSRU 2011 (28) 
Physiotherapist £34 per hour PSSRU 2011 (28) 
Exercise physiotherapist £34 per hour Same as physiotherapist 
Practice nurse (face-to-face) £51 per hour PSSRU 2011 (28) 
Nurse £39 per hour PSSRU 2011 (28) 
Pedometer £14 per unit Shaw et al. (147) 
Physical activity diary £0.96 per unit 
UEA print service 
(www.uea.ac.uk/print-services) 
Physical activity information 
pack 
£1.21 per unit 
UEA print service 
(www.uea.ac.uk/print-services) 
Trained facilitator* £10.89 per hour 
NHS Staff Earnings 2011 
(http://goo.gl/WDpmv) 
Telephone call £0.13 per min BT Tariff Guide (http://goo.gl/QjVvG) 
Text messaging £0.11 per SMS text BT Tariff Guide (http://goo.gl/QjVvG) 
Postal cost £0.75 per letter The Royal Mail Price Finder 
* Median FTE total earnings for broad non-medical occupational groups 
The costs of a pedometer intervention include the cost of a pedometer, intervention 
material and consultation time with either a GP, nurse or physiotherapist. Each RCT 
included in the meta-analysis was costed for each item of resource use based on the 
description of the intervention reported. Unit costs for nurse and physiotherapist were 
taken from the PSSRU unit costs (28). The cost of a pedometer was taken from a 
community-based pedometer study (Walking for Wellbeing in the West) (147). Costs of 
production and delivery of exercise diary (A4 size black and white paper) and information 
booklet (A4 size colour paper) were estimated from the unit cost of printing and binding 
on A4 size paper (The UEA print service). 
Table 4-31: Intervention costs associated with implementing BIs promoting PA 
Brief interventions No. of 
studies 








primary care (101) 
9 RCTs 3,445 12 months £71.26 
Action planning 
interventions (437) 
14 RCTs 1,864 10 (2–52) weeks £33.21 
Pedometer 
interventions (151) 
8 RCTs 277 11 (4–24) weeks £54.33 
Current practice 
(‘doing nothing’) 
  - - 
128 
Advice/counselling interventions included advice or counselling sessions given face-to-
face or by phone (or both) and written materials. A counselling session with primary care 
clinician was assumed as a standard primary care consultation with a general practitioner 
lasting around 12 minutes. Unit costs for primary care consultation, general practitioner, 
physiotherapist and practice nurse were taken from the PSSRU unit costs (28). Costs of 
production and delivery of written material (information booklet) were estimated from the 
unit cost of printing (front-page colour, four pages black and white print) and binding on 
A4 size paper.  
Action planning intervention included the cost of printing and developing materials (e.g. 
activity logbook, calendar, pamphlet), adoption of intervention material (e.g. visual 
education material) tailored to local context, designing and operating the web-portal for 
SMS texting service, staff (nurse, health worker or fitness instructor’s time) for 
induction/training of participants; and other costs such as fitness club membership (437). 
In a typical action planning BI, the questionnaire prompted participants to formulate an 
action plan. Unit costs of administering the questionnaire (nurse admin time) were taken 
from the NHS staff earnings Jul-Sept 2010 (http://goo.gl/WDpmv), and health and social 
care costs were derived from the PSSRU unit costs for the nurse, health worker, physician 
or other health professional time (28). Costs of production and delivery of the physical 
activity questionnaire and toolkit were estimated from the unit cost of printing and binding 
on A4 size paper (The UEA print service; www.uea.ac.uk/print-services) and standard UK 
post rates (The Royal Mail Price Finder, http://www.royalmail.com/price-finder). Costs of 
phone calls and text messages were taken from standard BT prices (BT Tariff Guide, 
http://goo.gl/QjVvG). The cost of fitness club membership was estimated at £33 per month 
(Sportspark, http://www.sportspark.co.uk). 
Finally, the cost per participant was then evaluated as a weighted average of intervention 
costs for each RCT in the meta-analysis. Full details on costing of each intervention are 
provided in Appendix C2. 
4.7 Results from the first iteration of the model 
The above sections defined the decision problem, detailed the development and 
calibration of the decision model, and estimated intervention effectiveness (in MET-hours) 
and costs, this section now reports the results from the first iteration of the model reporting 
incremental cost per QALY for all the three BIs included in this analysis. The economic 
evaluation of BIs was undertaken from the perspective of UK NHS reporting incremental 
cost per QALY. 
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4.7.1 Point estimates 
Table 4-32 presents the mean costs, QALYs, and net benefits at a willingness to pay 
(WTP) of £20,000 per QALY and associated standard errors for the base-case analysis. 
Over a time horizon of 10 years, the point estimates for per person costs and QALYs for 
all interventions were similar. Pedometer BIs dominated both advice/counselling and 
action planning BIs, i.e. pedometer BIs were both less expensive and more effective. 
When compared with current practice, all three BIs were both more effective and more 
costly. 
 
Table 4-32: Cost-effectiveness of brief interventions over ten years (base case costs, 
QALYs and NBs) 
Brief intervention Mean cost (SE) Mean QALY (SE) Mean NB* (SE) 
Current practice £1,712 (583)  7.848 (0.228) £ 155,254  (5,072) 
Action planning £1,738  (583) 7.851 (0.228) £ 155,291  (5,079) 
Advice/counselling in primary care £1,758  (580) 7.857 (0.229) £ 155,378  (5,084) 
Pedometer interventions £1,723  (579) 7.864 (0.229) £ 155,549  (5,097) 
*NB calculated at a WTP of £20,000 per QALY, ICER: incremental cost-effectiveness ratio 
The QALY gains associated with the BIs were as expected. Pedometer interventions were 
more effective (in terms of MET-hours) than advice/counselling and action planning 
interventions. The higher costs associated with delivering advice/counselling interventions 
is reflected in the results, having a higher mean cost compared to other BIs.  
4.7.2 Analysis of uncertainty 
The model was run probabilistically, using Monte Carlo simulation (n=10,000 iterations for 
the whole cohort of 10,000 patients each time) to determine the expected costs, expected 
outcomes (QALYs gained) and expected cost-effectiveness.  
Figure 4-10 plots the incremental costs versus incremental QALYs comparing each BI 
with current practice for the 10,000 iterations, illustrating the uncertainty surrounding the 
expected incremental cost and incremental QALYs for all three BIs. The plot shows the 
points scattered across all four quadrants of the CE plane, with the majority of the points 




Figure 4-10: The cost-effectiveness plane for promoting PA in primary care 
The joint distribution of costs and effects from the probabilistic analysis plotted in Figure 
4-10 demonstrated the impact of uncertainty in model parameters on the model outcomes. 
The spread through the origin passing through the horizontal and vertical axes represent 
uncertainty in incremental costs and QALYs. The extent of the spread also indicates the 
extent of uncertainty. 
The cost-effectiveness acceptability curve (CEAC) for BIs is illustrated in Figure 4-11. The 
CEAC shows the probability that BIs are cost-effective at different values for the maximum 
willingness to pay threshold (λ).  
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At a WTP threshold value of £20,000 per QALY, the probability that pedometer 
interventions will be cost-effective is 56%. The advice/counselling intervention was 
optimal in 22% of the 10,000 iterations at a WTP of £20,000 per QALY. The CEAC shows 
that at a monetary threshold of £20,000 per QALY the probability that action planning 
interventions and usual care being cost-effective in comparison to pedometers and 
advice/counselling interventions is less than 13%. 
At a monetary threshold of less than £1,000 per QALY, the no intervention ‘current 
practice’ is the most cost-effective (had a higher probability of being cost-effective) 
compared to other BIs. 
4.7.3 Scenario analyses 
In the base-case analysis, it was assumed that the effect of BIs (increases in MET-hours) 
decays over time at a rate of 55% per year. This assumption was based on previous 
modelling studies estimating the long-term effect of PA interventions. However, the true 
rate of decay for these behavioural interventions is unknown. The sensitivity analyses 
below present the impact of assumption on decay rates on the cost-effectiveness results. 
In these analyses, the decay rate varies between 0% (no decay in intervention effect i.e. 
lifelong behaviour change) and 100% (intervention effects reversed after the first year 
post-intervention). 
Figure 4-12 shows the effect of a change in intervention decay rates to expected net 
benefit (Y-axis). At a higher decay rate, the expected NBs of all interventions were quite 
similar which ultimately dropped below that of current practice. At lower decay rates, the 
expected NBs were higher for pedometers ad advice/counselling interventions followed 
by action planning interventions. This is to be expected as the decay rates increases, the 
treatment effect (MET-hour change) declines towards that of current practice (zero effect).  
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Figure 4-12: Sensitivity analysis of intervention cost-effectiveness to decay in intervention 
effects at a WTP of £20,000/QALY 
Having examined the impact of varying decay rates on cost-effective results and results 
from the previous RCT with more than one-year follow-up (143), it would be difficult to 
maintain the level of activity after any PA intervention. Indeed Elley and colleagues (143) 
reported higher incremental costs associated with a change in at least moderate intensity 
activity per kcal/kg/day at 24 months compared to 12 months. In other words, the physical 
activity advice and counselling intervention in primary care was less cost-effective at 24 
months than at 12 months. This was because there were fewer people who were moved 
from sedentary to active and maintained this at 24 months than at 12 months. 
It will be difficult to maintain the same level of activity achieved due to brief interventions 
over time. Behaviour change interventions require personal commitment, encouragement 
and support over time. Thus, now it is logical to examine what would be the optimal time 
to repeat these interventions given the fact that NHS health check happens every five 
years. In order to answer this question, scenario analyses with the interventions being 
repeated once every 2, 5 and 10 years were performed. Figure 4-13 shows the impact of 
intervention repeat years on expected net benefits. While performing these analyses, the 

































Figure 4-13: Sensitivity analysis of intervention cost-effectiveness to the intervention 
repeat year at a threshold value of £20,000/QALY 
In all the three repeat year scenarios, pedometer BIs were found to be the optimal option. 
The expected NB for pedometer interventions was highest when the intervention was 
repeated once every 2 years. The pedometer BIs had higher MET-hour gains compared 
to other BIs as a result had higher expected NBs compared to other BIs. 
The model included disease conditions that have established links to physical (in)activity. 
This might underestimate the potential impact of physical activity on other disease 
conditions, most notably mental health. The effect of physical activity on the prevention of 
depression is still a subject of debate (440) and a clear dose-response relationship 
between physical activity, and reduced depression is not readily apparent (441). To 
explore this further, a scenario analysis was performed by including a short-term effect of 
increased physical activity on health-related quality of life.  
Only a few studies measured the short-term improvements in quality of life associated 
with physical activity in the general population (442,443), as most of the studies focused 
on older adults and those with chronic conditions (444). A pragmatic RCT evaluating the 
national exercise referral scheme in Wales (445) provided utility data. This ‘utility gain’ 
(0.03 ± 0.023) was added in the first year of intervention to reflect the short-term benefits 
of physical activity. 
Table 4-33 presents the cost and QALY outcomes of including short-term health gains 
































base-case analysis; pedometer BIs being the most cost-effective intervention. However, 
there was a parallel shift upwards for the three BIs. This is because of applying the same 
‘utility boost’ for all BIs irrespective of their effect size. The probabilities of pedometer and 
advice/counselling BIs being cost-effective at a threshold value of £20,000 per QALY 
increased to 61% and 24%, respectively, up from 56% and 22% in the base case scenario. 
 
Table 4-33: Cost-effectiveness of BIs when accounting for short-term direct health 
benefits of physical activity 
Brief intervention Mean cost Mean QALY Mean NB* (SE) 
Advice/counselling £ 1,758 7.8869 £ 155,980 (5,105) 
Action planning £ 1,736 7.8818 £ 155,900 (5,093) 
Pedometers £ 1,721 7.8936 £ 156,152 (5,115) 
Current practice £ 1,713 7.8484 £ 155,255 (5,078) 
*NB calculated at a WTP of £20,000 per QALY. 
 
4.7.4 Value in future research: EVPI & EVPPI 
The above sections presented the PSA results and explored the decision uncertainty by 
illustrating the probability of each BI being cost-effective at different willingness to pay 
thresholds. Additional scenario analyses examined the structural and parameter 
uncertainty. Now following the iterative process in decision making it is important to 
consider given the current evidence, and decision uncertainty: (i) should the intervention 
be adopted, and (ii) is there further value of conducting research in this area? Adoptions 
decision should be made on expected values, i.e. choose the intervention strategy that 
has a highest expected net benefit. The value of information analysis would be useful to 
formally evaluate whether further research is necessary to support the decision to adopt 
or reject the intervention. 
The expected value of perfect information (EVPI) was calculated by extending the PSA, 
i.e. using the probabilities of each BI being cost-effective which were generated in the 
CEAC calculation over a range of willingness to pay threshold values. The EVPI results 
showed that at a WTP of £20,000 per QALY, the base-case per person EVPI associated 
with a decision between pedometer BIs and current practice was £97. 
To understand the EVPI value, it is useful to consider the PSA results and the decision 
uncertainty presented in Figure 4-11. The results showed that at a threshold value above 
£1,000 per QALY, pedometer BIs is most likely that it will be cost-effective, but at a 
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threshold value of £20,000 per QALY, there is only 56% probability of cost-effectiveness. 
Given that there is a 44% probability that the optimal intervention strategy will be the wrong 
decision. The EVPI is equivalent to the opportunity loss of choosing pedometer BIs in 44% 
of instances that the optimal strategy would have been wrong given perfect information. 
At a threshold value of £20,000 per QALY, the expected value of further research is £97 
per decision. 
As this value is per person value, it is important to represent EVPI per decision in terms 
of the relevant population who would benefit from the additional information. In order to 
determine the effective English population, defined as those eligible for an NHS health 
check (40-74 year olds and without a pre-existing condition). Given that approximately 
30% of the population are on a primary care disease register (446), the effective 
population over a 10-year time horizon equates to approximately 20 million adults (Table 
4-34). The future population was discounted at 3.5% per annum. 
The population EVPI results are presented in Figure 4-14. The EVPI per decision 
translated to a population level EVPI of £1.85 bn to the NHS Health Check population. 
This means that at a threshold value of £20,000 per QALY, the upper limit for research 
into which intervention is most cost-effective is £1.85 bn.  
 
Figure 4-14: Expected value of perfect information (EVPI) against varying WTP values for 
































Willingness-to-pay per QALY (£/QALY)
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Table 4-34: Effective Health Check population 
 
Total resident 
population aged 40 
to 74 (447) 
Estimated on the 







A B C = (A-B) D 
Prevalent population 21,88,7396 6,566,219 15,321,177 15,321,177 
Incident population (year 1)  764,005 229,202 534,803 516,718 
Incident population (year 2) 731,914 219,574 512,340 478,275 
Incident population (year 3) 699,168 209,750 489,418 441,427 
Incident population (year 4) 685,626 205,688 479,938 418,238 
Incident population (year 5) 668,403 200,521 467,882 393,944 
Incident population (year 6) 662,338 198,701 463,637 377,169 
Incident population (year 7) 660,465 198,140 462,325 363,383 
Incident population (year 8) 700,813 210,244 490,569 372,544 
Incident population (year 9) 738,069 221,421 516,648 379,081 
Total 7,198,218 8,459,460 19,738,737 19,061,956 
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Having established that further research is likely to be worthwhile, it is useful to consider 
what type of research is required. Further research in this decision problem does not 
necessarily mean that we need a large scale, RCT. Instead, the type of research depends 
on the different parameters that require further information. For example, utility values can 
be collected as a part of large RCT. However, if they are the main source of uncertainty, 
it would be much more efficient and cheaper to determine utility values from observational 
studies. Thus, to define the type of further research that is required to reduce decision 
uncertainty, we need to consider what is driving the uncertainty and which parameters 
would add the most value through further research. The expected value of perfect 
parameter information (EVPPI) is used to identify the parameters for which collecting 
additional information would be of most value. 
EVPPI was undertaken to explore which groups of parameters would add most value 
through further research. The various model parameter inputs were considered, and 
model parameters were grouped into the following six sub-groups that were deemed to 
be of potential value in further research on intervention effects, utility values, costs, the 
risk of MI, the risk of stroke, and parameters used in systolic blood pressure equation. 
Of these six parameter groups, the treatment effect is the only one group which would 
require a randomised trial to gain further information. A planned randomised trial to gather 
intervention effect data could also gather information on costs and quality of life for 
disease states without requiring additional duration for longer-term follow-up. The EVPPI 
was run 500 × 1,000 iterations for each of the six parameter groups, using a threshold 
value of £20,000 per QALY. The EVPPI analysis reports result in terms of value per 
decision but is important to consider this value to the relevant (effective) population who 
would benefit from the additional information. The population EVPPI was based on the 
same patient population (Table 4-34) and time horizon (10 years) specified in the EVPI 
calculation. The results of the EVPPI are presented in Figure 4-15. 
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Figure 4-15: EVPPI results for the base case at a WTP value of £20,000 per QALY – 
population level 
Among the groups of different parameters, intervention effects had the highest population 
EVPPI of £708 million followed by costs (£690 million) and risk of stroke (£684 million) 
parameters at a WTP of £20,000 per QALY. Utilities and probability of MI had an EVPPI 
similar to the SBP equation group. This means that at a threshold value of £20,000 per 
QALY, the effects of pedometer interventions accounted for most of the decision 
uncertainty. 
4.8 Discussion 
This chapter presented the development of a decision analytical model and the use of 
available evidence to evaluate the potential cost-effectiveness of BIs to promote physical 
activity in primary care. The chapter also explored uncertainty in the point estimates and 
demonstrated that using the value of information analysis techniques model results can 
be examined in terms of decision uncertainty to estimate the value of further research. 
This is useful information for the decision makers and funders in order to prioritise 
allocation of limited resources. The results will now be summarised followed by a 
discussion of using VoI methods. 
4.8.1 Cost-effectiveness results 
The model estimated the expected costs and health outcomes of BIs promoting physical 
activity for apparently healthy adults who are eligible for NHS health checks in primary 
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care. The cost-effectiveness plane showed that there was a great deal of uncertainty as 
to whether choosing pedometer BIs over advice/counselling or action planning 
interventions. All the three BIs considered in the analysis had similar expected NBs, with 
pedometer interventions having slightly higher expected NB than other BIs. The cost-
effectiveness acceptability curve showed that the probability of pedometers BI being the 
optimal intervention strategy was only 56% (when all BIs were evaluated simultaneously) 
at a threshold value of £20,000 per QALY. This means that we can be certain in 56% of 
cases that the pedometer BIs is a cost-effective strategy. 
The scenario analyses explored the impact of model assumptions on the degree which 
intervention effects are maintained over time (decay rates). The results showed, as 
expected, BIs become less cost-effective at higher intervention decay rates and more 
cost-effective at lower (or zero) decay rates. It is important to note that the three BIs 
considered in the analysis represent a broad class of interventions. Conceptually, a meta-
analysis combines results from multiple studies, which are statistically similar and 
provides a summary estimate. However, not all comparators included within individual 
studies were usual care or current practice. While these BIs had the potential to be 
delivered in primary care or community settings, these three classes of BIs were 
somewhat heterogeneous.  
Ideally, decision-makers should be making decisions on long-term expected cost-
effectiveness. So, whilst we are highly uncertain, the currently ‘best bet’ would be to opt 
for pedometer BIs. The benefits of pedometer BIs are highly uncertain and probably small, 
but then so is the cost. This level of uncertainty leads to an EVPI of £1.85 billion for the 
NHS health check population in England assuming a time horizon of 10 years. The higher 
expected net benefit for pedometer BIs could be explained by the larger intervention 
effects (expressed in MET-hours) than the other BIs. Thus, there is considerable decision 
uncertainty, and therefore it is potentially worthwhile collecting additional information to 
inform the decision regarding cost-effectiveness. 
Having established that further research in this area is worthwhile, it is necessary to 
identify which parameter or a group of parameters that contribute the most of the overall 
decision uncertainty and for which future research is the most promising. The EVPPI 
analysis found that there was potential value in understanding all six (group of) 
parameters, but the treatment effect parameter had the highest EVPPI value. With a 
population value of £708 million, it is clear that further research on this parameter would 
be beneficial and help reduce uncertainty in the cost-effectiveness decision. However, this 
is the necessary but not sufficient condition. EVSI and ENBS give a clear indication if it is 
beneficial to conduct further research on this parameter but it was not feasible to perform 
these analyses due to computational burden. 
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This indicated that a new study would be of most value to collect unbiased evidence on 
the effectiveness of pedometer BIs in primary care. If such a trial were being undertaken, 
it would be advantageous to collect information on cost and utility parameters as well.  
4.8.2 Model conclusions 
The review of economic evidence undertaken for this research found that although PA 
interventions are generally considered good value for money, there is limited evidence 
regarding the long-term cost-effectiveness of (very) brief interventions promoting physical 
activity in primary care. Therefore, a decision model was designed, developed, and 
populated based on data from the available literature or routine data sources. The model 
was calibrated against seven calibration targets such that simulated values of parameters 
match the observed parameters as closely as possible. 
The model calibration achieved a weighted mean deviation of 12% using the random 
search method. Based on the WMD, it is difficult to conclude how small or large the WMD 
was compared with other risk factor or disease outcome models as there is only one study 
(428) that used a similar approach to calibrate cervical cancer model in the USA. Taylor 
et al. (428) reported a 7% goodness of fit metric (WMD) using the Nelder-Mead and 10% 
using the random search method. Given that the WMD of 12% in this study, the goodness 
of fit metric in this study was comparable with Taylor et al. study. Though their model was 
specific to cervical cancer whereas the current model is a multi-disease model. 
The cost-effectiveness results showed that pedometer BIs to be a cost-effective way of 
promoting physical activity in primary care when compared to BIs such as action planning 
or advice/counselling in primary care. Offering the pedometer BI once every two years 
appeared to be the most efficient repeat interval. However, the cost-effectiveness of 
pedometer BI is conditional on the assumed intervention decay rate and the ability of 
repeat contacts to maintain physical activity. A new study will not eliminate uncertainty but 
is expected to reduce it. Therefore, the expected value of sample information (EVSI) of 
such a study (e.g. randomised trial) will be less than the EVPI. 
An attempt was made to calculate the EVSI and the expected net gain of sampling, which 
is computed as EVSI less the total cost of a proposed study, but due to computational 
demands, it was not possible to generate meaningful and stable results. The EVSI 
analysis requires two-level expectations (Monte Carlo simulations) to be evaluated and 
this “nested” evaluation would lead to a further significant computational burden (161). 
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Chapter 5 Designing trials following an iterative approach 
Although physical activity interventions in primary care are considered good value for 
money, there was limited evidence on the cost-effectiveness of brief PA interventions in 
primary care (Chapter 2). In 2013, the NICE updated 2006 guidance on four commonly 
used methods to increase PA (112) and produced specific guidance on brief advice for 
adults in primary care (448) in which three economic evaluation studies were identified for 
full review. The limited evidence from three studies included in the NICE guidance 
suggested that brief advice on PA in primary care is more cost-effective than usual care. 
Results from the first iteration of the model indicated that the use of pedometer brief 
interventions is the most cost-effective strategy to promote PA in primary care. In addition, 
the value of information analysis showed that there is a value in further exploring the 
effectiveness of pedometer brief interventions. 
The next logical step following the iterative approach is to conduct a primary study. Parallel 
to the review of economic evidence of brief PA interventions in primary care (Chapter 2) 
and economic modelling (Chapter 4), the VBI study research team conducted a feasibility 
study to select the most promising VBIs which could be implemented during the NHS 
Health Check (449). Pedometer interventions were selected from the feasibility study as 
the most promising VBI for the trial evaluation (450). Nevertheless, these steps did not 
happen sequentially because of timing. At the time of selecting pedometer VBI as a 
candidate VBI to be tested in full-scale trial, the VoI results were not available. This limited 
the influence of VoI on the study design. 
The first part of this chapter describes the VBI trial, i.e. the case of the VBI explanatory 
trial followed by within-trial economic evaluation. The within-trial economic evaluation 
evaluates the potential cost-effectiveness of pedometer-based VBI (‘Step It Up’) to 
increase PA in primary care compared to NHS Health Check only (usual care) over the 
trial period. The second part of the chapter (sections 5.4 to 5.5) describes the updating of 
the evidence base used in Chapter 4 with the results from the VBI trial, and then presents 
the results from the second iteration of the model. The results from the second iteration 
of the model include an assessment of the incremental costs and QALYs from pedometer-
based VBI over the long term (10 years) and VoI analysis. Model results are summarised 
followed by a discussion of the practical realities of applying the iterative approach. This 
approach of updating the evidence and re-running the model is in line with the iterative 
framework for economic evaluations described in Chapter 3. The second iteration of the 
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model allows further investigation of the role of VBIs in PA promotion in primary care to 
inform adoption and research priority setting decisions. 
5.1 The case of VBI explanatory trial and economic evaluation 
The VBI study is described earlier in section 1.6 (of Chapter 1). In brief, this was a five-
year research programme funded by the NIHR Programme Grant for Applied Research 
which aimed to develop and evaluate VBIs to increase physical activity that could be 
delivered in a Health Check or another primary care consultation. 
The first stage was a development stage in which evidence and expertise from multiple 
sources were combined to develop a short-listing of promising VBIs. The generation and 
short-listing of VBIs was done through the review of existing evidence (113,451,452), 
consultation with stakeholders, and the VBI study team discussion. This exercise short-
listed four promising VBIs that could be implemented during health check consultations: 
(a) motivational intervention; (b) action planning interventions; (c) pedometer intervention; 
and (d) physical activity diary intervention. The first iteration of the model (Chapter 4) 
included three brief interventions namely (a) exercise advice by the GP; (b) action 
planning interventions; and (c) pedometer interventions compared against usual care (‘do 
nothing’). The feasibility study (449) assessed the feasibility and acceptability of the four 
short-listed VBIs using qualitative interviews with four practitioners and 68 patients. 
Considering the practicability (acceptability, feasibility and cost), and potential efficacy 
from the outset, the feasibility study demonstrated that all four VBIs were acceptable and 
feasible as part of the routine Health Check consultation (449). These criteria were 
considered of equal importance as cost and effectiveness and were given equal weights. 
In the next phase, a pilot trial, hereafter called the VBI pilot trial was conducted to evaluate 
the potential efficacy, feasibility, acceptability and cost of three VBIs in primary care to 
select the most promising intervention for the evaluation in a subsequent large-scale RCT 
(450). The three VBIs evaluated as part of the usual Health Check consultations were 
motivational VBI, pedometer VBI and combined (motivational plus pedometers) VBI 
compared against Health Check consultation only. 
Three hundred and ninety-four adults aged between 40-74 years from 8 GP surgeries 
were recruited in the pilot trial (450), and were allocated to receive one of three VBIs as 
part of the usual Health Check consultation (motivational: n=83, pedometer: n=74, or 
combined: n=80) or the Health Check consultations only (control arm; n=157) by block 
randomisation. This pilot trial aimed to assess the potential efficacy, feasibility, 
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acceptability and cost of three VBIs against the health check alone; and select the most 
promising VBI for evaluation in a subsequent large-scale RCT designed to provide robust 
estimates of effectiveness and cost-effectiveness (450). Physical activity was objectively 
measured by tri-axial accelerometer. Participants were asked to wear the accelerometer 
around their waist for 7 days during all walking hours. 
Accelerometers measure bodily movements in terms of acceleration, i.e. change in 
velocity over time enabling intensity of PA to be quantified (453). These devices can 
measure human activity on the vertical axis (uniaxial) or the anteroposterior and/or lateral 
(biaxial or triaxial) planes. Accelerometers usually provide a count value which is 
frequently used to describe the intensity, frequency and duration of PA, and often also a 
step value, per epoch (454). Energy expenditure, which is a composite of counts from 
these three planes of motion, can be estimated from vector magnitude counts using a 
proprietary algorithm (455). 
The pilot trial results (450) showed that the Motivational and Pedometer VBIs had the 
greatest potential to increase PA compared to the Health Check only. Combined VBI had 
the lowest potential efficacy (i.e. the probability of a positive difference between an 
intervention arm and control arm in mean PA measured by accelerometry at four weeks), 
and Pedometer VBI was the only VBI deliverable within 5 minutes. Practitioners felt most 
confident delivering the Pedometer and Combined VBIs, and the average cost of the VBIs 
ranged from £6.83 per participant for the Motivational VBI to £20.98 per participant for the 
combined VBI (2013 prices) (450). Based on the four criteria (efficacy, acceptability, 
feasibility and cost), Pedometer VBI was selected for evaluation in the main trial to 
estimate the effectiveness, cost-effectiveness and potential public health impact (456). 
The section below describes the evolving evidence base on VBI promoting PA in primary 
care and summaries the effectiveness evidence from the VBI trial. 
5.2 Evolving VBI evidence – the effect of the intervention on 
accelerometer assessed physical activity outcomes (The VBI trial) 
Following the feasibility study (449) and pilot trial (450), the most likely to be effective and 
cost-effective intervention, pedometer-based VBI (VBI trial), was selected to evaluate in 
the large-scale trial. The trial was a pragmatic multicentre randomised controlled trial of 
two parallel groups (pedometer VBI versus Health Check alone) with 1:1 individual 
allocation. Mitchell et al. (456) set out the protocol for methods, including for the economic 
evaluation. In brief, the trial recruited 1,007 study participants from 23 general practices 
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in East of England – 12 practices in Cambridgeshire, 8 in Hertfordshire and Bedfordshire, 
and 3 in Norfolk. Participants were recruited through the NHS Health Check programme. 
The study was conducted between October 2014 and December 2015. The study was 
approved by the East of England – Cambridge East Research Ethics Committee 
(14/EE/1004) and the trial was registered with Current Controlled Trials, number 
ISRCTN72691150. 
Study participants included those eligible for the NHS Health Check (114), i.e. aged 
between 40 to 74 years without pre-existing conditions. The trial excluded participants 
who were not able to provide written informed consent and patients whom their GP 
considered unsuitable for inclusion (456). 
 
Figure 5-1: CONSORT flow diagram showing participant flow through the VBI trial 
Source: Adapted from Figure 1, Hardeman et al. (457) 
The control group received the usual NHS Health Check only. The health check included 
blood pressure measurement, calculation of BMI from measured height and weight, and 
taking a blood sample (116). The intervention group received the pedometer-based 
Participants underwent 
randomisation (n=1,007) 
Allocated to control 
(n=502) 
Allocated to intervention 
(n=505) 
Lost to follow-up 
(n=84) 
Lost to follow-up 
(n=58) 
Participants with 
sufficient wear time of 
accelerometer (n=442) 
Participants with 







use data (n=416) 
Participants with 
healthcare resource 
use data (n=440) 
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intervention (‘Step It Up’) at the end of NHS Health Check. ‘Step It Up’ consisted a five 
minute (brief) face-to-face discussion with practice nurse or healthcare assistant, 
provision of a Yamax Digiwalker SW200 pedometer, a Step Chart for self-monitoring, and 
a ‘Step It Up’ Booklet (456). The ‘Step It Up’ booklet included (456) (a) UK government 
PA recommendations, (b) instructions on how to use the pedometer, (c) health benefits of 
becoming physically active, (d) a graph showing that small changes in PA can lead to 
significant health benefits, (e) tips for achieving more steps, and (f) links to other PA 
resources. 
A total of 1,007 participants were randomised (Figure 5-1) in the trial: 505 participants 
were allocated to the intervention arm and 502 to the control arm of the trial. The trial 
outcomes were measured by accelerometer and questionnaires at three-months post-
intervention. The final analysis included study participants who provided sufficient 
accelerometer data, i.e. at least four days of data with ≥600 minutes per day of wear time, 
to measure primary outcome (n=859). The primary outcome of the trial was physical 
activity measured by tri-axial accelerometry expressed as average vector magnitude 
acceleration – counts per minute (456). 
5.3 Within-trial economic analysis 
Table 5-1 shows the outcomes of accelerometer measured PA at 3 months follow-up. The 
primary outcome, i.e. counts per minute were similar between the groups with an adjusted 
intervention effect of 8.8 counts per minute increase (95% CI: -18.7 to 36.3) relative to 
control. PA outcome was adjusted for gender, five-year age group and primary care 
practice. Likewise, there were no significant differences between trial arms in 
accelerometer measured step counts per day, and time spent in moderate, moderate to 








Table 5-1: Primary and secondary accelerometry outcome data at 3 months follow-up 
 
Intervention (n=417) 
Mean (95% CI) 
Control (n=442) 
Mean (95% CI) 
Intervention vs control 





668 (648 to 689) 660 (641 to 679) 8.8 (-18.7 to 36.3) 0.53 
Step counts per 
day 
8,419 (8,110 to 8,729) 8,191 (7,911 to 
8,471) 
242 (-172 to 656) 0.25 
Time (min/day) in 
moderate activity† 
72.0 (68.8 to 75.2) 71.8 (68.9 to 74.8) 0.3% (-5.4% to 
6.5%) 
0.91 
Time (min/day) in 
moderate to 
vigorous activity† 
77.1 (73.7 to 80.6) 77.0 (73.8 to 80.3) 0.9% (-4.9% to 
7.2%) 
0.76 
Time (min/day) in 
vigorous activity† 




* Counts per minute are vector magnitude counts per minute 
† Means are geometric means for time in activity at different intensities and compared as a 
percentage increase of the intervention group to the control 
‡ Comparison of means is adjusted for gender, five-year age group and practice 
Source: Adapted from Table 2, Hardeman et al. (457) 
An economic analysis alongside the VBI trial was designed (456). The objective of the 
analysis was to compare the costs and cost-effectiveness of a very brief pedometer-based 
intervention with health check alone from the NHS and Personal Social Services 
perspective (NHS and PSS), and societal perspective. The predefined outcome of the 
within-trial economic analysis was the incremental cost per incremental MET-hour of 
physical activity gained estimated from accelerometer counts (456). 
The VBI trial participants wore either ActiGraph GTEX+ or ActiGraph w-GT3X-BT (456) 
accelerometer. ActiGraph website listed 12 different MET algorithms (458) that could be 
used to convert accelerometer counts to MET-hour. Of these 12 algorithms, only 8 
algorithms (from 6 studies) were derived from the adult population who wore an 
















50 adults (25 males, 25 
females) during treadmill 
exercise at three different 












was worn on 
hip) 
25 participants completed four 
bouts of overground walking at 
a range of self-selected speeds, 
played two holes of golf, and 
performed indoor (window 
washing, dusting, vacuuming) 
and outdoor (lawn mowing, 



















was worn on 
hip) 
70 participants completed one 
to six activities within the 
categories of yard work, 
housework, family care, 











Walking on a 
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(accelerometer 
was worn on 
hip) 
28 subjects (11 male, 17 
female) walked on a motorized 














worn on hip) 
28 participants (14 men, 14 
women) walked at a normal 
pace, walked at a fast pace and 
jogged at a comfortable pace on 
an indoor track. One activity 
monitor was worn on the hip 
and one on the lower back. In a 
field study, 34 subjects (18 men, 
16 women) each wore two 
monitors (hip and low back 















worn on hip) 
72 adults (35-45 year olds) 
walked around a level, paved 
quadrangle at what they 
perceived to be a moderate 
pace. Speed, heart rate, and 
Borg rating of perceived 






CPM) - (0.012 
× BM) 
Note:  BM = body mass (kg), CPM = counts per minute, CSA = Computer Science and 
Application, Inc. 
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These eight algorithms listed above used an earlier version of ActiGraph accelerometer 
(model 7164) which are uniaxial accelerometers. In contrast, the VBI trial participants 
wore tri-axial ActiGraph (ActiGraph GTEX+ or ActiGraph w-GT3X-BT) accelerometer 
(456) which measure PA during walking with more precision than the uniaxial 
accelerometer (465). These studies used different domains of PA, for example, treadmill 
exercise, routine activities of daily living (Table 5-2:). Due to these differences and 
uncertainties over the algorithm to convert accelerometer counts per minute to MET-
hours, the analysis below presents an incremental cost per incremental 1000 steps 
increase per day. The VBI trial presents data on accelerometer-measured counts per 
minute as well as other outcomes including step counts per day allowing calculation of 
other incremental cost-effectiveness ratios as desired. 
5.3.1 Identification and measurement of resource use 
The VBI trial prospectively collected resource-use data as an integral part of the trial. A 
search of the Database of Instruments for Resource Use Measurement (DIRUM) 
(www.DIRUM.org) was performed to identify any questionnaires that were used in primary 
care to collect resource usage data. Based on which a bespoke questionnaire was 
developed to collect resource use data at three-month follow-up. The resources monitored 
included health service use in primary care and secondary care, and out-of-pocket 
expenditure on health, sports clubs or other physical activities. The primary care 
consultations included all face-to-face, home visits and telephone consultations with GP, 
practice nurse or other healthcare professional. For patients admitted to the hospital, the 
length of stay and reason of admission were noted. 
The effect of any health problems on the ability to work and perform regular activities 
(workplace productivity) was assessed using an adapted version of the validated Work 
Productivity and Activity Impairment (WPAI): General Health Questionnaire (466). The 
WPAI-general health (WPAI-GH) questionnaire consists of six questions (Appendix D1): 
1=currently employed; 2=hours missed due to health problems; 3=hours missed other 
reasons; 4=hours actually worked; 5=degree health affected productivity while working; 
6=degree health affected productivity in regular unpaid activities (466). These six WPAI 
questions were added at the end of the resource use data collection questionnaire 
resulting in 16 questions altogether.  
An accelerometer and resource use questionnaire were sent to study participants at three 
months after their Health Check. Participants completed the questionnaire and returned 
by mail. 
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All resource use data were collected at the end of 3 months after the respondents Health 
Check using a self-administered questionnaire. Trial administrative/management records 
were used identify of intervention materials such as a pedometer, booklets. Intervention 
delivery time was not recorded in the trial, and it was assumed 5 minutes based on the 
time taken to deliver pedometer VBI in the pilot trial (450). 
5.3.2 Valuation and aggregation of cost 
NHS resource use was valued using national tariffs extracted from the published UK 
sources. All costs were expressed in 2014-15 (the study year) pounds sterling (£) and 
inflated to the same base year when appropriate using HCHS inflation index (467). As the 
study period was less than one year, costs and outcomes were not discounted. Quantities 
of resources (NHS and social care services) used were multiplied by unit costs and 
summed to generate a total cost per participant. Lost productivity was measured in terms 
of wages forgone by multiplying the UK national median hourly wage rate (468) and the 
number of hours reported as taken off work by an individual. 
5.3.2.1 Estimating costs  
The unit costs of GP and community services, and services from other healthcare 
providers were based on PSSRU estimates (Table 5-3). Unit costs for physiotherapist 
home visit and other allied healthcare professionals (home visit or surgery consultation) 
were assumed to be the same as a physiotherapist surgery consultation. Allied health 
professional telephone consultations were assumed to be half of the surgery consultation. 
 
Table 5-3: Unit costs of primary care, therapy services and social care 
Resource item Unit cost Source and basis of estimate 
Primary care   
GP surgery consultation £44.00 Derived from the cost per surgery consultation 
from PSSRU 2014-15 (467) p. 177 including 
qualification 
GP home visit £116.30 PSSRU 2012-13 (469) p. 191 per out of 
surgery visit inflated to 2015 prices using the 
HCHS index (PSSRU 2014-2015 (467) p. 242) 
GP telephone consultation £27.00 PSSRU 2014-15 (467) p. 177, per surgery 
consultation lasting 7.1 min incl. direct care 
staff costs and qualifications 
Nurse surgery consultation £14.47 PSSRU 2014-15 (467) p. 174, per hour of 
face-to-face contact including qualification × 
15.5 min per surgery consultation 
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Table 5-3 (continued) 
Resource item Unit cost Source and basis of estimate 
Nurse home visit £56.00 PSSRU 2014-15 (467) p. 174, per hour of 
face-to-face contact including qualification 
(assumes home visit takes one hr) 
Nurse telephone consultation £14.47 Assumed same as surgery consultation 
Specialist nurse surgery 
consultation 
£25.00 PSSRU 2014-15 (467) p. 175, per surgery 
consultation (15 mins) including qualifications 
Community nurse/midwife 
consultation 
£27.92 PSSRU 2014-15 (467) p. 169, assumed same 
as community nurse, 25 min consultation 
including qualification 
Therapy services or other allied health professional costs 
Physiotherapist surgery 
consultation 
£47.95 PSSRU 2012-13 (469) p. 175, mean cost for 
one-to-one contact inflated to 2015 prices 
using the HCHS index (PSSRU 2014-2015 
(467) p. 242) 
Physiotherapist home visit £47.95 Assumed same as Physiotherapist surgery 
consultation 
Other AHP surgery 
consultation 
£47.95 Assumed same as Physiotherapist surgery 
consultation 
Other AHP home visit £47.95 Assumed same as Physiotherapist surgery 
consultation 
Other AHP telephone 
consultation 
£23.97 Assumed half of the surgery consultation 
Chiropractor surgery 
consultation 
£55.00 Mean cost of chiropractor consultation (470) 
Chiropodist surgery 
consultation 
£41.83 PSSRU 2012-13 (469) p. 178, mean cost for a 
contact in chiropody/podiatry services inflated 
to 2015 prices using HCHS index (PSSRU 
2014-2015 (467) p. 242) 
Osteopathic consultation £41.83 Assumed same as a chiropodist 
Cognitive behaviour therapy £98 PSSRU 2014-15 (467) p. 90, per session 
Social care   
Health visitor surgery 
consultation 
£25.33 PSSRU 2014-15 (467) p. 171, per hour of 
patient-related work including qualification- 
assumed patient contact time of 20 min 
Social worker office visit £79.00 PSSRU 2014-15 (467) p. 188, per hour of 
client-related work including qualification 
Other costs   
Travelling costs £0.45 HMRC (471) cost of car transport per mile 
Time off work (hourly wage) £14.08 ONS Annual Survey of Hours and Earnings 
2015 (468), median gross (for men and 
women) hourly earnings 
Note: 
AHP: Allied Health Professionals, HCHS: Hospital and Community Health Service, HMRC: 
Her Majesty’s Revenue and Customs, ONS: Office for National Statistics, PSSRU: Personal 
Social Services Research Unit 
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For costs relating to outpatient, inpatient or day case procedure, a healthcare resource 
group (HRG) code was identified based on the description of the reasons given for 
outpatient visit, inpatient stay or day case procedure. If the participant did not record the 
reason for secondary care, i.e. hospital visit or inpatient stay, a weighted average cost 
extracted from the National Reference Costs 2014-15 Tariff (472) was used (Table 5-4). 
Table 5-4: Secondary care costs 
Resource item Unit cost (£) Source and basis of estimate 
Outpatient appointment 114.50 Reference Costs 2014-2015 (472), weighted 
average of all outpatient attendance 
Hospital inpatient stay 3,573.02 Reference costs 2014-2015 (472), weighted 
average of all elective inpatient stays 
Day case procedure 720.78 Reference costs 2014-2015 (472), day cases 
HRG data, worksheet DC, weighted average 
A&E attendance 131.92 Reference costs 2014-2015 (472), worksheet 
EM, a weighted average of all A&E attendance 
Cost of mammogram 48.23 Robertson et al. (473), inflated to 2015 prices 
using the HCHS index (PSSRU 2014/2015 
(467) p. 242) 
Note: 
A&E: Accident and Emergency, HCHS: Hospital and Community Health Service, Reference 
Costs: Department of Health and Social Care unit costs,  
Patients’ out of pocket expenditures such as road transport to a health club using their 
own vehicle were costed at £0.45 per mile as per HMRC guidance (471). Only 2 
participants reported the use of hospital or community transport and thus this category of 
cost was excluded from the analysis. 
5.3.3 Productivity costs 
Productivity costs were defined as costs due to lost or impaired ability to work or to engage 
in leisure activities (466). The WPAI-GH questionnaire considered the number of hours 
missed from work due to any health problems, the number of hours missed from work 
because of other reasons (such as vacation, holidays or time off), hours worked and 
productivity while working. The WPAI-GH measures productivity (questions 5 and 6) using 
a visual analogue scale ranging from zero (health problem did not affect work) to ten 
(health problems completely prevented from working) (466). The scoring of WPAI 
instrument yields four types of scores: (a) absenteeism – work time missed, (b) 
presenteeism – impairment at work or reduced on the job effectiveness, (c) work 
productivity loss – overall work impairment, i.e. absenteeism plus presenteeism, and (d) 
activity impairment due to health. These scores are expressed in percentages by 
152 
multiplying the scores by 100 which was done using scoring instructions for the WPAI 
general health (474). Productivity loss costs were calculated by multiplying the total 
number of hours lost by their hourly income. 
5.3.3.1 Cost of the intervention  
The cost of the ‘Step It Up’ intervention includes time spent by the practice nurse or 
healthcare assistant in delivering the intervention and intervention materials. The pilot trial 
(450) recorded the intervention delivery time and the mean delivery time for pedometer 
VBI was 5 minutes. Cost per minute of face-to-face contact for practitioner was based on 
figures from the PSSRU 2015 unit costs (467), taking the midpoint of the relevant scales 
and including employer costs and appropriate overheads. The cost of a pedometer, 
pedometer booklet and step-chart are sourced from the trial records. 
5.3.4 Measurement, valuation and aggregation of outcomes 
The primary outcome of the trial was PA determined by accelerometer worn for 
approximately one week: total volume of body movement expressed as average vector 
magnitude acceleration (counts per minute) at three-month follow-up (456). Step counts 
(average step counts per day) and the average number of minutes per day spent in 
sedentary/light activity, moderate activity, vigorous activity and moderate or vigorous 
activity, all measured using the accelerometer, were secondary outcomes. 
5.3.5 Method of analysis 
5.3.5.1 Missing data 
Of the 1,007 participants randomised, 859 participants provided ‘adequate’ wear time data 
on the primary outcome at three-month follow-up. Data were considered ‘adequate’ if 
there were at least four days of accelerometer data, with ≥600 minutes/day of wear time. 
Eight hundred and sixty-four participants returned the completed resource use 
questionnaire: 422 in the intervention and 442 in the control arm. Of the 859 who had valid 
data on primary outcome, 856 (99.6%) participants had resource use data available, i.e. 
only three participants did not have resource use data available (Figure 5-1). The 
economic analysis included complete case dataset (n=856) that is those participants who 
had valid data on primary outcome and completed resource use questionnaire. In the 
sensitivity analysis, to account for missing health care, transportation and lost productivity 
costs (n=859), the mean imputation technique was used (475), and the results amongst 
the complete case sample and full sample with imputed data were compared. 
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5.3.5.2 Incremental cost-effectiveness analyses 
The analysis followed that specified in the within-trial health economic analysis plan in the 
study protocol (456). The analysis used patient-specific resource use and costs, and 
health outcomes. Incremental cost and incremental health effect, here, the difference in 
the average number of step counts per day per participant between study groups were 
calculated. Regression analysis was used to adjust incremental cost and health outcome 
estimates for baseline covariates. Predefined covariates (456) included in the model are 
primary care practice, gender and age group. The ICER was expressed in thousands of 
steps, thus representing incremental cost per 1,000 additional step counts achieved. 
Subgroup analyses were conducted to examine the differential mean cost between the 
intervention and control groups by pre-specified subgroup variables: gender, age (40-59; 
60-74 years), educational qualifications, marital status, employment status, occupation 
and household income (<£31,000, ≥£31,000). 
5.3.5.3 Sensitivity analyses 
Cost-effectiveness planes and cost-effectiveness acceptability curves (CEACs) were 
constructed to reflect the stochastic uncertainty surrounding the mean incremental cost-
effectiveness (476). A non-parametric bootstrapping analysis (477) (resampling with 
replacement, 10,000 iterations) was used to generate scatterplot of the increment cost 
and incremental health effect. The CEAC indicates the probability of the ‘Step It Up’ 
intervention being cost-effective at varying society’s willingness to pay per an additional 
1000 steps. 
5.3.6 Results 
Baseline characteristics of 1007 participants randomised were similar in each group 
(Table 5-5). The mean age of the participants was 56 years, and two-thirds were female. 







Table 5-5: Baseline characteristics of participants allocated to intervention and control 
Characteristics 
No of people randomised at 
baseline 
No of people with sufficient 








Mean (SD) age 56.5 (9.4) 55.7 (9.6) 56.7 (9.3) 56.5 (9.5) 
Female % (number) 61 (305) 63 (316) 61 (269) 62 (260) 
White ethnicity % (number) 95 (476) 96 (484) 95 (420) 96 (401) 
Married or cohabiting % 
(number) 
81 (375/465) 80 (383/480) 81 (330/411) 81 (320/398) 
Have dependants % 
(number) 
35 (164/468) 39 (186/482) 33 (137/411) 38 (153/399) 
Work status n=472 n=482 n=411 n=396 
Paid work 61 (286) 62 (301) 60 (246) 60 (236) 
Unemployed/homemaker 6 (29) 6 (28) 6 (24) 6 (22) 
Full-time student 0 (0) 0 (1) 0 (0) 0 (1) 
Retired 32 (152) 31 (148) 34 (141) 35 (137) 
Other 1 (4) 1 (4) 0 (0) 0 (0) 
Income n=410 n=424 n=358 n=351 
Less than £18,000 26 (105) 21 (88) 25 (90) 19 (67) 
£18,000 - £30,999  22 (91) 22 (94) 23 (84) 23 (81) 
£31,000 - £51,999 28 (114) 29 (124) 29 (104) 31 (108) 
£52,000 - £100,000 18 (72) 20 (85) 16 (59) 20 (71) 
> £100,000 7 (28) 8 (33) 6 (21) 7 (24) 
Occupational group n=295 n=314 n=255 n=250 
Manual 24 (71) 27 (84) 22 (55) 25 (62) 
Non-manual 68 (200) 65 (203) 70 (179) 68 (169) 
Other 8 (24) 9 (27) 8 (21) 8 (19) 
Highest qualification n=485 n=494 n=425 n=409 
None 9 (46) 9 (44) 8 (34) 9 (36) 
GCSE 60 (290) 66 (326) 62 (264) 67 (276) 
Note: Values are % (numbers) unless otherwise stated 
Source: adapted from Table 1, Hardeman et al. (457) 
Table 5-6 presents data on resource use by type of contact for each arm of the trial. 






Table 5-6: Average health and social care utilisation per participant, using complete cases, 





Mean (SD) Mean (SD) 
Primary Care Consultations      
GP surgery visit (442, 422) 0.50 (0.85) 0.46 (0.72) 
Nurse surgery visit (442, 422) 0.28 (0.63) 0.23 (0.55) 
Other HP surgery visit (442, 422) 0.15 (0.65) 0.12 (0.52) 
GP home visit (442, 422) 0.00 (0.00) 0.01 (0.08) 
Nurse home visit (442, 422) 0.002 (0.05) 0.00 (0.00) 
Other HP home visit (442, 422) 0.01 (0.24) 0.01 (0.11) 
GP phone consultation (442, 422) 0.07 (0.53) 0.07 (0.28) 
Nurse phone consultation (442, 422) 0.03 (0.21) 0.01 (0.10) 
Other HP phone consultation (442, 422) 0.01 (0.08) 0.02 (0.21) 
Hospital visits      
Outpatient visit (442, 422) 0.28 (0.69) 0.22 (0.65) 
Day case procedures (442, 422) 0.01 (0.12) 0.02 (0.15) 
Hospitalisations (442, 422) 0.004 (0.07) 0.01 (0.08) 
A&E visit (442, 422) 0.02 (0.14) 0.01 (0.15) 
Health club membership      
Health club visits  (138, 156) 2.46 (1.54) 2.55 (1.57) 
Time spent on travel to health club  (139, 155) 2.00 (1.20) 1.99 (1.22) 
Loss of productivity, hours      
Hours off work due to illness (263, 244) 0.32 (2.46) 0.26 (2.12) 
Hours off work due to other 
reasons 
(254, 237) 1.97 (6.11) 2.16 (7.62) 
 
5.3.6.1 Cost of intervention and healthcare services 
Delivery of ‘Step It Up’ intervention cost £18.04 per participant. The cost of intervention 
included a face-to-face nurse consultation (£4.67), a pedometer (£11.25), pedometer 
booklet (£1.52) and step-chart (£0.60). The duration of face-to-face consultation was not 
recorded in the trial but based on the pilot trial (450), in which delivery of pedometer VBI 
was shorter than five minutes, practice nurse’s five minute time was costed. 
Comparing the ‘Step It Up’ with Health Check only at three-month follow-up (Table 5-7) 
show that the average cost per participant was higher in the intervention group. The 
inclusion of ‘Step It Up’ delivery cost to NHS costs resulted in the intervention group 
costing £16.72 (95% CI: -31 to 64, p=0.49) more per participant than the control group. 
Total societal costs which included NHS costs, out of pocket expenditure and lost 
productivity were £54.07 (95% CI: -97 to 205, p=0.48) more per participant in the 
intervention group. When adjusted for covariates, at three months, the costs of the 
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intervention group were higher than that of the control group for both NHS and societal 
perspectives. 
 














Effects      
Total PA volume 
(counts per 
minute) 
(417, 442) 668 (213) 660 (202) 8 (14) 9 (14) 
Step counts per 
day 




228 (212) 242 (211) 
Costs      
Cost of 
intervention 
(416, 440) 18.04 
(0.00) 
0.00 (0.00) 18.04 
(0.00) 
 




-3.14 (3.95)  










































* Comparison of means is adjusted for gender, five-year age group and practice. 
5.3.6.2 Cost-effectiveness 
Based on the adjusted incremental estimates, the ICER was £96.32 per 1000 steps using 
the NHS costs and £238.89 per 1000 steps using the societal perspective respectively 
(Table 5-8). The values presented in Table 5-8 are bootstrapped mean and 95% credible 
intervals. The main trial reported that the intervention group increased daily step counts 
by 242 (95% CI: -172 to 656) compared with control group (442 control and 417 
intervention) whereas the incremental step counts presented in the table are for 856 (440 
control and 416 intervention) observations with complete cost and outcomes data only. 
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Table 5-8: Cost-effectiveness analysis from the NHS and societal perspectives  
Analysis 




Inc step counts 
(95% CI) 
ICER Inc cost 
(95% CI) 






(-26 to 69) 
224 
(-193 to 640) 
£96.32 
21.21 
(-26 to 69) 
242 


















CI confidence interval, ICER incremental cost-effectiveness ratio for 1000 additional steps, Inc 
incremental. Incremental costs and step counts were adjusted for gender, five-year age group 
and practice. 
The cost-effectiveness planes (Figure 5-2) showed that the joint distribution of incremental 
costs and health outcomes with the majority (69% using NHS perspective and 65% using 






Figure 5-2: Cost-effectiveness plane for the ‘Step It Up’ versus the control group at three 
months using (a) NHS perspective, (b) societal perspective 
The CEAC (Figure 5-3) showed that if the society is willing to pay a greater amount for 
additional steps, the likelihood that the ‘Step It Up’ is cost-effective rises to 53% (NHS 
perspective) when society’s willingness to pay reaches £100 for 1000 additional steps. 
When considering the NHS perspective, the probability that the intervention would be 
cost-effective is 84% (highest probability) at a willingness to pay threshold of £1150 per 
1000 additional steps. Likewise, using the societal perspective, the likelihood that the 
‘Step It Up’ is cost-effective rises to 36% when willing to pay value reaches to £100 for 
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1000 additional steps, with 81% (highest probability) at a willingness to pay threshold of 
£1450 per 1000 additional steps. 
 
Figure 5-3: Cost-effectiveness acceptability curve  
 
5.3.6.3 Value of lost productivity 
On average 58% participants in the intervention (n=402) and 62% in control arm (n=422) 
were in work. Participants in the intervention group who were employed full time lost fewer 
work hours during the previous seven days compared to the control group (-0.06, 95% CI: 
-0.49 to 0.37) but the difference did not reach statistical significance. They also reported 
slightly higher presenteeism and overall better work impairment scores. On average 1% 
of the participants in both study groups missed work due to poor health. No significant 
difference in impairment while working due to health and overall work impairment due to 









































Willingness-to-pay for an additional 1,000 steps (£)
NHS perspective Societal perspective
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(95% CI) N Mean (SD) [Min-Max] N Mean (SD) [Min-Max] 
Participants in work (n=824) 422 62.1 (48.6)  402 58.4 (49.3)  
-3.6  
(-10.3 to 3.1) 
Percent work time missed due to 
health (absenteeism) 
233 1.1 (9.4) [0–100] 214 0.9 (6.8) [0–75] 
-0.22 
(-1.7 to 1.3) 
Percent impairment while working 
due to health (presenteeism) 
249 4.9 (11.3) [0–60] 221 6.0 (13.9) [0–70] 
1.1 
(-1.2 to 3.3) 
Percent overall work impairment 
due to health 
229 5.0 (11.5) [0–60] 210 6.7 (15.9) [0–80] 
1.7 
(-0.9 to 4.3) 
All participants (n=819)          
Percent activity impairment due to 
health 
421 12.7 (23.2) [0–100] 390 11.8 (21.7) [0–100] 
- 0.9 
(-4.0 to 2.2) 
Note: 




5.3.6.4 Subgroup analysis 
Table 5-10 reports the incremental cost, outcome (steps counts) and ICER between 
intervention and control group in subgroups. The absolute cost and outcome differ across 
subgroups; however there were no significant differences between study groups within 
any one subgroup. 
Table 5-10: Cost-effectiveness analyses of ‘Step It Up’ versus Health Check only in 
patient-groups, using NHS perspective 









Total (n=853) 21.55 
(-26 to 69) 
224 
(-193 to 640) 
96.32 
(-996 to 1168) 
Gender Female (n=529) -25.11 
(-81 to 30) 
130.15 
(-367 to 628) 
-192.89 
(-1811 to 1526) 
Male (n=327) 83.92 
(-2 to 170) 
348.10 
(-395 to 1092) 
241.08 
(-1799 to 2140) 
Age 40–59 years (n=488) 30.04 
(-15 to 75) 
322.85 
(-247 to 893) 
93.04 
(-834 to 1016) 
60–74 years (n=368) 1.88 
(-91 to 95) 
17.62 
(-585 to 620) 
106.99 
(-2282 to 1653) 
Educational 
qualification 
None or GCSE 
(n=607) 
-2.69 
(-63 to 58) 
292.27 
(-216 to 801) 
-9.20 
(-736 to 835) 
Other (n=224) 19.84 
(-10 to 50) 
11.92 
(-763 to 787) 
1665.13 
(-1012 to 838) 
Marital status Single (n=158) 98.79 
(-17 to 214) 
435.27 
(-653 to 1523) 
226.96 




(-60 to 52) 
183.08 
(-291 to 657) 
-22.08 
(-1699 to 1367) 
Paid work Paid work (n=479) 42.61 
(-16 to 101) 
275.09 
(-292 to 842) 
154.89 
(-1370 to 1641) 
No paid work 
(n=370) 
-6.81 
(-85 to 70) 
34.21 
(-586 to 654) 
-199.04 
(-1366 to 1487) 
Occupation Manual (n=117) 107.29 
(-105 to 319) 
1080.21 
(-356 to 2516) 
99.32 




(-33 to 46) 
49.39 
(-536 to 635) 
133.37 
(-774 to 784) 
Income < £31,000 (n=319) -34.22 
(-113 to 45) 
196.29 
(-567 to 959) 
-174.32 
(-1693 to 1583) 
≥ £31,000 (n=537) 47.47 
(-12 to 107) 
217.98 
(-274 to 710) 
217.76 
(-2127 to 2614) 
Note: *incremental cost per 1000 additional steps, 95% non-parametric credible intervals (CrI) 
based on 10,000 bootstraps. 
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5.3.7 Discussion 
The within-trial analysis showed no significant differences between groups in objectively 
measured physical activity (counts per minute, and step counts per day) and healthcare 
resource use at three-month follow-up. The ‘Step It Up’ intervention cost £18.04 per 
patient. When the NHS perspective was used, intervention participants increased their 
physical activity by 1000 step counts per day at an incremental cost of £96 above the 
control arm. An intervention is considered cost-effective if (a) it costs less and is more 
effective than the comparator intervention or (b) costs more and is more effective, but 
society is willing to pay for the additional benefit (step counts). In the latter scenario, the 
ICER is less than λ, i.e. the threshold value that society is willing to pay for additional 
steps. 
Johnson et al. (478) evaluated the cost-effectiveness of a lifestyle based pedometer 
programme in primary care in Australia and reported a similar outcome to this study. 
However, their study included adults with type-2 diabetes where the ‘Step It Up’ 
intervention included apparently healthy adults. The ICER for Johnson et al. (478) study 
was AU$ 111 (£54, 2015 prices (134)) per 1000 step counts which was lower than the 
present study. Johnson et al. also estimated implied threshold value of AU$ 176 (£86, 
2015 prices (134)) per additional 1000 steps. There is no such threshold value for 
additional step counts in England thus it is unclear if the society is willing to pay £96 for 
an additional 1000 steps. There was also uncertainty surrounding the point estimate, at a 
threshold value of £100 per additional 1000 steps, the probability that ‘Step It Up’ is cost-
effective is 53% (NHS perspective) which increases to 84% (highest probability) at a 
threshold value of £1150 per 1000 additional steps. 
The within-trial analysis was nested within a well-designed population-based pragmatic 
RCT and used individual patient level data (both cost and effectiveness data) collected at 
three-month follow-up. The trial captured both NHS resource use and patients’ out of 
pocket expenditure on health and sports. However, the trial did not measure PA at 
baseline nor collect data on the quality of life impacts (such as QALY gains) of the 
intervention rather WPAI questionnaire was used to assess the effect of any health 
problems on the ability to work and perform regular activities. 
The QALY is a common outcome used in the economic evaluation. As the VBI trial did not 
collect EQ-5D data, this limited the comparison of cost-effectiveness results from the 
within-trial economic analysis with other studies reporting cost per QALY outcome 
including results from the first iteration of the decision model described in Chapter 4. The 
cost of pedometer intervention used in the first iteration of the model (Table 4-31) was 
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£54.33 (£58 when inflated to 2015 price using the HCHS index (467)) which was higher 
than the cost of ‘Step It Up’ (£18.04, 2015 price). The higher cost of pedometer 
interventions used in the first iteration of the model was due to the fact that the pedometer 
interventions included in the Bravata et al. meta-analysis (151) were more intensive than 
‘Step It Up,’ i.e. included > 5 minutes of PA consultation that increased the cost of the 
intervention. The model included both intervention and associated disease costs over a 
10-year time horizon, with health outcomes measured in terms of QALYs. The within-trial 
economic analysis, however, included intervention and healthcare resource use costs 
over a 3-month period. 
Previous studies indicated a positive association between PA and health-related quality 
of life in general and older adult population (443,479,480), but this evidence is mostly 
based on cross-sectional data which limits the generalisability. Baseline measurement in 
a pragmatic trial such as ‘Step It Up’ may preclude an intervention effect over behaviour 
(119,481,482). Furthermore, the earlier feasibility pilot (450) conducted as part of the VBI 
research programme showed that baseline measurement reduced health check uptake. 
In addition, this was not acceptable to GP practices, as health check constitutes routine 
care. The study population were healthy middle-aged adults (i.e. without pre-existing 
conditions) and who were already relatively active. This may have limited capacity for a 
VBI to have an effect over and above the health check alone. Although one would not 
expect much change in health-related quality of life in 3 months’ time in an apparently 
healthy population post-intervention, it was not possible to report cost per QALY outcome 
as the trial did not use QALYs to value health outcomes. As a result, it is not possible to 
check if the ICER is above or below the NICE threshold value of £20,000 to 30,000 per 
QALY. 
Previous meta-analyses indicated that pedometer-based interventions increase walking 
by 2,000 to 2,500 steps per day (151,436). The PACE-UP trial evaluated the effectiveness 
and cost-effectiveness of a pedometer-based 12-week programme to increase PA among 
adults aged 45-75 year olds in London and found a significant effect at 3 and 12 months 
(1173 and 677 additional steps respectively) (483). The PACE-UP trial included 20 
minutes of consultation with the practice nurse compared to 5 minutes in the VBI trial. 
The study found no evidence of the effect of a pedometer-based VBI (‘Step It Up’) 
regarding objectively measured physical activity at three-month follow-up compared to 
usual NHS Health Check only. The within-trial economic analysis showed a small added 
cost for a small and uncertain benefit, with a most plausible estimate of the incremental 
cost-effectiveness of £96 per 1000 additional steps. 
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Costs included in the decision model (Chapter 4) were intervention and disease costs. 
The trial included intervention costs and costs associated with healthcare resource use 
over 3 months that included any contacts in primary care (for example GP visits) and 
hospital care (outpatient, inpatient, day case procedures and A&E). The model used 
QALYs to value health outcome whereas health benefits were measured in terms of 
increase in step counts in the trial. Following the iterative framework, the next logical step 
is to incorporate the evidence from the VBI trial, i.e. updating the effectiveness evidence 
used and re-running of the decision model developed in Chapter 4. 
The sections below describe updating the evidence base and model parameter for the 
second iteration of the model followed by cost-effectiveness and value of information 
analyses. The discussion section compares the results with the first iteration of the model 
and within-trial economic analysis. It also discusses the practical realities of applying the 
iterative approach. 
5.4 Incorporating evidence from the VBI trial into the decision 
model reported in chapter 4 
The VBI trial (456) was the first to consider pedometer-based VBIs compared to the NHS 
Health Check alone. The evidence from the VBI trial updates knowledge and 
understanding of the VBIs in primary care and their potential benefits. As per the decision 
analytic model for evaluating PA interventions, evidence from the VBI trial did not result 
in any structural changes to the model. Prior to the VBI trial, there was limited evidence 
on the effectiveness and cost-effectiveness of VBIs (less than 5 minutes) in primary care 
(113,149,451,452), and therefore the VBI trial has revised the knowledge and 
understanding of the (very) brief PA interventions in NHS Health Check population. 
Despite the increasing number of PA interventions evaluated in the primary care and/or 
community setting (detailed in Chapter 2), little evidence on the effectiveness and cost-
effectiveness of brief interventions in PA promotion were available for the first iteration of 
the decision analytic model presented in Chapter 4. In 2006, NICE endorsed the 
importance of PA as a means of promoting good health and preventing disease and 
produced guidance on four common methods used to increase the PA levels (112). The 
four interventions considered in this guidance were brief interventions in primary care, 
exercise referral schemes, pedometers, and community-based walking and cycling 
schemes. The guidance was subsequently updated in 2013, with separate guidance for 
brief PA interventions in primary care (448). The guidance aims to support the routine 
provision of brief PA advice in primary care practice. The review of economic evidence 
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conducted for the updated guidance on brief advice in primary care reviewed three papers 
including one study based on an Australian population indicated cost-effectiveness of brief 
advice on PA in primary care compared to usual care, but the evidence was based on 
weak effectiveness data and did not fully explore uncertainty. 
5.4.1 The VBI trial evidence 
As mentioned in above (sections 5.1 and 5.2), the VBI trial was conducted to assess the 
effectiveness and cost-effectiveness of a pedometer-based very brief advice to increase 
PA in primary care (456). Section 5.2 summarised the effectiveness evidence of the VBI 
trial, i.e. a mean increase of 242 steps per day (95% CI: -172 to 656) at three-month 
follow-up. However, this difference did not reach statistical significance at the conventional 
5% level. 
The effectiveness evidence used for pedometer BIs in the first iteration of the decision 
analytic model (Chapter 4) used evidence from a meta-analysis of 8 RCTs evaluating the 
effectiveness of pedometer interventions (151). The review reported that intervention 
participants significantly increased their PA by 2491 steps per day (95% CI: 1098 to 3885, 
p<0.001) than control participants. This meta-analysis compared the mean change in 
steps per day from baseline between study groups. To update the meta-analysis with the 
new evidence from the VBI trial, we require both baseline and follow-up PA measurement 
for both groups. One of the limitations of the VBI trial was that it did not objectively 
measure physical activity at baseline. As a result, to update the evidence base with new 
effectiveness data from the VBI trial, we require some assumptions regarding baseline 
activity levels. 
A PubMed search was performed to identify any pedometer-based RCTs in the UK 
general practice. From the search hits, two RCTs of pedometer interventions were 
identified: the VBI pilot trial – a feasibility study (450) and the PACE-UP trial (484) which 
are described briefly below. 
The VBI pilot trial (450) compared three VBIs with NHS Health Check. The three 
interventions compared (described in section 5.1) were motivational VBI, pedometer VBI 
and motivational plus pedometer VBI (combined). The follow-up duration of the pilot trial 
was four weeks, and PA was objectively measured using accelerometers at 4-week 
follow-up. 
Harris et al. (484) conducted a three-arm parallel cluster RCT to assess the effectiveness 
of a pedometer-based walking intervention delivered by post or through primary care 
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nurse supported PA consultations (PACE-UP). The intervention group with nurse support 
received a pedometer, patient handbook, PA diary and three individually tailored nurse 
consultations on PA whereas post-intervention participants did not receive nurse support. 
The consultation duration ranged from 10 to 20 minutes. The intervention group with nurse 
support was of interest to this study. The trial recruited 1023 patients from six general 
practices in South London, UK aged between 45 to 75 years and assigned to either control 
group or one of two intervention groups (postal or nurse intervention). Physical activity 
was measured using an accelerometer at baseline, 3 months and 12 months. 
Table 5-11 summaries the baseline characteristics of the VBI trial (457), VBI pilot trial 
(450) and PACE-UP trial (484). Both the VBI pilot and the main trial had a higher 
proportion of female study participants compared to the PACE-UP trial. VBI trial 
participants were more active than the PACE-UP trial when PA was (subjectively) 
measured at baseline. Both the VBI trial and PACE-UP trial used general practice physical 
activity questionnaire (GPPAQ) (485) to measure the baseline activity level. The GPPAQ 
was commissioned by the Department of Health and Social Care in 2006 and developed 
by the London School of Hygiene and Tropical Medicine (485). It is designed as a 
screening tool to assess PA levels within primary care and provides a simple 4-level 
physical activity index (PAI) reflecting an individual’s current PA. The GPPAQ forms part 




Table 5-11: Baseline characteristics of pedometer-based studies conducted in the UK general practice and baseline PA measurement 
 











Mean age (SD), years 55.7 (9.6) 56.5 (9.4) 53.3 (8.4) 53.9 (10.1) – – 
Gender n (%) female 316 (63) 305 (61) 45 (61) 92 (59) 128 (37) 115 (34) 
Ethnicity n (%) white 484 (96) 476 (95) 72 (97) 147 (97) 267 (80) 253 (78) 
Employment status, n (%) 
employed 
301 (62) 286 (61) 56 (79) 106 (68) 190 (56) 190 (57) 
Physical activity status (GPPAQ), n (%)      
Inactive 69 (14) 63 (13) – – 156 (47) 159 (49) 
Moderately inactive 81 (16) 97 (19) – – 83 (25) 69 (21) 
Moderately active 178 (35) 176 (35) – – 60 (18) 50 (16) 
Active 177 (35) 166 (33) – – 34 (10) 44 (14) 
Baseline step-counts per day, 
mean (SD) † 





Step-counts per day at 1m 








* Nurse support group 
† accelerometry data adjusted for the week and day of wearing the accelerometer 
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The effectiveness evidence was updated using R package for meta-analysis ‘meta’ (487). 
As the VBI trial did not collect objectively measure baseline PA, the following assumptions 
were made while updating the evidence base (meta-analysis): 
5.4.1.1 Base case assumption 
In the base case, only PA measurement at follow-up was compared. This was done 
because objectively measured baseline PA data were not available for the VBI trial 
participants. For this, PA measurement at follow-up was extracted from the original 
pedometer meta-analysis (151) then VBI trial data were added in, and the meta-analysis 
was updated. 
 
Figure 5-4: Forest plot of the difference in the change in step counts at follow-up among 
participants randomly assigned to pedometer interventions vs control (base case) 
Source: Adapted from Bravata et al. (151) and Hardeman et al. (457).  
The updated evidence (Figure 5-4) gives an effect size of 1,819 steps per day (95% CI: 
684 to 2954, p<0.01) which was lower than the one used in the first iteration of the 
evidence (2491 steps; 95% CI: 1098 to 3885). 
5.4.1.2 Sensitivity analysis 
Two sensitivity analyses were performed to test the base case assumption while updating 
the effectiveness of pedometer interventions. In the first scenario, VBI trial participants 
were assumed to have the same baseline PA levels reported for the PACE-UP trial 
participants (484). For this, baseline activity level for control group (mean= 7379; sd=2696 
168 
steps/day) and the nurse-support intervention group (mean=7653; sd=2826 steps/day) 
were used. Figure 5-5 shows that 572 intervention participants significantly increase 
physical activity by 2143 steps per day more than 564 control participants (95% CI: 936 
to 3351 steps per day, p<0.01; I2=93).  
 
Figure 5-5: Forest plot of the difference in the change in step counts among participants 
randomly assigned to pedometer interventions vs control using baseline PA data from the 
PACE-UP trial (scenario 1) 
Source: Adapted from Bravata et al. (151), Hardeman et al. (457) and Harris et al. (484). 
In the second scenario, it was assumed that the baseline PA measures (steps/day) for 
both study groups in the VBI trial were similar and replaced by PA data for the of control 
group participants in the pilot trial (450). This assumption is based on the fact that baseline 
characteristics of study participants for both groups of the VBI pilot and main trial were 
similar (Table 5-11). As the baseline PA measurement was not available for the VBI pilot 
trial participants, accelerometer-measured step counts at one-month follow-up for the 
control group (health check only) of the VBI pilot trial (450) were used. Given the same 
patient population, i.e. NHS Health Check, similar baseline characteristics of study 
participants and study setting in both pilot and the main trial, it is reasonable to assume 
same PA levels for NHS Health Check population.  
This assumption effectively gives the same mean difference in change in steps/day for 
the VBI trial, i.e. an increase of 228 steps/day. Figure 5-6 shows the difference between 
the increase in physical activity (step counts per day) among intervention and control 
group participants. The effect size for this scenario is 2172 steps per day (95% CI: 1019 
to 3326; p<0.01). 
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Figure 5-6: Forest plot of the difference in change in step counts among participants 
randomly assigned to pedometer interventions vs control while using control group PA 
level from the VBI pilot trial for VBI trial participants (scenario 2) 
Source: Adapted from Bravata et al. (151), Hardeman et al. (457) and Pears et al. (450). 
5.4.2 Changes to the decision analytical model 
Prior to the VBI trial, there was limited evidence on the effectiveness and cost-
effectiveness of VBIs in promoting PA in primary care. Incorporating the pedometer VBI 
evidence from the VBI trial into the decision analytic model developed in Chapter 4 did 
not require any structural adjustments to the decision model. The VBI trial provided the 
short-term effectiveness of a pedometer VBI and the cost of ‘Step It Up’ intervention. 
5.4.3 Parameterisation of the decision analytical model 
5.4.3.1 Short-term effectiveness of pedometer VBI 
By using the method described above to update the evidence base for pedometer 
intervention, the short-term effectiveness of the pedometer intervention was updated. In 
the base case, i.e. using PA levels at follow-up (Table 5-12) shows that 572 intervention 
participants significantly increase their step counts per day by 1819 (95% CI: 684 to 2954, 
p<0.01) more than 564 control participants. However, this result was heterogeneous 
















hours per day, 
mean (95% CI) 
Pedometer (base case) 9 1,136 1,819 
(684 to 2,954) 
5.41 
(2.03 to 8.79) 
Pedometers (scenario 1) 9 1,136 2,143 
(936 to 3,351) 
6.38 
(2.78 to 9.97) 
Pedometers (scenario 2) 9 1,136 2,172 
(1,019 to 3,326) 
6.46 
(3.03 to 9.89) 
Current practice (‘doing 
nothing’) 
 – – – 
In the scenario analyses where baseline PA measurement for VBI trial participants was 
assumed to have similar PA levels measured at baseline for the PACE-UP trial, an 
increase of 2143 steps (95% CI: 936 to 3351) was observed. When the baseline PA 
measurement for VBI trial participants was assumed to have the same PA levels of those 
control group participants at follow-up in the VBI pilot trial, the effect size of the pedometer 
intervention was 2172 (95% CI: 1019 to 3326). In these two scenario analyses, the effect 
size of the updated evidence was similar but higher than the base case scenario. 
5.4.3.2 Cost parameters  
The cost of the pedometer VBI was updated after updating the evidence as described in 
section 5.4.1. The updated meta-analysis now includes nine RCTs including the VBI trial. 
While running the first iteration of the model, the cost of the pedometer intervention was 
estimated based on the description of the intervention provided for individual studies 
included in the Bravata meta-analysis (151). The cost of the ‘Step It Up’ intervention was 
£18.04 (457). To update the cost of intervention, the original cost of pedometer 
intervention estimated in Chapter 4 was inflated to 2014-15 prices using inflation indices 
from the Hospital and Community Health Services (HCHS) (467). This gives the (revised) 








Original cost estimated for the 
first iteration of the model* 
Total cost, 
2015 £ 
Araiza et al 2006 15 £14.96 £15.85 
Butler and Dwyer 2004 17 £14.00 £14.83 
de Bplok et al 2006 8 £82.96 £87.88 
Hultquist et al 2005 31 £14.96 £15.85 
Izawa et al 2005 24 £14.96 £15.85 
Moreau et al 2001 15 £14.96 £15.85 
Ransdell et al 2004 and 
Ornes et al 2005 
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£183.55 £194.43 
Talbot et al 2003 17 £65.21 £69.08 





Total 597  £28.30 
Note:  
* Price year used in the original estimation of intervention cost was for 2010-11 (as described 
in section 4.6.4). 
The health state costs as per the original model are maintained but updated to reflect 
2015 prices using the HCHS index (467).  
5.4.3.3 Quality of life parameters 
While running the first iteration of the model, there was limited evidence on the short-term 
improvements in quality of life associated with increased activity in general population as 
most of PA interventions focused on those with chronic conditions (442-444). As a result, 
the effect of short-term health gains (utility boost) was examined in the sensitivity analysis 
by adding a ‘utility gain’ in the first year of intervention to reflect short-term benefits of 
increased PA. For this data from a pragmatic RCT evaluating ‘exercise referral’ scheme 
in Wales (445) was used. The sensitivity analysis showed a parallel upward shift in NMB 
for the three BIs evaluated and did not change the adoption decision (Table 4.31). 
As the VBI trial did not measure the effect of the intervention on quality of life, a PubMed 
search was performed using keywords ‘pedometer’ AND (‘quality of life’ OR ‘EQ-5D’) AND 
‘primary care’ to identify any pedometer-based PA interventions measuring other health-
related outcomes. The search found only one UK based study – the PACE-UP trial (483), 
a three-arm trial evaluating a pedometer-based walking intervention with or without nurse 
support (483). Harris and colleagues (483) measured the changes in health-related quality 
of life for the PACE-UP trial and found no significant effects on quality of life at either three 
months or 12 months follow-up. Utility changes at 3 months and 12 months for nurse 
support arm (pedometer plus nurse support) compared to the control arm were -0.01 (95% 
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CI: -0.03 to 0.01) and -0.01 (95% CI: -0.03 to 0.01) respectively (483). The health-related 
quality of life was measured via the EQ-5D-5L. This study (483) provided updated 
evidence on short-term health gains (utility boost) due to PA interventions. As the study 
did not find any significant short-term health gains from pedometer intervention (compared 
to control), the utility boost is not included in sensitivity analysis while updating the model. 
5.4.4 The second iteration of the model 
Similar to the analyses conducted in Chapter 4, the economic evaluation here is 
undertaken from the perspective of NHS with a ten-year time horizon. As per NICE 
recommendations, both costs and benefits (QALYs gained) were discounted at an annual 
rate of 3.5 per cent per year (2). The model was run probabilistically using a Monte Carlo 
simulation with 10,000 iterations to propagate the uncertainty in the individual model 
parameters. This gives a distribution of expected costs and expected outcomes (QALYs 
gains) associated with each PA intervention. The mean values of these 10,000 point 
estimates for costs and QALYs were used to calculate the mean cost-effectiveness ratio 
in terms of expected incremental costs associated with pedometer VBI compared to usual 
care per incremental QALYs gained. The joint distribution of incremental costs and 
incremental QALYs are presented through the cost-effectiveness plane (1) to illustrate the 
uncertainty associated with incremental costs and incremental QALYs. 
The decision uncertainty associated with the cost-effectiveness of pedometer VBI 
compared to usual care is presented using CEAC (476). The CEAC shows the probability 
that pedometer VBI and usual care interventions are cost-effective at threshold values, 
i.e. the maximum willingness to pay threshold. A sensitivity analysis was performed 
around the assumptions on intervention decay rates and intervention repeat year. Two 
scenario analyses were performed around the assumptions on baseline PA measurement 
values for the VBI trial participants (as described in section 5.4.1). Finally, a value of 
information analysis was performed to re-address the research priority setting decision, 
i.e. whether there is value for collecting additional data. 
The EVPI is the price that a decision maker would be willing to pay in order to completely 
resolving uncertainty in all input parameters that influence whether pedometer intervention 
is preferred as the result of CEA. The EVPPI gives the value of eliminating uncertainty in 
a subset of input parameters to the decision model (Chapter 3). 
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5.5 Cost-effectiveness analysis 
Cost-effectiveness results were obtained from the 10,000 Monte Carlo simulations of the 
probabilistic model. The cost-effectiveness of pedometer VBI compared to usual care is 
estimated based on the updated meta-analysis of pedometer interventions (section 
5.4.3.1). The base case analysis only uses PA measurement data at follow-up. In addition, 
the base-case analysis assumes that intervention effect is sustained for the first year then 
decays at a rate of 55% per annum. 
5.5.1 Results of the base case analysis 
Table 4-32 presents the mean costs, QALYs and net benefits at a willingness to pay 
threshold value of £20,000 per QALY and associated standard errors in the base case 
and scenario analyses. The base case results show that pedometer intervention was less 
costly (£11) and more effective (0.013 QALYs) than current practice. The 95% confidence 
interval around the incremental costs and benefits are -£229 to £202 and -0.017 to 0.043 
respectively. Incremental costs and QALYs for two scenario analyses are similar to the 
base case results, i.e. pedometer intervention is less costly and more effective compared 
to usual care.  
 







Mean NB* (SE) 
Base case       
Current practice £1,801 (618)  7.907 (0.236) £156,340  (5,270) 
Pedometer interventions £1,790 (616) 7.920 (0.237) £156,609 (5,289) 
Scenario 1 - using baseline PA data from the PACE-UP trial 
Current practice £1,801 (618) 7.907 (0.236) £156,336 (5,271) 
Pedometer interventions £1,785 (614) 7.921 (0.238) £156,643 (5,294) 
Scenario 2 - using VBI pilot trial control group PA measurement at follow-up 
Current practice £1801 (619) 7.907 (0.237) £156,336 (5,272) 
Pedometer interventions £1787  (615) 7.921 (0.238) £ 156,640  (5,293) 
* NB at £20,000 per QALY gained 
5.5.2 Probabilistic cost-effectiveness results (base case) 
The Monte Carlo simulation produced a pair of 10,000 estimated cost and QALYS. The 
incremental costs and QALYs are plotted in the incremental cost-effectiveness plane 
(Figure 5-7). The incremental CE plane illustrates the existence and extent of uncertainty 
surrounding the incremental cost and effect (QALY gained). The plot shows that the points 
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scattered across all four quadrants of the CE plane indicating considerable uncertainty 
surrounding the extent of the differences in costs and QALYs. 
 
 
Figure 5-7: Incremental cost-effectiveness plane for comparison between pedometer and 
current practice 
Of the 10,000 pairs of incremental costs and effects, almost half (43.9%) of the points are 
located on the South East quadrant indicating that pedometer intervention is likely to be 
more effective and less costly than current practice. Approximately one-third of the points 
(35.4%) are in the North East quadrant suggesting that pedometer intervention may be 
more effective and more costly than current practice. The remaining points are equally 
split between South West (10.1%) and North West (10.6%) quadrants. 
The CEAC (Figure 5-8) represents the decision uncertainty surrounding the cost-
effectiveness of pedometer intervention. In a situation where the decision maker is not 
prepared to pay any amount for additional QALY gains (i.e. the ceiling ratio is zero), the 
probabilities of pedometer and current practice being cost effective are 0.54 and 0.46 
respectively. Assuming a ceiling ratio of £20,000 per QALY gained, the probability that 
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Figure 5-8: Cost-effectiveness acceptability curves (pedometer vs current practice) 
 
5.5.3 Sensitivity analyses 
Sensitivity analyses were performed to test the assumption used while updating the short-
term effectiveness evidence (meta-analysis) of pedometer interventions. The results from 
the 10,000 Monte Carlo simulation using the updated evidence under two different 
scenarios (scenario 1 and scenario 2) are presented in Table 4-32. In addition, multiple 
CEACs were produced where the probability of pedometer intervention being cost-
effective was plotted against the ceiling ratio (WTP threshold) for each assumption. The 
estimated NMBs for current practice and pedometer intervention under both assumptions 
were similar. Using baseline PA data from the PACE-UP trial (scenario 1) and using VBI 
pilot trial control group follow-up PA measurements (scenario 2) in the meta-analysis did 
not affect the general conclusion of pedometer intervention being less costly and more 
effective than current practice. 
In the scenario analyses, the probability of pedometer-based VBI being cost-effective 
(Figure 5-9) was higher than the control group (health check only). This probability was 
slightly higher in scenario analyse 1 and 2 than base case assumption. It is because the 










































assumption. In addition, the effect sizes for scenario analysis 1 and 2 were similar (6.38 
MET-hr and 6.46 MET-hr respectively). 
 
 
Figure 5-9: Multiple CEAC for different assumptions used while updating the evidence 
base for pedometers versus current practice 
 
5.5.4 Scenario analyses 
Scenario analyses were performed to test the effect of a change in intervention decay rate 
and intervention repeat years to expected net benefits. Figure 5-10 shows the effect of a 
change in intervention decay rates to expected NMBs. As expected, at a lower 
intervention decay rate the expected NMB of pedometer intervention was higher than the 
current practice. As the intervention decay rate increases, the intervention effects (MET-
hour change) declines towards that of current practice. As a result, the expected NMB of 
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Figure 5-10: Sensitivity analysis of intervention cost-effectiveness to decay in intervention 
effects at a ceiling ratio of £20,000 per QALY 
 
There is a lack of clarity on the extent of behaviour maintenance in PA interventions 
among the adult population (488), and PA interventions are not expected to have a lifelong 
change in PA behaviour. Scenario analyses were performed by varying the intervention 
repeat years (2, 5 and 10) to examine the optimal time to repeat pedometer intervention 
 
Figure 5-11: Sensitivity analysis – intervention repeat year: cost-effectiveness of 





















































Figure 5-11 shows the consequences of repeat years on expected NMBs. Pedometer 
intervention had the highest expected NMBs in all the three repeat year scenarios, and 
among the repeat years, pedometer intervention had highest NMB when the intervention 
was repeated once every 2 years. 
5.5.5 Value of information analysis 
Value of information is related to the value of reducing uncertainty such that a decision 
may include the option to acquire more information (see Chapter 3, section 3.3.3). The 
potential value of additional information is estimated by determining the value of acquiring 
perfect information (EVPI), as perfect information would eliminate the cost of uncertainty 
altogether. The per-patient EVPI when deciding between pedometers and current 
practice, over the ranges of NICE threshold values of £20,000 to £30,000 per QALY, 
ranges from £26 to £180 per NHS Health Check patient. 
Figure 5-12 shows the relationship between population EVPI over 10 years and different 
values of the willingness to pay threshold per QALY. At a threshold value of £20,000 per 
QALY, the value of further research for the NHS Health Check population (19.06 million, 
Table 4.32) is £796 million. Here at a ceiling ratio of £20,000 per QALY, the probability 
that pedometer intervention is cost-effective is 0.78, and the probability that current 
practice is cost-effective is 0.22. 
 
Figure 5-12: Population EVPI for pedometer intervention versus current practice (using 
































As the population EVPI gives the upper limit for research into which the intervention is 
cost-effective, it is useful to consider which parameters this future evidence will be of most 
valuable. This is examined using EVPPI which provides the value of eliminating 
uncertainty in those individual or group of parameters. As in the first iteration of the model, 
six group of parameters are considered to indicate the maximum potential value 
associated with further data collection. The six groups of parameters are intervention 
effect, utility values, costs, the risk of MI, the risk of stroke, and parameters used in the 
SBP equation. 
The computation of EVPPI requires a two-level Monte Carlo simulation, and an 
appropriate number of runs for inner and outer loops of the Monte Carlo Simulation should 
be chosen. Few runs in the outer loop result in a lack of precision while few runs in the 
inner loop result in a biased estimate of EVPPI (489,490). Furthermore, a larger number 
of interactions result in much longer computation time. Brennan et al. (159) carried out an 
empirical investigation on the impact of the number of inner and outer loop runs on EVPPI. 
They suggested that the number of inner and outer loops should not, in general, be equal 
and in most situations, 500 inner loops for each of the 100 outer loop iterations lead to 
convergence and sufficiently accurate EVPPI results. The EVPPI was run with a relatively 
high number of simulations – 1000 inner loops and 500 outer loops for each of the six 
parameter groups using a ceiling ratio of £20,000 per QALY. 
 
Figure 5-13: EVPPI results for the base case at a ceiling ratio of £20,000 per QALY: NHS 
Health Check population 
Population EVPPI for different parameters with a threshold value of £20,000 per QALY is 
given in Figure 5-13. The results of the EVPPI analysis indicates that if further data 
collection were to provide evidence on the parameters used in the SBP prediction 
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equation would be worth a maximum of £786 million for the NHS Health Check population. 
Other group of parameters also had similar per-person EVPPI, but the population EVPPI 
for cost parameters was slightly higher (£767 million) than other parameters (risk of stroke, 
utilities, treatment effect and risk of MI). 
5.6 Discussion 
The decision model developed at the outset of this thesis has been employed iteratively 
to handle the developing and evolving evidence base of very brief PA interventions in 
primary care. This iterative approach started with reviewing the existing evidence on the 
cost-effectiveness of brief PA interventions (Chapter 2). The review included both trial- 
and model-based economic evaluations of PA interventions in primary care or community 
setting. The evidence in addition to effectiveness evidence of brief PA interventions was 
used to develop a decision model to estimate the long-term costs and benefits associated 
with brief interventions (BIs) promoting PA. 
In this chapter, a second iteration of the decision analytic model was performed to re-
address the adoption and research priority setting decisions. The first iteration of the 
model (Chapter 4) evaluated three BIs in PA promotion using effectiveness evidence from 
the meta-analysis of RCTs. In the original analysis, it was demonstrated that among the 
three BIs (exercise advice/counselling in primary care, action planning interventions, and 
pedometer interventions) considered, pedometer BI was the cost-effective way of 
promoting PA in primary care, i.e. had the highest expected net benefits amongst the BIs 
considered. The initial VoI analysis demonstrated there was value in collecting additional 
information particularly in the effectiveness of pedometer intervention. Following the 
collection of effectiveness evidence and analysis of data from the VBI trial, effectiveness 
and cost-effectiveness of pedometer-based VBI in primary care was evaluated, and the 
model was re-run updating the evidence base. The pedometer meta-analysis (151) used 
in the original analysis in Chapter 4 was updated using the effectiveness evidence from 
the VBI trial (457). 
Results from the second iteration of the model showed that pedometer VBI is cost-
effective, but there was increasing uncertainty surrounding the incremental costs and 
QALYs. The scenario analyses exploring the impact of model assumptions on the 
maintenance of intervention effects over time and intervention repeat year showed, as 
expected, similar results observed from the first iteration of the model. That is pedometer-
based VBI become less cost-effective at higher intervention decay rates, and repeating 
the intervention once every two had the highest expected NMB. 
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Only two pedometer-based PA interventions estimated the long-term cost-effectiveness 
with QALY outcomes in primary care. In their PACE-UP trial, Harris et al. (483) estimated 
the long-term cost-effectiveness of the pedometer-based intervention. Their study 
reported an ICER of £16,368 per QALY for pedometer plus nurse support intervention 
compared to the control group. However, when postal delivered pedometer intervention 
was considered, the nurse-support intervention group was not cost-effective, i.e. postal 
delivery group dominated the nurse-support group. Harris et al. used previously published 
Markov model (136) which included two PA status – remained inactive and became active 
as a result of intervention in the run-in period (first year). The activity level was defined as 
achieving ≥150 minutes of MVPA per week. The classification of activity levels utilised 
self-reported data captured by the short International Physical Activity Questionnaire 
(IPAQ) to estimate the odds ratio for moving from inactive to an active health state. The 
VBI model included intervention effects (input) in terms of MET-hours and included more 
disease conditions that had known links to physical inactivity. 
Over et al. (146) estimated the long-term costs and effects of counselling and pedometer 
use to increase PA in the Netherlands and reported an ICER of €11,100 per QALY 
(£9,910, 2015 price). At a ceiling value of €20,000 per QALY, the pedometer plus 
counselling intervention had a probability of 0.66 to be cost-effective which was similar to 
the present study. Both of the studies described above did not perform VoI analysis. 
The VoI analysis conducted in this chapter suggested that there would be value in 
collecting additional evidence. The population EVPI at a threshold value of £20,000 per 
QALY was £796 million for the Health Check population over ten years. At the same 
ceiling ratio, the population EVPI in the original analysis was £1.85 billion – when 
converted to 2015 prices the value was £1.96 billion. The updating of the meta-analysis 
using data from the VBI trial reduced uncertainty surrounding the intervention 
effectiveness hence the lower population EVPI compared to the original analysis. Of the 
nine studies included in the updating of the pedometer meta-analysis, the VBI trial was 
the largest study (n=859). Population EVPPI values for six parameter groups were similar, 
but SBP prediction equation had slightly higher per-person EVPI than other parameters. 
It does not necessarily mean that we need a large RCT to collect additional information 
on the parameters used in the SBP equation. Instead, it would be much efficient to and 
cheaper to determine the parameter values for the SBP prediction equation from 
observational studies. As discussed in Chapter 4, an attempt was made to calculate the 
expected value of sample information and expected net gain of sampling, but it was not 
computationally feasible to generate meaningful and stable results. 
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Having conducted an iterative economic evaluation of (very) brief pedometer intervention, 
Chapter 6 presents the practical realities of applying iterative approach, lessons learned 
from the case study and the recommendations for future economic evaluation of very brief 
interventions promoting physical activity with evolving evidence. 
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Chapter 6 Discussion and Conclusions 
6.1 Introduction  
The aim of the thesis was to examine the feasibility of using an iterative framework for 
economic evaluation in healthcare. The thesis used a case study for this purpose and 
further explored the practical and methodological issues of applying an iterative approach 
to economic evaluation, and considered potential reasons as to why the framework has 
not been widely implemented. 
The iterative approach to economic evaluation has been proposed as good practice to 
appraise health technologies or interventions (4-6,43,72,74,82,491). The implementation 
of this approach starts with evidence synthesis and decision analytical modelling to 
evaluate the cost-effectiveness of indicative studies, and progresses to more rigorous 
assessments, updating the decision over time as new evidence becomes available. 
Decision analytic models play a key role within the iterative framework and such modelling 
exercises carried out prior to conducting the primary research allow explorative evaluation 
of the cost-effectiveness of healthcare technologies or interventions. The PSA and VoI 
analysis enables an assessment to be made with regards to the sample uncertainty 
surrounding the cost-effectiveness decision (43). Using the PSA results, VoI techniques 
help to determine whether future research is worthwhile, help explore the type of research 
required to address uncertainty (feasibility or pilot studies) and help design a primary study 
to collect additional information. This framework allows incorporation of best available 
evidence at the time of decision making. Reiteration of the entire process provides greater 
confidence in cost-effectiveness estimates used to inform decisions, and it potentially can 
be performed throughout the lifecycle of the technology in order to optimise the use of 
health care resources (6,43,72,491). Despite the aforementioned benefits of applying the 
iterative framework in economic evaluations, the application of this approach for the 
purpose of informing policy decisions in healthcare is limited. Economic analyses 
developed alongside clinical trials are often conducted as a one-off exercise as they are 
usually funded to justify reimbursement decisions. Thus, such studies rarely use pre-trial 
economic modelling and VoI method. 
This thesis explored the feasibility and benefits of applying the iterative framework in 
practice to evaluate the cost-effectiveness of healthcare interventions, using a case study 
example. This final chapter outlines the main results of this research project, discusses 
the methodological challenges, draws conclusions and makes recommendations for 
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further research. The first part provides an overview of the thesis by summarising aims, 
methods and main results. This is followed by a section that discusses the findings and 
relevant observations, as well as a discussion of the implications of the thesis and an 
identification of areas for future research. 
6.2 Summary of the main findings and limitations 
Chapter 1 introduced the basic concepts in economic evaluation in healthcare, the use of 
the iterative framework, the overall aims of the thesis and an overview of the structure of 
the thesis. The chapter started with providing a background to economic evaluations in 
health care along with key steps for conducting an economic evaluation. It also described 
the trial based approach to economic evaluation in which economic evaluation can be 
conducted using existing evidence on resource use, cost, intervention effects and quality 
of life. Economic evaluations provide a framework that helps decision makers in deciding 
which intervention or health technology to adopt from a list of alternative strategies. The 
process of decision making in health care should, ideally, be iterative (i.e. not static) to 
take account of new evidence and changes in circumstances. For example, there can be 
incremental innovations such as the availability of new therapies or novel approaches to 
the delivery of care. Consequently, the iterative approach to economic evaluation is 
purported to represent good practice for the appraisal of health technologies or 
interventions on an on-going basis. 
As the research questions explored the current research gap, i.e. limited application of the 
iterative framework in economic evaluation of healthcare interventions, Chapter 2 
assessed the current economic evidence on BIs promoting PA in primary care and 
community setting. This literature review included both economic evaluations conducted 
alongside trials as well as model-based economic evaluations and appraised them against 
the Drummond checklist (24). The review found that brief interventions such as exercise 
advice were inexpensive, can increase individuals’ PA at reasonable costs and are cost-
effective, given commonly accepted thresholds. This review highlighted methodological 
issues that limited the ranking of ‘best bet’ BIs from a list of interventions evaluated. Other 
issues identified were the quality of evidence used in model-based economic evaluations 
and assumptions around the maintenance of PA levels beyond the trial period. This 
suggested a need of a single framework so that all the interventions can be compared, 
i.e. a decision analytic model to transform the short-term (costs and intermediate disease-
specific) outcomes into longer-term outcomes (QALYs). However, it was difficult to 
determine whether the interventions were truly brief, i.e. <30 minutes in duration according 
to the NICE definition (112). 
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Chapter 3 provided an overview of the iterative framework and described the stages 
involved in detail. VoI method has been proposed as a systematic decision analytic 
approach to understand the need for further research and play a key role within the 
iterative process to identify the focus of research and optimal research design. The merits 
and drawbacks of using such a method within the iterative framework were discussed. 
From the existing literature, it was not clear how the VoI method was used in an iterative 
process. Thus, a literature review was performed with an aim to explore how the VoI 
method was used within the iterative process to inform further research. The literature 
search found that when mapped with the 5 stages of the iterative framework, only two 
studies reported all the five steps of the iterative process. The analysis showed that the 
adoption and application of VoI approach in healthcare is still limited, and in most cases, 
studies do not proceed further after identifying future research priorities. 
Chapter 4 corresponds with stages 2 and 3 of the iterative approach in economic 
evaluation involving the synthesis of evidence and development of a decision analytic 
model. This chapter described the decision problem, provided the rationale for using a 
decision model, detailed the development of this model to assess the cost-effectiveness 
of brief PA interventions in primary care and, in doing so, demonstrated the benefits of 
using an iterative process for synthesising existing evidence to inform the model. 
Additionally, the chapter examined the feasibility of including disease conditions that were 
shown to have links with physical (in)activity, the viability of modelling techniques given 
the availability of evidence and practical issues regarding the calibration of a complex 
decision model. A probabilistic microsimulation model was developed for this purpose 
using the available evidence in a systematic manner. 
Following the development and calibration of the decision model, three ‘classes’ of brief 
PA interventions were evaluated. The effectiveness evidence for these ‘classes’ came 
from systematic reviews and meta-analysis of RCTs. Within the meta-analysis, the studies 
included were somewhat heterogeneous. Uncertainty in the model results was explored 
using probabilistic sensitivity analysis and scenario analyses. Cost-effectiveness 
acceptability curves were used to summarise decision uncertainty followed by the use of 
VoI techniques to examine the value in future research. The results of the VoI analysis 
supported a case of primary research. Having established that further research in this 
area is worthwhile, the EVPPI analysis found that treatment effect (of pedometer 
intervention) parameter had the highest EVPPI value. This finding indicates that primary 
research should focus on the collection of data to examine the treatment effect in order to 
reduce uncertainty associated with the decision problem. However, EVPPI value is the 
necessary but not sufficient condition for conducting further research as EVPPI results 
only give a value in reducing the uncertainty in a parameter or groups of parameter. EVSI 
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and ENBS provide sufficient condition as to whether it is beneficial to conduct further 
research on this parameter but these analyses were not performed due to computational 
burden.  
In the context of this thesis, it would have been preferable to inform the design of the trial 
following an iterative approach whereby EVSI was undertaken. However, this was not 
feasible within the context of the VBI study due to timing issues. At the time when pilot 
trial (456) conducted as a part of wider VBI programme grant selected pedometer VBI to 
test in a full-scale trial, the VoI results from the first iteration of the model were not 
available. As a result, the VoI analysis was not able to inform the design of the trial by 
estimating the optimal sample size. Chapter 5 provided an overview of the case of VBI 
explanatory trial following the iterative process and evolving VBI evidence base. This 
chapter presented the within-trial cost-effectiveness results comparing pedometer-based 
VBI ‘Step It Up’ to usual care (i.e., NHS health check alone). The within-trial analysis 
showed no significant differences between groups in objectively-measured PA and 
healthcare resource use at three-month follow-up. The ‘Step It Up’ intervention costed 
£18.04 more per patient (using the NHS perspective), and participants receiving the 
intervention increased their PA level by 1000 step counts per day at an incremental cost 
of £96 above the control arm. As quality of life data, such as EQ-5D, was not collected 
alongside the VBI trial, within-trial cost-effectiveness results were not directly comparable 
with the results from the first model iteration (Chapter 4). 
In addition to performing a within-trial economic analysis, Chapter 5 incorporated evidence 
from the VBI trial into the decision model reported in Chapter 4. The pedometer meta-
analysis was updated to incorporate evidence from the VBI trial, and the model was re-
run. This was done to readdress the adoption and research priority setting decisions 
following incorporation of new evidence. Results from the updated decision analytic model 
showed that pedometer VBI is cost-effective, but there was increasing uncertainty 
surrounding the costs and QALYs. The VoI analysis showed that there is value in 
conducting further research and EVPPI statistics indicated that conducting research to 
determine parameter values for SBP prediction equation would be much efficient. This 
does not necessarily mean that we need a large RCT to collect additional information on 
these parameters and it would be much more efficient to determine parameter values for 
the SBP predication equation from observational studies. 
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6.3 Reflections on the iterative framework in an economic 
evaluation 
This thesis explored the feasibility of applying the iterative framework in evaluating 
healthcare interventions. This section now presents a reflection on the theoretical and 
conceptual understanding highlighted in Chapter 3 in relation to the application of the 
iterative framework in VBI study. 
6.3.1 Time constraints 
The main aim of the VBI programme grant was to develop and evaluate VBIs to increase 
PA that could be delivered in routine primary care consultations such as NHS health 
check. Before conducting a definitive trial, the VBI study conducted a pilot study (449) to 
test feasibility, acceptability and potential efficacy of promising VBIs. Parallel to the pilot 
study, a decision analytic model described in Chapter 4 was under development. 
However, the selection of pedometer VBI for the main trial happened before conducting 
the VoI. 
The development of the model and calibration process took longer than expected. In the 
model, the effect of PA on the risk of CVD conditions occurring was mediated via changes 
in the risk factor values. Systematic reviews and meta-analyses of epidemiological studies 
(section 4.4.1.2) quantified a direct link between PA and health outcomes, i.e. reduced 
risk of diseases such as CVD and cancers with an increase in PA. Additionally, the model 
included more than ten co-morbidities, and varied sources were used to inform the model 
parameters. Model calibration ensured that model predictions are consistent with the 
observed data from epidemiological studies. The complexity of the decision model meant 
that model calibration process took a long time (approximately 80 processor days), even 
though it was developed in a modular form. Initially, the Nelder-Mead algorithm was used 
to calibrate the model, but it could not further minimise the goodness of fit value after 703 
iterations with a weighted mean deviation of 18%. As a result, the random search method, 
a less efficient but widely used method in health economics was chosen. This resulted in 
a longer time to develop the model and perform VoI. 
Although preliminary results from the early iteration of the model indicated that the 
pedometer intervention was a cost-effective intervention amongst the BIs compared, it 
was not possible to influence the design of the trial (in iterative fashion) and determine 
sample size. The sample size calculation for the trial was thus based within the context of 
a frequentist trial design. In the case of VBI study, funding was already secured to conduct 
188 
a trial. However, in practice, this may not be the case as once the modelling study 
identifies future research priorities, funding is sought for the research. In theory, VoI 
results could be used to determine the funding decisions or as an additional input in the 
research prioritisation process. In their pilot study, Claxton et al. (72) showed that with 
very short timeliness, it is possible to undertake VoI analysis that can feed into the priority 
setting process. The model they used in their case study were Markov models compared 
to patient-level simulation model developed in Chapter 4. Setting up and implementing 
Markov models are much easier and time efficient compared to discrete event simulation 
models, and the VBI model included more than ten comorbidities. Claxton et al. also 
highlighted the issues around time frames for carrying out VoI in the context HTA 
programme in the UK. Systematic reviews and decision analytic modelling that are 
typically carried out before conducting VoI analysis take time. In the case of VBI study, 
evidence synthesis and decision analytical modelling stages of the iterative process had 
a short time period to contribute in the design of the trial. As mentioned earlier, within the 
time frame of selecting a candidate VBI for exploratory study (main trial), it was not 
possible to fully explore VoI techniques and estimate the optimal sample size of the VBI 
trial. 
6.3.2 Computation 
Despite a strong case being presented in this thesis in support of using an iterative 
framework, there was difficulty in employing VoI methods particularly an EVSI approach. 
Conducting VoI analysis was time-consuming and computationally expensive. For 
example, conducting EVPPI for a parameter or a group of parameters took around 1,100 
processing hours. Although the research had access to high-performance computing 
(HPC) cluster and the model codes were parallelised, it was still computationally 
expensive. Furthermore, model calibration was also computationally expensive. The more 
efficient Nelder-Mead search algorithm did not converge as a result a less efficient 
directed random search method was chosen which resulted in a longer processing time, 
approximately 80 processor days.  
The EVSI analysis is a worthwhile and useful exercise to inform the design of a future 
trials. Although an attempt was made to conduct an EVSI analysis, it was not possible to 
generate meaningful and stable results given the limited resources available, i.e., time 
constraints and the number of computer nodes available per user on the HPC cluster. 
EVSI techniques are computationally heavy as the analysis require two-level expectations 
(Monte Carlo simulations) to be evaluated implies an additional level of computational 
burden (161). Previous literature reviews on the use of VoI methods also highlighted this 
challenge (166,167). 
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6.3.3 Practicality and ease of use 
The application of the first two steps of the iterative framework, i.e. systematic review and 
decision analytic modelling, required a fair amount of time. There was a steep learning 
curve to start writing model codes in a new programming language, R. Most of the time 
was devoted to assessing the papers included in these reviews and translating PA 
outcomes into MET-hours. Systematic reviews and meta-analyses assessing the effect of 
BIs reported their effect size in mean difference or standardised mean difference. As a 
result, a common exposure metric, such as MET-hour was required to allow comparison 
of results. In addition, the PA exposure results reported in the meta-analyses were not 
comparable. Translating PA outcomes into METs took a considerable time. Besides this, 
structuring the decision model, populating the model and running PSA and VoI analyses 
took considerable amount of time. Calculation of EVPI was relatively straightforward. 
However, EVPPI analysis was more complex and time consuming. Initially, the model 
codes were implemented sequentially which meant that it took a considerable amount of 
time to run the EVPPI analysis. To reap the benefits of the HPC cluster, model codes 
were parallelised so that more than one computer node could be used to run the model. 
This required additional skills such as vectorising R codes and familiarisation with the 
cluster so that the operations occurred in parallel. 
6.4 Strengths and limitations 
In the context of a resource-constrained healthcare system, resource allocation decisions 
need to be guided by evidence on the expected costs and benefits of competing activities. 
An iterative approach to economic evaluation provides a framework that enables decision 
to be updated by incorporating new evidence when such evidence becomes available. 
This framework supports the process of gathering new information and, potentially, 
reducing uncertainty in order to improve decision-making. Clearly, if the VoI analysis 
suggested there is no value in conducting further research, the process stops at stage 3, 
and the model is updated once new evidence is available. Most of the studies identified 
that recommended further research did not proceed to explain the implications that this 
would have for the decision-making process. At the time the present analysis took place, 
the study was funded and on-going thus the practical application was carried out in a 
prospective manner. 
There were limitations to the approach applied while carrying out this research. First, the 
baseline population parameters were determined mostly by age and gender that means 
it does not allow for interdependencies, for example, BMI may have a role in determining 
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SBP in addition to age and gender. This would require access to and analysis of data from 
longitudinal studies. Indeed, an attempt was made to get access to the Fenland Study, a 
cohort study that collects data on key lifestyle determinants of metabolic disease, 
however, the application did not receive a favourable outcome. As a result, baseline 
characteristics were sampled using the health survey for England summary statistics 
(368). The first iteration of the model used 2011 costings but the within trial and second 
iteration of the model used 2015 costings. It would have been preferable to use the same 
price year for both iterations and updating the base year used in the first iteration of the 
model. However, due to practicality issues, availability of time being the main factor, this 
was not possible. 
A key assumption was made in the evaluation of BIs related to the sustainability of the 
intervention effect. There is little known about the sustainability of PA interventions beyond 
12 months. The existing literature suggested that PA disengagement usually occurs six 
months after PA intervention ended (492) and cost-effectiveness of PA interventions 
decrease over time (143). In the base case analysis, it was assumed that the intervention 
effect decays at a rate of 55% after one year of receiving the intervention. This assumption 
was based on two previously published modelling studies conducted in this area 
(141,146). From the search of the literature in Chapter 2, it was clear that cost-
effectiveness of BIs decrease over time unless there is continued contact so that activity 
levels are maintained over time. Thus, it is reasonable to assume that without continued 
contact, it is difficult to maintain the same PA levels post-intervention. Next, different PA 
interventions involve different behaviour change components, and it is possible that the 
same decay rates may not be true for all BIs. However, given the limited evidence 
available, the same rate was applied for all BIs, and different decay rates were tested in 
sensitivity analyses to explore the likely impact on the adoption decision. As expected 
sensitivity analyses suggested that BIs are more cost-effective at lower rates. 
Due to time constraints and practical reasons, the second iteration of the model only used 
updated costs and intervention effects. A literature search was carried out to synthesise 
evidence concerning PA and health that captured studies published up to January 2015. 
In the past 2 years, five systematic reviews and meta-analyses were published. These 
recent studies examined the dose-response association between PA and risk of type2 
diabetes (493-496), CVD (493), IHD (495), stroke (495), heart failure (497), breast cancer 
(495), and colon cancer (495). Four meta-analyses examining the incidence of type 2 
diabetes and PA suggested a (non-linear) curvilinear dose-response curve for PA and 
incidence of type 2 diabetes. While calibrating the model, RRs of CHD and stroke were 
used, and these values were 0.86 and 0.86 for 11.3 METs and 11.5 MET-hr/week 
respectively relative to 0 MET-hr/week. In their meta-analysis, Kyu et al. (495) reported 
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an RR of 0.837 and 0.843 for IHD and stroke respectively for 600-3999 MET-
minutes/week relative to inactive (<600 MET-minutes/week). The PA category included in 
this analysis (600-3999 MET-minutes/week) refers to the lower levels of activity category. 
The results of new meta-analyses that assessed the association between PA and 
cardiovascular, as well as results for the association between PA and stroke events, were 
similar to those employed in the model. 
However, the effect of PA on the incidence of type 2 diabetes seemed more favourable 
than the value used in the model. The model used estimates derived in a meta-analysis 
by Jeon et al. (296) that were based on dose-response data and reported a reduction of 
11% for type 2 diabetes among those who achieved 11 MET-hr/week relative to an 
inactive adult. However, the meta-analyses published after the study by Jeon et al. 
showed a reduction in risk ranging between 16% (495) to 26% (493,494). This suggests 
the benefits of PA on the incidence of type 2 diabetes were underestimated in the model. 
However, VBIs evaluated in the model did not have a large effect size and the dose-
response equations used were not linear (i.e., curvilinear) so one would expect no 
significant changes in terms of health outcomes. The RR estimates from Kyu et al. (495) 
study for breast and colon cancer were similar to those used in the model. Additionally, 
the current analysis might have underestimated the potential impact of PA on other 
disease conditions, most notably mental health. Mental health was not included in the 
model as prevention of depression due to PA is still a subject of debate (440,441), and a 
clear dose-response relationship between PA and mental health outcomes was not 
identified. 
The model uses a time horizon of 10 years which may have excluded the long-term 
benefits of increasing PA. Using a longer time horizon would require additional 
assumptions, for example on the maintenance of PA and the study population 
demographics. Thus, a pragmatic approach was employed to avoid the additional 
computational burden and the additional structural uncertainty associated with a longer 
time horizon. Lastly, this study performed a decision analysis from a healthcare provider’s 
perspective (i.e., NHS and personal social service), in order to inform policymakers in the 
UK. There may be costs that fall outside the scope of this approach such as costs 
associated with productivity loss or out of pocket expenditures incurred by the participants. 
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6.5 Areas for further research 
6.5.1 Fully exploiting VoI within an iterative context 
In this thesis, due to increased computational demands and timing issues, it was not 
possible to undertake EVSI or ENBS in order to determine an appropriate research design 
and sample size of a trial. The results from the original iteration of the model indicated 
that there is further value in collecting additional information to reduce decision uncertainty 
and the EVPPI results showed that, of the six parameters estimated, the treatment effect 
parameter had the highest population EVPPI value. An additional study to estimate this 
parameter would cost less than £708 million at a ceiling ratio of £20,000 per QALY. The 
EVSI analysis, which is the necessary condition, was needed to inform the design of the 
study. If funding were available for further research in this area (physical activity), the 
model developed here could be simplified and used to fully exploit the iterative framework 
by extending VoI analysis to undertake EVSI and ENBS. This will help to determine the 
design and sample size of a new study. 
Furthermore, it would be ideal to update the decision model with newly available 
information, for example, updated information is available on the dose-response 
relationship between PA and health outcomes which the second iteration of the model did 
not incorporate for pragmatic reasons. Owing to the high computation costs associated 
with VoI analysis, in recent years that has been a progressive evolution and simplification 
of the methods (498-500), and development of a computationally efficient method for EVSI 
analysis are underway (169,501). When such computationally efficient methods are 
available, it will make the full exploitation of VoI methods within the iterative framework 
less burdensome. 
Next, from the literature search conducted in Chapter 3, it was not clear how decision 
makers and funding bodies, such as the NICE, use VoI results to inform decisions or 
whether VoI results are helpful in research prioritisation and funding decisions. 
6.5.2 Future economic evaluation of PA interventions 
In this thesis, just one case study was employed to examine the feasibility and suitability 
of iterative framework to evaluate a public health intervention characterised by evolving 
evidence and uncertainty. More case studies in this area would provide further insight into 
the practicalities and other issues associated with applying the framework.  
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One of the issues in PA modelling is the maintenance of intervention effects over time. At 
the time of writing, there is a lack of accessible longitudinal data available for estimating 
changes in PA levels over the course of a lifetime. Cross-sectional studies, such as Health 
Survey for England provide a snapshot of the prevalence of PA in different age groups 
and gender. However, this approach is not able to quantify the trajectories of PA levels 
and very few economic evaluations of PA interventions estimating long-term costs and 
health outcome associated with PA intervention considered this aspect by applying 
different PA maintenance rates post-intervention. For example, in their base case 
analysis, Cobiac et al. (141) used 50% and Over et al. (146) used 55% decay in 
intervention effects after one year. Existing evidence suggests that maintenance of 
behaviour changes over time i.e. changes in activity levels, in the long-term is challenging 
(96,151). Furthermore, PA interventions are complex public health interventions involving 
different behaviour techniques such as goal setting, self-monitoring and motivational 
interviewing. Such interventions have different ‘active ingredients’ that bring about 
behaviour change. As a result, maintenance of PA effects over time may differ between 
BIs. 
The VBI trial found no effect of pedometer-based VBI in the NHS health check population. 
The target population, i.e. apparently healthy 40-74 year olds were already relatively 
active compared to the general population, and as such, the intervention may have limited 
capacity to impact on PA. However, this does not take other effects that NHS health 
checks may have into account. Brief interventions could potentially lead to increases in 
PA levels in older adults and people with long-term conditions. 
6.5.3 Policy implications 
This thesis showed that application of the iterative framework would enable a more 
dynamic decision-making approach because it accounts for new evidence and changes 
in circumstances. The analysis showed that the two-year time point is the optimal time to 
repeat brief PA interventions in primary care. Given the fact that the NHS health check 
happens every five years, financial constraints in the NHS and recent 
innovation/application of digital technologies in health care, it could be possible that such 
digital interventions may support more patient engagement. This engagement would allow 
offering repeated VBIs or referral to follow-up support. Interventions such as mobile health 
apps have the potential to support people, for example, by offering advice on increasing 
their PA levels, using prompts or cues and signposting to PA services. However, the 
uptake of new interventions such as these would be conditional on the availability of robust 
evidence demonstrating that they represent a cost-effective use of NHS resources.  
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6.6 Conclusions  
This thesis discussed and demonstrated the feasibility of applying an iterative framework 
in economic evaluation through a case study of practical application. The thesis showed 
that it is feasible to apply the framework while evaluating public health interventions and 
decision models could be employed at an early stage in this process. Decision modelling 
and value of information estimates in particular help to explore uncertainty and determine 
whether conducting further research is worthwhile. This approach provides a framework 
that allows the synthesis of existing available evidence and incorporates evolving 
evidence in order to reduce uncertainty and make informed decisions. Although there are 
several merits of applying this framework there are also a few drawbacks. These include 
time constraints, not being able to follow the steps of the iterative process sequentially 
and not being able to fully exploit the VoI methods. Undertaking VoI analyses, particularly 
EVSI, is challenging due to computational demands which limit their application in practice 
to inform the design of future trials. Development of new, computationally efficient 
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Appendix A: Literature review on economic evidence of 
brief PA interventions 
 
A1 Search strategies for identification of literature on economic evidence of brief 
physical activity interventions 
Medline, Embase, PsycINFO (via OvidSP) 
1. physical exertion/ 
2. exp physical fitness/ 
3. exp Physical Education/ and exp Training/ 
4. exp Sports/ 
5. dance/ or exp recreation/ 
6. exp exercise/ 
7. exp Exercise/ or exp Physical Activity/ 
8. (physical* adj5 (fit* or train* or activ* or endur* or exert* or educat*)).ti. 
9. (exercis* or danc* or sport* or walk* or bicycl*).ti. 
10. ((lifestyle* or life-style*) adj5 activ*).ti. 
11. ((lifestyle* or life-style*) adj5 physical*).ti. 
12. inactiv*.ti. 
13. (sedentary adj5 (lifestyle* or life-style* or population* or occupation* or behav*)).ti. 
14. or/1-13 
15. (increase* or promot* or improv* or prevent* or reduc*).ti. 
16. (intervention* or advis* or advice or counsel* or prescri* or educat* or program* or 
scheme*).ti. 
17. ((brief or opportunist$ or concise or short or direct or lifestyle or written or oral or 
verbal or personali?ed or individuali?ed) adj2 (advice or counselling or counselling 
or negotiation$ or guidance or discussion$ or encouragement or intervention$ or 
program$ or meeting$ or session$)).ti,ab. 
18. (health adj5 (promot* or behav*)).ti. 
19. (prevent* adj5 medicine).ti. 
20. (behav* adj5 (chang* or modif*)).ti. 
21. ((lifestyle* or life-style) adj5 chang*).ti. 
22. ("motivational interview*" or "motivational counselling" or "motivational counseling" 
or "motivational intervention*").ti. 
23. exp Health Promotion/ 
24. exp Health Behavior/ 
25. exp Preventive Medicine/ 
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26. exp Counseling/ 
27. or/16-26 
28. 14 and 15 and 27 
29. economics/ 
30. "costs and cost analysis"/ 
31. (economic$ or cost or costs or costly or costing or price or prices or pricing).ti,ab. 
32. (expenditure$ not energy).ti,ab. 
33. value for money.ti,ab. 
34. budget$.ti,ab. 
35. or/29-34 
36. ((energy or oxygen) adj cost).ti,ab. 
37. (metabolic adj cost).ti,ab. 
38. ((energy or oxygen) adj expenditure).ti,ab. 
39. or/36-38 
40. 35 not 39 
41. 28 and 40 
42. letter.pt. 
43. historical article.pt. 
44. editorials.pt. 
45. or/42-44 
46. 41 not 45 
47. Animals/ 
48. Humans/ 
49. 47 not (47 and 48) 
50. 46 not 49 
51. limit 50 to english language 
52. limit 51 to full text 
53. remove duplicates from 52 
 
CINAHL, EconLit, SPORTDiscus (via EBSCOhost)  
S1 physical exertion+ 
S2 physical fitness+ 
S3 physical education AND training+ 
S4 ti sports 
S5 dancing+ 
S6 ti exercise 
S7 exercise therapy+ 
S8 TI (physical* n5 (fit* or train* or activ* or endur* or exert* or educat*)) 
S9 TI (exercis* or danc* or sport* or walk* or bicycl*) 
S10 TI (lifestyle* OR life-style*) N5 activ* 
229 
S11 TI (lifestyle* OR life-style*) n5 physical* 
S12 ti inactiv* 
S13 sedentary n5 (lifestyle* or life-style* or population* or occupation* or behav*) 
S14 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11 
OR S12 OR S13 
S15 TI increase* or promot* or improv* or prevent* or reduc* 
S16 TI intervention* or advis* or advice or counsel* or prescri* or educat* or program* 
or scheme* 
S17 TI (brief or minimal) n5 intervention* 
S18 TI health n5 (promot* or behav*) 
S19 TI prevent* n5 medicine 
S20 TI behav* n5 (chang* or modif*) 
S21 TI ((lifestyle* or life-style) adj5 chang*) 
S22 TI ("motivational interview*" or "motivational counselling" or "motivational 
counseling" or "motivational intervention*") 
S23 Health promotion+ 
S24 Health Behavior+ 
S25 Preventive medicine+ 
S26 Counseling+ 
S27 s16 or s17 or s18 or s19 or s20 or s21 or s22 or s23 or s24 or s25 or s26 
S28 S14 AND S15 AND S27 
S29 Economics+ 
S30 "costs and cost analysis"+ 
S31 TI (economic$ or cost or costs or costly or costing or price or prices or pricing) 
S32 TI expenditure$ NOT energy 
S33 TI value for money 
S34 TI budget$ 
S35 (S29 or S30 or S31 or S32 or S33 or S34) 
S36 (S28 and S35) 
 
Cochrane library (NHS EED, HTA, CENTRAL, DARE)  
#1 MeSH descriptor: [Physical Exertion] explode all trees 
#2 MeSH descriptor: [Physical Fitness] explode all trees 
#3 MeSH descriptor: [Physical Education and Training] explode all trees 
#4 MeSH descriptor: [Sports] explode all trees 
#5 MeSH descriptor: [Dancing] explode all trees 
#6 MeSH descriptor: [Exercise] explode all trees 
#7 MeSH descriptor: [Exercise Therapy] explode all trees 
#8 (brief or minimal) intervention:ti,ab,kw  
#9 MeSH descriptor: [Health Promotion] explode all trees 
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#10 MeSH descriptor: [Preventive Medicine] explode all trees 
#11 MeSH descriptor: [Counseling] explode all trees 
#12 (#1 or #2 or #3 or #4 or #5 or #6 or #7)  
#13 brief:ti,ab,kw OR minimal:ti,ab,kw  
#14 intervention:ti,ab,kw  
#15 #8 or (#13 and #14)  
#16 #9 or #10 or #11  





Physiotherapy Evidence Database (PEDro) 





A2 Data extraction form 
Table A-1: Data extraction table 1 
Record No.  
Author, date  
Journal name  
Year of publication  
Title  
Country  
Study participants  
Age  
Setting  
Study period  
Intervention type  
Brief description of intervention(s)  
Comparator intervention included  
Number of interventions  
Number of brief interventions  
PA categories included  
Activity level  
Mode of intervention delivery  
Perspective of economic analysis  
Type of economic analysis  
Data source used  
Price year  
Cost and outcome discounted Yes/No 
Discount rate  
Model-based economic evaluation Yes/No 
Model structure  
Disease conditions included in the model  
Health outcome measured  
Source of effectiveness data  
Outcome reported  
Sensitivity analysis performed Yes/No 
PSA performed  
ICER point estimate  
 
232 
Appendix B: Review of VoI Methods 
B1 Search strategy 
MEDLINE (MEDLINE in process & Other non-index citations) and Embase via 
OvidSP 
# Search terms  
1 value of information.mp  
2 value of perfect information.mp.   
3 value of* information.mp.   
4 expected net benefit of sampling.mp.   
5 expected value of* information.mp.   
6 (evpi* or evppi* or evsi* or enbs*).mp.   
7 or/1-6   
8 exp cost utility analysis/   
9 exp cost effectiveness analysis/   
10 exp cost benefit analysis/   
11 exp decision making/   
12 exp medical decision making/   
13 exp decision theory/   
15 exp decision model/   
16 exp probability/   
17 exp uncertainty/   
18 or/8-17   
19 (value adj4 information).mp.   
20 7 or 19   
21 18 and 20   
22 decision making.mp.   
23 trial design.mp.   
24 research priorit*.mp.   
25 priority setting.mp.   
26 health priorit*.mp.   
27 22 or 23 or 24 or 25 or 26   
28 21 and 27   
29 cost.mp.   
30 28 and 29   




Web of science 
#1 TS = "value of information" OR TS = "value of perfect information" OR TS = "value 
of * information" OR TS = "expected net benefit of sampling" OR TS = "expected 
value of * information" OR TS = evpi* OR TS = evppi* OR TS = evsi* OR TS = enbs* 
#2  TS = ("cost utility analysis" OR "cost effectiveness analysis" OR "cost benefit 
analysis" OR "decision making" OR "medical decision making" OR "decision theory" 
OR "decision model" OR "probability" OR "uncertainty") 
#3  TS = ("decision making" OR "trial design" OR (research priorit*) OR "priority setting" 
OR (health priorit*)) 
#4 #1 AND #2 AND #3 
#5 TS = cost 
#6 #4 AND #5 
 
CINAHL via EBSCOhost 
S1 value of information OR value of perfect information OR value of * information OR 
expected net benefit of sampling OR expected value of * information OR evpi* OR 
evppi* OR evsi* or enbs* or engs* 
S2 MH cost utility analysis OR MH cost effectiveness analysis OR MH cost benefit 
analysis  
S3 MH cost* OR MH cost analysis+  
S4 MH decision making* OR medical decision making OR MH decision theory OR MH 
decision model OR MH probability OR MH uncertainty  
S5 MH decision making* OR MH trial design OR MH research prior* OR MH priority 
setting OR MH health priorit* 
S6 S2 OR S3 OR S4  
S7 (S2 OR S3 OR S4) AND (S1 AND S5 AND S6)  
S8 S7 (limiters – Published Date: 19900101-20171231 
 
EconLit via EBSCOhost 
S1 value of information OR value of perfect information OR value of * information OR 
expected net benefit of sampling OR expected value of * information OR evpi* OR 
evppi* OR evsi* or enbs* or engs* 
S2 MH cost utility analysis OR MH cost effectiveness analysis OR MH cost benefit 
analysis  
S3 MH cost* OR MH cost analysis+  
S4 MH decision making* OR medical decision making OR MH decision theory OR MH 
decision model OR MH probability OR MH uncertainty  
S5 MH decision making* OR MH trial design OR MH research prior* OR MH priority 
setting OR MH health priorit* 
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S6 S2 OR S3 OR S4  
S7 (S2 OR S3 OR S4) AND (S1 AND S5 AND S6)  
S8 S7 (Limiters - Published Date: 19900101-20171231) 
 
Cochrane Library (Cochrane Database of Systematic Reviews, CENTRAL, 
Cochrane Methodology register, DARE, HTA, NHS EED) 
#1 "value of information" or "value of perfect information" or "expected net benefit of 
sampling" or (evpi*) or (evppi*) or (evsi*) or (enbs*)  
#2 MeSH descriptor: [Cost-Benefit Analysis] explode all trees 
#3 MeSH descriptor: [Costs and Cost Analysis] explode all trees 
#4 MeSH descriptor: [Decision Making] explode all trees 
#5 MeSH descriptor: [Decision Theory] explode all trees 
#6 MeSH descriptor: [Decision Support Techniques] explode all trees 
#7 MeSH descriptor: [Models, Economic] explode all trees 
#8 MeSH descriptor: [Models, Statistical] explode all trees 
#9 MeSH descriptor: [Decision Making] explode all trees 
#10 MeSH descriptor: [Health Priorities] explode all trees 
#11 MeSH descriptor: [Health Policy] explode all trees 
#12 #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11  
#13 value near/4 information  
#14 #1 or #13  
#15 #12 and #14 Publication Year from 1990 to 2017 
 
Health Technology Assessment (NIHR Database) 
“Value of Information” OR “Iterative approach” 
 
Scopus 
TITLE-ABS-KEY ( ( "value of information" ) OR ( "value of perfect information" ) OR ( evpi 
) OR ( evppi ) OR ( evsi ) OR ( evsi ) ) AND TITLE-ABS-KEY ( ( "cost benefit 
analysis" ) OR ( "cost utility analysis" ) OR ( "cost effectiveness analysis" ) OR ( 
"cost analysis" ) ) OR TITLE-ABS-KEY ( ( "decision making" ) OR ( "medical decision 
making" ) OR ( "decision theory" ) OR ( "decision model" ) ) AND TITLE-ABS-KEY 
( ( "trial design" ) OR ( "research prior*" ) OR ( "priority setting" ) OR ( "health priorit*" 
) ) AND SUBJAREA ( mult OR agri OR bioc OR immu OR neur OR phar OR mult 
OR medi OR nurs OR vete OR dent OR heal OR mult OR arts OR busi OR deci OR 




B2 Data extraction form for VoI Review 
Table B-1: Data extraction table 2 
Review ID  
Author, date  
Report title  
Publication type  
Journal  
Type of study  
Type of economic analysis  
Country  
Setting  
Study participants  
Sample size  
Intervention  
Comparators  
Study period (follow-up)  
Type of outcome measures  
Method of measure  
Main aim of the paper  
Disease or condition  
Source of effectiveness data  
Source of cost data  
Price year  
Currency  
WTP threshold  
Expected costs or outcomes discounted  
Model type  
Study perspective  
Time horizon  
Cycle length  
Decision uncertainty assessment  
Software used  
Sensitivity analysis  
ICER  
VoI type  
Individual EVPI  
Population EVPI  
Population discounted  
Life time of intervention  
EVPPI  
EVSI (n)  
ENBS or ENGS  
Author conclusions  
Future research recommendation  
Stages of iterative evaluation included  
Study funding source  
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Appendix C: Cost-effectiveness of brief PA interventions 
C1 Search terms for the methodological review 
A. physical activity  
1. epidemiology.mp. 
2. exp "epidemiology"/ 
3. 1 or 2 
4. model$.ti,ab. 
5. 3 and 4 
6. letter.pt. 
7. editorial.pt. 
8. historical article.pt. 
9. 6 or 7 or 8 
10. 5 not 9 
11. Animals/ 
12. Humans/ 
13. 11 not (11 and 12) 
14. 10 not 13 
15. exp Physical Exertion/ 
16. Physical fitness/ 
17. exp "Physical education and training"/ 
18. exp Sports/ 
19. exp Dancing/ 
20. exp Exercise therapy/ 
21. (physical$ adj5 (fit$ or train$ or activ$ or endur$)).tw. 




26. (exercise$ adj aerobic$).tw. 
27. (("lifestyle" or life-style) adj5 activ$).tw. 
28. (("lifestyle" or life-style) adj5 physical$).tw. 
29. or/15-28 
30. Health education/ 
31. Patient education/ 
32. Primary prevention/ 
33. Health promotion/ 
34. Behavior Therapy/ 
35. Cognitive Therapy/ 







42. 29 and 41 
43. 14 and 42 
 
B. Type 2 diabetes mellitus  
1. epidemiology.mp. 
2. exp "epidemiology"/ 
3. 1 or 2 
4. model$.ti,ab. 
5. 3 and 4 
6. letter.pt. 
7. editorial.pt. 
8. historical article.pt. 
9. 6 or 7 or 8 
10. 5 not 9 
11. Animals/ 
12. Humans/ 
13. 11 not (11 and 12) 
14. 10 not 13 
15. exp Diabetes Mellitus, Type 2/ 
16. exp Diabetes Complications/ 
17. (obes$ adj6 diabet$).tw,kf,ot. 
18. (MODY or NIDDM or T2DM).tw,kf,ot. 
19. (non insulin$ depend$ or noninsulin$ depend$ or noninsulin?depend$ or non 
insulin?depend$).tw,kf,ot. 
20. ((typ? 2 or typ? II or typ?2 or typ?II) adj diabet$).tw,kf,ot. 
21. (diabet$ adj (typ? 2 or typ? II or typ?2 or typ?II)).tw,kf,ot. 
22. ((adult$ or matur$ or late or slow or stabl$) adj6 diabet$).tw,kf,ot. 
23. or/15-22 
24. exp Diabetes Insipidus/ 
25. diabet$ insipidus.tw,kf,ot. 
26. 24 or 25 
27. 23 not 26 
28. 14 and 27 
 
C. Heart disease 
1. epidemiology.mp. 
2. exp "epidemiology"/ 
3. 1 or 2 
4. model$.ti,ab. 
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5. 3 and 4 
6. letter.pt. 
7. editorial.pt. 
8. historical article.pt. 
9. 6 or 7 or 8 
10. 5 not 9 
11. Animals/ 
12. Humans/ 
13. 11 not (11 and 12) 
14. 10 not 13 
15. Heart Diseases.sh. 
16. exp Heart Diseases/ 
17. *Cardiovascular Diseases/ 
18. *Arteriosclerosis Obliterans/ 




23. *Coronary Thrombosis/ 
24. exp Hypertension/ 
25. *Vascular Diseases/ 
26. *Coronary Aneurysm/ 








35. (atrial and fibrillat*) 
36. sick next sinus 
37. tachycardi* 









47. 46 not exp animals/ 
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48. 46 and humans/ 
49. or/47-48 




2. exp "epidemiology"/ 
3. 1 or 2 
4. model$.ti,ab. 
5. 3 and 4 
6. letter.pt. 
7. editorial.pt. 
8. historical article.pt. 
9. 6 or 7 or 8 
10. 5 not 9 
11. Animals/ 
12. Humans/ 
13. 11 not (11 and 12) 
14. 10 not 13 
15. cerebrovascular disorders/ 
16. exp basal ganglia cerebrovascular disease/ 
17. exp brain ischemia/ 
18. exp carotid artery diseases/ 
19. stroke/ 
20. exp brain infarction/ 
21. exp cerebrovascular trauma/ 
22. exp intracranial arterial diseases/ 
23. exp intracranial arteriovenous malformations/ 
24. exp "Intracranial Embolism and Thrombosis"/ 
25. exp intracranial hemorrhages/ 
26. vasospasm, intracranial/ 
27. vertebral artery dissection/ 
28. aneurysm, ruptured/ and exp brain/ 
29. brain injuries/ 
30. brain injury, chronic/ 
31. exp carotid arteries/ 
32. endarterectomy, carotid/ 
33. *heart septal defects, atrial/ or foramen ovale, patent/ 
34. *atrial fibrillation/ 
35. (stroke or poststroke or post-stroke or cerebrovasc$ or brain vasc$ or cerebral vasc$ or cva$ 
or apoplex$ or isch?emi$ attack$ or tia$1 or neurologic$ deficit$ or SAH or AVM).tw. 
36. ((brain$ or cerebr$ or cerebell$ or cortical or vertebrobasilar or hemispher$ or intracran$ or 
intracerebral or infratentorial or supratentorial or MCA or anterior circulation or posterior circulation 
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or basal ganglia) adj5 (isch?emi$ or infarct$ or thrombo$ or emboli$ or occlus$ or hypox$ or 
vasospasm or obstruction or vasculopathy)).tw. 
37. ((lacunar or cortical) adj5 infarct$).tw. 
38. ((brain$ or cerebr$ or cerebell$ or intracerebral or intracran$ or parenchymal or intraventricular 
or infratentorial or supratentorial or basal gangli$ or subarachnoid or putaminal or putamen or 
posterior fossa) adj5 (haemorrhage$ or hemorrhage$ or haematoma$ or hematoma$ or 
bleed$)).tw. 
39. ((brain or cerebral or intracranial or communicating or giant or basilar or vertebral artery or 
berry or saccular or ruptured) adj5 aneurysm$).tw. 
40. (vertebral artery dissection or cerebral art$ disease$).tw. 
41. ((brain or intracranial or basal ganglia or lenticulostriate) adj5 (vascular adj5 (disease$ or 
disorder or accident or injur$ or trauma$ or insult or event))).tw. 
42. ((isch?emic or apoplectic) adj5 (event or events or insult or attack$)).tw. 
43. ((cerebral vein or cerebral venous or sinus or sagittal) adj5 thrombo$).tw. 
44. (CVDST or CVT).tw. 
45. ((intracranial or cerebral art$ or basilar art$ or vertebral art$ or vertebrobasilar or vertebral 
basilar) adj5 (stenosis or isch?emia or insufficiency or arteriosclero$ or atherosclero$ or 
occlus$)).tw. 
46. ((venous or arteriovenous or brain vasc$) adj5 malformation$).tw. 
47. ((brain or cerebral) adj5 (angioma$ or hemangioma$ or haemangioma$)).tw. 
48. carotid$.tw. 
49. (patent foramen ovale or PFO).tw. 
50. ((atrial or atrium or auricular) adj fibrillation).tw. 
51. asymptomatic cervical bruit.tw. 
52. exp aphasia/ or anomia/ or hemiplegia/ or hemianopsia/ or exp paresis/ or deglutition disorders/ 
or dysarthria/ or pseudobulbar palsy/ or muscle spasticity/ 
53. (aphasi$ or apraxi$ or dysphasi$ or dysphagi$ or deglutition disorder$ or swallow$ disorder$ 
or dysarthri$ or hemipleg$ or hemipar$ or paresis or paretic or hemianop$ or hemineglect or 
spasticity or anomi$ or dysnomi$ or acquired brain injur$ or hemiball$).tw. 
54. ((unilateral or visual or hemispatial or attentional or spatial) adj5 neglect).tw. 
55. exp hypoxia-ischemia, brain/ 
56. or/15-55 
57. 56 not exp animals/ 




E. Breast cancer 
1. epidemiology.mp. 
2. exp "epidemiology"/ 
3. 1 or 2 
4. model$.ti,ab. 




8. historical article.pt. 
9. 6 or 7 or 8 
10. 5 not 9 
11. Animals/ 
12. Humans/ 
13. 11 not (11 and 12) 
14. 10 not 13 
15. exp breast neoplasms/ 
16. exp "neoplasms, ductal, lobular, and medullary"/ 
17. exp fibrocystic disease of breast/ 
18. or/15-17 
19. exp breast/ 
20. breast.tw. 
21. or/19-20 
22. (breast adj milk).ti,ab,sh. 
23. (breast adj tender$).ti,ab,sh. 
24. or/22-23 
25. 21 not 24 
26. exp neoplasms/ 
27. and/25-26 
28. exp lymphedema/ 
29. and/25,28 
30. (breast adj25 neoplasm$).ti,ab,sh. 
31. (breast adj25 cancer$).ti,ab,sh. 
32. (breast adj25 tumour$).ti,ab,sh. 
33. (breast adj25 tumor$).ti,ab,sh. 
34. (breast adj25 carcinoma$).ti,ab,sh. 
35. (breast adj25 adenocarcinoma$).ti,ab,sh. 
36. (breast adj25 sarcoma$).ti,ab,sh. 
37. (breast adj50 dcis).ti,ab,sh. 
38. (breast adj25 ductal).ti,ab,sh. 
39. (breast adj25 infiltrating).ti,ab,sh. 
40. (breast adj25 intraductal).ti,ab,sh. 
41. (breast adj25 lobular).ti,ab,sh. 
42. (breast adj25 medullary).ti,ab,sh. 
43. or/30-42 
44. 18 or 27 or 29 or 43 
45. exp mastectomy/ 
46. 44 or 45 
47. exp "Analytical, Diagnostic and Therapeutic Techniques and Equipment"/ 
48. 25 and 47 
49. 46 or 48 
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50. exp mammary neoplasms/ 
51. (mammary adj25 neoplasm$).ti,ab,sh. 
52. (mammary adj25 cancer$).ti,ab,sh. 
53. (mammary adj25 tumour$).ti,ab,sh. 
54. (mammary adj25 tumor$).ti,ab,sh. 
55. (mammary adj25 carcinoma$).ti,ab,sh. 
56. (mammary adj25 adenocarcinoma$).ti,ab,sh. 
57. (mammary adj25 sarcoma$).ti,ab,sh. 
58. (mammary adj50 dcis).ti,ab,sh. 
59. (mammary adj25 ductal).ti,ab,sh. 
60. (mammary adj25 infiltrating).ti,ab,sh. 
61. (mammary adj25 intraductal).ti,ab,sh. 
62. (mammary adj25 lobular).ti,ab,sh. 
63. (mammary adj25 medullary).ti,ab,sh. 
64. or/50-63 
65. 49 or 64 
66. (breast adj25 self$).ti,ab,sh. 
67. (breast adj25 screen$).ti,ab,sh. 
68. exp mammography/ 
69. exp breast self examination/ 
70. or/65-69 
71. mammograph$.tw. 
72. 25 and 71 
73. 70 or 72 
74. humans/ 
75. 73 and 74 
76. 14 and 75 
 
F. Colorectal cancer 
1. epidemiology.mp. 
2. exp "epidemiology"/ 
3. 1 or 2 
4. model$.ti,ab. 
5. 3 and 4 
6. letter.pt. 
7. editorial.pt. 
8. historical article.pt. 
9. 6 or 7 or 8 
10. 5 not 9 
11. Animals/ 
12. Humans/ 
13. 11 not (11 and 12) 
14. 10 not 13 
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15. (colorectal neoplasm or colorectal tumor or colorectal adenoma or colorectal cancer or 
colorectal carcinoma or colorectal disease or colonic or sigmoid neoplasms or rectal neoplasms or 
anus neoplasms).mp. 
16. exp "Colorectal-Neoplasms"/ 
17. 15 or 16 
18. 17 not exp animals/ 
19. 17 and humans/ 
20. or/18-19 
21. 14 and 20 
 
G. Kidney cancer 
1. epidemiology.mp. 
2. exp "epidemiology"/ 
3. 1 or 2 
4. model$.ti,ab. 
5. 3 and 4 
6. letter.pt. 
7. editorial.pt. 
8. historical article.pt. 
9. 6 or 7 or 8 
10. 5 not 9 
11. Animals/ 
12. Humans/ 
13. 11 not (11 and 12) 
14. 10 not 13 
15. renal.mp. or kidney$.tw. [mp=protocol supplementary concept, rare disease supplementary 
concept, title, original title, abstract, name of substance word, subject heading word, unique 
identifier] 
16. (nephritis or nephrotic or nephrosis or nephropath$).tw. 
17. 15 or 16 
18. exp *kidney neoplasms/ or *ureteral neoplasms/ or *urethral neoplasms/ 
19. 17 and 18 
20. (animals/ not humans/) and animals/ 
21. 19 not 20 
22. 14 and 21 
 
H. Lung cancer 
1. epidemiology.mp. 
2. exp "epidemiology"/ 
3. 1 or 2 
4. model$.ti,ab. 




8. historical article.pt. 
9. 6 or 7 or 8 
10. 5 not 9 
11. Animals/ 
12. Humans/ 
13. 11 not (11 and 12) 
14. 10 not 13 
15. exp Lung neoplasms/ 
16. (NSCLC or SCLC).tw. 
17. (lung or lungs or pulmonary or bronchus or brochogenic or bronchial or bronchoalveolar or 
alveolar).tw. 
18. (cancer* or carcinoma* or adenocarcinoma* or malignan* or tumor* or tumour* or 
neoplasm*).tw. 
19. 17 and 18 
20. 15 or 16 or 19 




C2 Summary of resource use estimation and cost of intervention  



















Araiza 2006 15 1 - - - 1 £ 14.00  – – – £0.96  £14.96  
Butler and 
Dwyer 2004 






- - 1 £ 14.00  £ 68.00  – – £0.96  £82.96  
Hultquist 
2005 
31 1 - - - 1 £ 14.00  – – – £0.96  £14.96  
Izawa 2005 24 1 - - - 1 £ 14.00  – – – £0.96  £14.96  
Moreau 
2001 












- £ 14.00  £ 136.00  £ 1.21   £ 32.34  – £183.55 
Talbot 2003 17 1 
12x5 mins 
practice nurse 
1 - - £ 14.00  £ 50.00  £ 1.21  – – £65.21  
Total 155       Weighted average cost per participant £54.33 
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Resource use Costs 
















1x key messages reinforced in 
GP letter 
    1  £ 16.13   £ 1.21  - -  £ 17.34  
76 
1x individualised advice on 
exercise 
    1  £ 25.50   £ 1.21  - -  £ 26.71  
78 
1x exercise assessment, 4x 
small-group exercise sessions 
physiotherapist 




3x exercise advice sessions 
exercise specialist 
       £ 25.50  - - -  £ 25.50  
Lamb 2002 131 1x group advice session 
3x telephone calls 
physiotherapist 
  1  £ 2.83   £ 1.21   £ 20.90  -  £ 24.94  
Elley 2003 226 1x 7 mins GP 
3x 5 min calls by exercise 
specialist; 3x5 min calls by 
nurse 




2x counselling session with 
primary care clinician 
2 telephone support call 
(practice nurse) x 5 mins  
  1  £ 72.00   £ 1.21   £ 7.80  -  £ 81.01  
Kolt 2007 83   
8x13 min (avg) phone call from 
exercise counsellor 
  1 -  £ 1.21   £ 72.45  -  £ 73.66  
Kinmonth 
2008 
105 4x sessions 9 telephone support calls      £ 41.92  -  £ 73.12  - £ 115.04  
109 1 session 6 telephone support calls 7 1 -  £ 1.21   £ 63.98   £.75   £ 73.94  
Lawton 
2008 
544 2x 10 min practice nurse 5x 15 min practice nurse   1  £ 17.00   £ 1.21   £ 58.50  -  £ 76.71  
Morey 
2009 
178 1x session health counsellor 12x 18 min phone call   1  £ 12.75   £ 1.21   £168.48 - £ 182.44  
Total 1,853   Weighted average cost per participant  £ 71.26  
247 






















Bycura 2009 40 – 10 min health worker, 6 min nurse 1 – – £ 6.88 £ 0.18 £ 7.06 
de Vet 2009 138 – 5 min nurse 1 – – £ 0.87 £ 2.32 £ 3.19 
Luszczynska 2006 104 




£ 22.45 £ 0.26 £ 22.70 
Milne 2002 93 1 10+5 min nurse admin 1 – £ 1.34 £ 2.62 £ 0.34 £ 4.30 
Murray 2009 29 
– 15 min nurse, 30x6 min fitness 
supervisor, 9 wk gym membership 
1 1 
– 
£ 127.00 £ 0.32 £127.32 
Prestwich 2003 (a1) 18 
– 
15 min nurse, 5 min fitness advisor 1 
– – 
£ 3.87 £ 2.08 £ 5.95 
Prestwich 2003 (a2) 19 
– 
20 min nurse, 5 min fitness advisor 1 
– – 
£ 6.07 £ 2.16 £ 8.3 
Prestwich 2009 (b1) 29 – 15 min health worker 1 – – £ 7.75 £ 0.40 £ 8.15 
Scholz 2006 (a) 103 – 15x2 min nurse, 9 min GP 1 – – £ 129.62 £ 11.32 £140.94 
Scholz 2007 (b) 71 – 15 min nurse, 20 min interviewer  1 – – £ 10.68 £ 1.05 £ 11.73 
Sniehotta 2005 (a) 56 – 25 min nurse, 15 min interviewer  1 – – £ 15.11 £ 11.26 £ 26.37 
Sniehotta 2006 (b) 68 – 25 min nurse +15 min interviewer 1 – – £ 15.11 £ 15.06 £ 30.17 
Thoolen 2009 78 1 2+5 min nurse 1 – £ 1.60 £ 23.18 £ 1.06 £ 25.84 
Waters 2006 54 1 digital timer 10 min nurse 1 
– 
£ 20 £ 1.75 £ 2.69 £ 24.43 
Total 900   Weighted average cost per participant £ 33.21 
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C3 Characteristics of the studies reviewed to inform the decision model 


























An economic model of 
effectiveness of lifestyle 
interventions in preventing 
the onset of diabetes among 
people with Impaired 
Glucose Tolerance (IGT ) 
Cohort of 
individuals starting 
at the age of 55 
years,  
preference scores 
from cost utility 
analysis database 
of Harvard 
university, CODE 2 
study, FDPS1 
Diet and exercise 
versus no 
intervention 





6 years DATA 4.0 Cost per QALY Only T2DM is 
included in 






An economic model of 
interventions promoting 
physical activity using multi-
stage lifetable analysis with 4 
health states: healthy, 
diseased, dead from the 




≥15 years, RR of 












 GP prescription 



























                                               
 
1 Finnish Diabetes Prevention Study (N Engl J Med 2001; 344:1343-1350) 
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Model to quantify lifetime 
health and economic 
consequences of 
preventing and treating 
obesity with lifestyle 
interventions in Switzerland 
Hypothetical cohort 
of 10,000 
overweight or obese 
aged 25-65 years. 












(regular PA and healthy 
eating including diet 

























Decision tree  Model to estimate health 
impacts, quality of life 
outcome and health care 
system costs and savings 






based on resource 
use data extraction 
from selected 
studies 
4 interventions  
 Brief interventions 
in primary care 
 Pedometers 
 Exercise referral 
 Walking and cycling 










50% drop off 
rates in PA, 
included PA 




















A simulation model 
(POHEM) to project 
physical activity from 2001 
to 2040 and its relationship 
to the onset of chronic 
conditions as well as the 
impact of health-adjusted 










aged 18+ years, 4 
PA categories 
Each intervention with 
4 PA categories: none, 
0-30 min/day, 30-60 
min/day, 60+ min/day 
 leisure time PA 
  walking for errands 
 biking for errands 
and 


























































Economic model of 
healthcare for T2DM for the 
UK assessing costs and 
complications of T2DM  
 
UKPDS and CORE2 
patients, cost data from 
South Glamorgan 
database and GPMDP2, 
data source for 
retinopathy (WESDR as 
a function of HbA1c), 
neuropathy (Eastman), 
nephropathy (WESDR 
and Eastman)  
4 broad classes of 
diabetic therapy: 
 Diet-only 




























A model to predict medical 
events, longevity, quality of 
life and medical care 
expenditures for groups and 
individuals with T2DM. 
Transitional period of 1 year. 
T2DM incidence and 
prevalence data from 
KPNW3, UKPDS, 
NHANES II4; CVD events 
from Framingham Heart 
Study(373), statistical 
models derived from 
Kaiser Permanent Data, 
risk factors include SBP, 
HDL, LDL, TG, and blood 
glucose measure, HbA1c 
Antihypertensive 
treatment (aspirin 



























                                               
 
2 GPMDP – General Practice Morbidity Database Project 
3 Kaiser Permanente Northwest trial 
4 US National Health and Nutrition Examination Survey 
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hypertension control and 
reduction in serum 
cholesterol level for T2DM 
patients.  
Cohorts aged ≥25 








of T2DM and CHD 




























A model (JADE) to project 
the long term impact on life 
expectancy and 
occurrence over 5, 10 and 
40 years of microvascular 
and macrovascular 
complications of diabetes 
when using different 
HbA1c thresholds for 




contains 5 related 





related events, and 
cost/QoL 
Six treatment regimens: 
 MF + SU 
 MF + rosiglitazone  
 MF + basal insulin 
 MDI 
(MF – metformin, SU – 
sulphonylurea,  





MI, CHF and stroke 




























A model-based on 14 risk 
equations; time varying risk 
factors (HbA1c, SBP, TC: 
HDL-C and smoking 
status), patient history of 
complications to predict the 
occurrence 
Data from UKPDS 
trial; 5,102 newly 
diagnosed diabetic 
patients, age 25-65 
years (5 year age 
band) 




first occurrence of 
fatal or non-fatal MI, 
other IHD, stroke, 
HF, amputation, 








































A model predicting rates of 
micro-vascular 
complications, CVD, and 
mortality that reflect the 
natural history of vascular 
and neuropathic 
complications of diabetes 
(NIDDM5) 
Cohort of 10,000 
diabetic patients 
aged 25-74 in the 
US, model 
parameters and 
hazard rates based 
on epidemiological 
of diabetes in the 
US population, 
WESDR 
A given treatment 
sequence where the 
number of switches 































A mathematical model of the 
anatomy, pathophysiology, 
tests, treatments, and 




T2DM and coronary 
artery disease 
(CAD) trials, risk 
equations from 
Framingham heart 
study, other sources 
include LIPID, HHS, 















T2DM, MI, CHD 
death, coronary 
events, CAD 

















A model to retrieve cost data 
for intensified treatment of 
diabetic foot ulcers and to 
estimate long-term outcome 
Retrospective real-
life data records of 
119 patients with 
acute ulceration, 
Austrian life table & 
Ramsey et al(505) 





















                                               
 
5 NIDDM = Non-Insulin-Dependent Diabetes Mellitus 
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A model analysing clinical 
and cost-effectiveness of 
primary prevention of T2DM 
patients in routine healthcare 
60–74 year olds 
from KORA6 survey 
2000, DPP study 








years, BMI≥24 and 
pre-diabetic status) 













Markov  A model predicting the 
complication rates and 
mortality of T2DM with and 
without Orlistat treatment 
assuming a 5 years catch up 
period; risk factors included 
in the model are HbA1c, BP 
and cholesterol, 6 monthly 










a data from Helsinki 
Heart Study (HHS) 
& UKPDS 34; cost 
data from CODE-2 
study 
Orlistat vs. no 
Orlistat 





10 years DATA 3.5 Cost per 
LYG 
 
                                               
 
6 Sub-study on cardiovascular risk factors and chronic diseases in inhabitants of Augsburg and surrounding counties (1998-ongoing); main aim - comparison with the WHO MONICA 
Augsburg surveys 
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A model to predict Predicts 
future level of obesity, 
consequences of health, 
health costs and life 
expectancy in English 
population. Risk factors 
included BMI, age, gender 





literature review  
BMI interventions – 
hypothetical 










50 years C++ Disease 
incidence, 













A model simulating diabetes-
related complications and 
their impact on costs with 
type 1 and type 2 diabetes. 
Consists of 2 modules – 
epidemiological based on 
risk equations and a health 
economics model 
Type 1 and T2DM 
patients in 
European countries, 




mortality rates from 
WHO lifetables 
(adjusted).  
A given treatment 



































Markov A model to simulate onset 
and progression of diabetic 
foot disease in patients with 
newly diagnosed T2DM, 6 
months transitional 
probability 
Cohort of diabetic 
patients with mean 
age 61 years, 








(optimal foot care) 
and intensive 
glycaemic control 
based on UKPDS 
33 
13 health states: 
3 risk health 
states, 6 wound 
type states, and 
4 outcome 
states 










death for all 
health states  
                                               
 
7 DCCT = Diabetes Control and Complications Trial 
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Model to determine the long-
term health outcomes and 
economic consequences of 
implementing different 
treatment policies or 
interventions in type 1 and 
type 2 diabetes mellitus, 15 
time-dependent inter-
connected sub-models 
Type 1 and type 2 
diabetes patients in 
European countries, 
uses UKPDS and 
Framingham risk 
equations, cycle 
length of one year 




































Markov  A model to investigate the 
order of magnitude of effects 
given different scenarios for 
T2DM screening policies; 2 
sub-models – screening 
model and treatment model 
 










from HSE; Δ in 
SBP, Cholesterol 
(UKPDS); HbA1c 
from diff sources  
Screening of 
diabetes patients 











                                               
 
8 Yorkshire and Humber Public Health Observatory 
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Estimates 10 years impact of 
changes in prevalence of 
obesity on incidence and 
prevalence of CHD, diabetes 
and mortality, and the NHS 
treatment cost; 3 scenarios – 
(1) continuation of BMI 
changes, (2) same level of 
BMI as of 2005 and (3) 
reduction of mean BMI by 
4.3% over a period of 10 
years 
Cohort of 2,500 
people sampled 
from Norfolk pop 
2005, risk equations 
from Framingham 
study and other 
cross-sectional 
studies to estimate 
disease incidence 
Public health 
campaign – healthy 
eating (5 a day 
community 
initiative) 
T2DM, CHD, MI, 
stroke and death 














A comprehensive computer 
simulation model to 
Predict the progression of 
diabetes and its 
complications and co-
morbidities and its quality of 
life and costs; 4 sub-models: 
disease, health utility, cost 








studies and RCTs, 
and controlled 
clinical trials; largely 
used WESDR 
baseline and 4- and 















stroke and CHD 




































programme aimed at 
CVD prevention.  





model adapted for 
costing(507), 
Framingham risk 
equation used to 
generate the 
expected pattern of 
first CV events 
according to age, 
sex and CVD risk 
2 scenarios 
involving small 
reduction in pop 
level of blood 
pressure or TC 
concentration 
 Legislation to 
reduce salt 
intake 


























Markov A cost-effectiveness 
analysis to measure the 
clinical benefit and cost 
of CAD screening in 
asymptomatic patients 




of 55-70 year old 
asymptomatic 
participant with 





smoking or LDL), 



























































A model describing the 
development of long term 
disease over time of 
demography, risk factor 
(BMI, PA) incidence, 
mortality and health care 
costs in the Dutch 
population. BMI and PA are 
modelled in 3 classes each 
A cohort of 20 to 85+ 
year olds representing 




































An epidemiological model to 
investigate the routine use of 
low dose aspirin in old 
people  
 
A simulated cohort of 
10,000 each men and 
women aged 70-74 years 
with no CV events, risk 
factor data from AusDiab 
study, incidence rates 
from VAED10, MONICA, 
NEMESIS11 trial 
Routine use of low 





















A model to project future 
mortality, morbidity, and cost 
of CHD in the US – 3 sub-
models: demographic-
epidemiologic, bridge and 
disease history sub-models  
Hypothetical cohort 
starting at age 35; data 
from the US census, 
HANES II, risk functions 





12 CHD (angina, 
MI, cardiac arrest, 
cardiac arrest with 
MI) 












                                               
 
9 The Dutch National Institute for Public Health and the Environment 
10 Victorian Admitted Episodes Database (VAED) 
11 North East Melbourne Stroke Incidence Study (NEMESIS) 
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A model to evaluate the 
cost-effectiveness of the 
prevention strategies that 
are available to unaffected 
women carrying a single 
BRCA1 or BRCA2 mutation 
with high cancer penetrance 
Unaffected carriers of a single 
BRCA1 or BRCA2 mutation 35-
50 years of age;  
Data source: SEER; incidence 
rates, preference ratings and 
costs derived from the literature 













lifetime Data Pro 
(TreeAge) 











A model to evaluate the 
cost-effectiveness of 70-
gene MammaPrint 
Signature versus Adjuvant! 
Online software (AS) 
Women aged ≤60 years with 
early stage breast cancer, base 
model with 70-gene signature 
validation study data and an 
alternative model using data from 
AS and SEER registry 
70-gene MammaPrint 
signature versus Adjuvant! 





















A discrete-event model that 
simulates breast cancer in a 
population over time 
generating cancer-registry 
like data sets. 4 interacting 
processes are modelled 
over time: natural history of 
breast cancer; breast 
cancer detection; breast 
cancer treatment; and 
competing cause mortality 
Simulated 2.95 million women in 
the US from 1950-2000 in 6 
month cycle, assuming all women 
in 1950 were cancer free, starting 
age 20 years (in 1950) to 100 
years or until they die 
WCRS12 and SEER13 data 
6 different adjuvant 
therapy with different time 




distant stage  













                                               
 
12 Wisconsin Cancer Reporting System (WCRS) state cancer registry 
13 National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) programme 
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of Breast Cancer 
Detection and 
Survival) 
A biologically motivated model of 
breast cancer development and 
detection allowing for arbitrary 
screening schedules and the 
effects of clinical covariates 
recorded at the time of diagnosis 
on post-treatment survival. 
Women aged 40-59 years, 
simulated from CNBSS14-1 
CNBSS-2 studies, follow-
up at 7 and 11-16 years,  
Data source: SEER, 


























A continuous-time, mathematical 
model of breast cancer incidence, 
tumour growth, detection and 
spread, survival and healthcare 
processes associated with breast 
cancer used to simulate 
postmenopausal population 
post-menopausal women 
aged <55 years (the US); 
data from SEER, and 
meta-analyses; cost data 





























A clinical point-based model to 
estimate chronic kidney disease 
risk at 4 years using clinical 
variables (age, BMI, diastolic BP, 
history of T2DM, and stroke) and 
biochemical measures 
(postprandial glucose, HBA1c, 
proteinuria and uric acid); 2 
models – clinical and biochemical 
5,168 Chinese participants, 
mean follow-up duration 
2.2 years, cox proportional 
hazard model to establish 
2 parsimonious models 
according to backward 
selection strategy 
















                                               
 
14 Canadian National Breast Screening Studies 
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Lung cancer model 
Das 2006 
(349) 
Markov A model to estimate potential 
clinical benefits and cost-
effectiveness of computed 
tomography (CT) for screening 
lung cancer in Hodgkin’s 
lymphoma survivors. Screening 
starting 5 years after initial 
diagnosis and continuing until 











Annual low-dose CT 










lung cancer and 
death 









Decision tree A model to evaluate the 
potential clinical and economic 
implications of annual lung 
cancer screening programme 
based on helical computer 
tomography (CT); time horizon 5 
years, disease stages (I, II, IIIA, 
IIIB and IV) 
Hypothetical cohort 
of 100,000 patients 
aged 60-74 years, 5 
year age grouping,  
Data from SEER 





 low dose helicat 
CT scan 






































Colorectal cancer model 
Allen 2005 
(346) 
Markov A model to compare the 
cost-effectiveness of four 
diagnostic strategies in the 
evaluation of rectal bleeding; 
time horizon – patient’s 
lifetime 
















Small polyp, large 
polyp, Dukes 
disease (stages A, 
B, C, and D) and 
death 





Markov A model to reflect the 
epidemiology of colorectal 
cancer (CRC) and estimate 
CRC incidence in persons at 
elevated risk of CRC 
conferred by a family history 
of CRC in a first-degree 
relative. 
40-85 year, 1 year 
cycle interval,  
 
Screening was done 
from age 40 through 
age 80 years. 
3 screening 
strategies 
 natural history 
 colonoscopy 
every 5 years 
 colonoscopy 






regional, or distant 
CRC; and dead  












A patient level model to 
estimate costs and savings 
of endoscopic colorectal 
cancer screening  
Patient aged 50—75 
years, screening 
delivered at 5 years 











polyp; large polyp; 
pre- and clinical 
stages (I, II, III, or 


















Appendix D: Within trial economic analysis 




NHS use, time off work and expenditure on physical 
activity Questionnaire 
As a part of this study we are interested to know if you have visited your GP or the hospital, 
or incurred any expenditure related to physical activity over the past three months, for 
example membership of any health or sports clubs (e.g. fitness club, fitness centre, gym), 
or any other physical activity related expenditure.  
We are also interested in whether you have taken any time off work or felt your productivity 
was affected due to any ill health recently. 
We would very much appreciate your help in gathering this information. 
Please read the questions carefully and tick () or provide information in the relevant 
boxes where requested.  
Please try to answer every question, except when there is a specific request to skip a 
section. If you cannot remember the exact answer to a question, please enter your best 
estimate. 
The information that you provide will be made anonymous and completely confidential. 
Your answers will be combined with the answers of other participants involved in the study 
and reported in such a way that they will not identify you or influence any NHS care you 
may receive. 
Please return the questionnaire in the enclosed pre-paid envelope. 
 




Primary Care Visits 
1. In the past 3 months, have you been seen by or spoken to 
your GP, a practice nurse or a health care assistant in person 
or on the telephone?  
Please do not include your recent health check appointment.  
Please tick () one box. 
(If NO, please go to Question 2) 
If yes, please write in the boxes below the number of times you have been seen or 
spoken to. Please complete each line. If none, please put a zero in appropriate box. 
 Number of times: 
  at your GP’s 
surgery 
at your home over the 
phone 
your general practitioner (GP):          
          
a practice nurse:          
          
Other health care professional:          
          
 
If you ticked ‘other health care professional’, please provide details below 




2. In the past 3 months, have you been to the hospital (NHS services) for any reason 
related to your health? 
Please tick () in one box 
(If NO, please go to Question 3) 
If yes, please write the number of times you have been into hospital and reasons: 
No. of visits  Reasons 
for an outpatient appointment 
(e.g. check-up, laboratory test, x-rays) 
   
    
for a day case procedure 
(e.g. inguinal hernia, varicose veins) 
   
    
admitted as an inpatient (involving 
overnight stay) 
   
    
Attended Accident and Emergency  
(A & E / emergency room) 
   
    
Other (please specify) _____________ 
_______________________________  
   
Yes   No  
Yes   No  
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If you had one or more inpatient stays, how many nights did 
you stay at the last visit? Please write the number of nights spent 
in the box. 
Expenditure on health, sports clubs or other physical activities 
3. In the past 3 months, have you been a member of any health or sports clubs/centres 
(e.g. local sports club, fitness club, fitness centre or gym)? Please tick () the 
appropriate answer.  
(If NO, please go to Question 10) 
4. When you travel to the fitness centre, sports club or gym, how do you normally get 
there? Please tick () the box that best describes how you travelled. If you used more 
than one form of transport, please indicate the way you travelled for the main (longest 
in terms of distance) part of your journey. 
 
 
Walk or cycle   
Hospital or community 
transport 
  Car  
        
Public transport (bus, 
train) 
  Taxi   Park &ride  
        
Other (please specify)   ____________________________________________________________________________________________________________________  
 
5. How much does the trip normally cost you? Please write the total amount spent on 
any bus, train or taxi fare or car parking. (For fares please write the total cost for the 
round trip, there and back). Please write zero if you did not incur any bus, train or taxi 
fare or car parking. 
Cost of fares 
and/or parking (£)  
  –   pence 
 
6. If you normally travel by private car, about how many 
miles do you travel each way? Please write the number 
of miles in the box. Please put zero if you did not travel 
by private car at all. 
 
7. In the last 3 months, on average how many visits did you make to a fitness centre, 
gym or other sport activity each week? If you do more than one activity please write 
the total number of visits. For example, if you go to the gym twice a week and a sports 




8. On average, how much time did you spend at each visit including travel time? 
Please write the number of hours and minutes in the box. 




  nights 









9. How much money did you spend on fitness centre, sports club or gym memberships 
over the past three months? Please write details below including any membership or 
joining fees as well as any regular payments for each attendance. If none, please write 
‘none’. 
Details Total Amount 
spent in the 




















10. Have you incurred any other out of pocket expenditure relating to physical activity 
over the last three months? For example, purchase of sportswear or footwear? If none, 
please write ‘none’ 
Details Total Amount 
spent in the 






















Productivity at work and time off work due to ill health 
The following questions ask about the effect of any health problems on your ability to work 
and perform regular activities. By health problems we mean any physical or emotional 
problem or symptom. Please fill in the blanks or circle a number, as indicated. 
 
11. Are you currently employed (working for pay)?  ____ NO ____ YES 
If NO, check “NO” and skip to question 15. 
 
The next questions are about the past seven days, not including today. 
12. During the past seven days, how many hours did you miss from work because of any 
health problems? Include hours you missed on sick days, times you went in late, left 
early, etc., because of any health problems. Do not include time you missed to 
participate in this study. 
_____HOURS 
 
13. During the past seven days, how many hours did you miss from work because of any 
other reason, such as vacation, holidays, time off to participate in this study? 
_____HOURS 
 
14. During the past seven days, how many hours did you actually work? 
_____HOURS (If “0”, skip to question 16) 
 
15. During the past seven days, how much did any health problems affect your productivity 
while you were working?  
 
Think about days you were limited in the amount or kind of work you could do, days 
you accomplished less than you would like, or days you could not do your work as 
carefully as usual. If health problems affected your work only a little, choose a low 
number. Choose a high number if health problems affected your work a great deal.  
Consider only how much health problems affected  
productivity while you were working. 
Health problems 
had no effect on 
my work 




0 1 2 3 4 5 6 7 8 9 10 




16. During the past seven days, how much did any health problems affect your ability to 
do your regular daily activities, other than work at a job?  
By regular activities, we mean the usual activities you do, such as work around the 
house, shopping, childcare, exercising, studying, etc. Think about times you were 
limited in the amount or kind of activities you could do and times you accomplished 
less than you would like. If health problems affected your activities only a little, choose 
a low number. Choose a high number if health problems affected your activities a great 
deal.  
 
Consider only how much health problems affected your ability  
to do your regular daily activities, other than work at a job. 
Health problems 
had no effect on 
my daily 
activities 
           Health problems 
completely 
prevented me 
from doing my 
daily activities 
0 1 2 3 4 5 6 7 8 9 10 
CIRCLE A NUMBER 
 
Questions 11 to 16 are based on an adapted version of the Work Productivity and Activity 
Impairment Questionnaire (Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of 
a work productivity and activity impairment instrument. PharmacoEconomics 1993; 4(5):353-65). 
 
Thank you for filling this questionnaire. 
Please post it back to us in the envelope provided.  





Appendix E: Conference Abstracts and Posters 
E1 Joint iHEA and ECHE World Congress (July 2014) – Abstract 
Development and validation of a decision model for very brief interventions 
promoting physical activity 
GC V, Wilson E, Suhrcke M, on behalf of the Very Brief Interventions (VBI) study team 
Word count: 479 
Background 
Physical inactivity is associated with a significant burden of chronic disease and a 
significant proportion of healthy life years lost in the UK. Evidence from clinical trials 
suggests that “(very) brief interventions” (VBIs) e.g. brief advice and/or exercise on 
prescription are effective in increasing physical activity in a primary care setting. However, 
these trials are insufficient on their own to inform decisions regarding the longer term cost-
effectiveness of interventions. Decision analytic modelling can help synthesising all 
relevant data for the cost-effectiveness evaluation of health care interventions in an 
explicit manner.  
Complex multi-disease decision models need validation and calibration in order to ensure 
predictive validity. In this paper, we first briefly describe the development of a model to 
estimate the cost-effectiveness of VBIs promoting physical activity in primary care. 
However, the primary focus of this paper is on the approach taken to validate and calibrate 
the model. 
Methods 
The VBI model is a discrete-event micro-simulation model developed in the ‘R’ 
programming language. It estimates long term cost and health consequences (including 
QALYs) from changes in physical activity (in MET-hours per week), specifically focusing 
on VBIs. The effect of increased physical activity is mediated through biomarkers (e.g. 
blood pressure, cholesterol levels and HbA1c), ultimately modelling their effect on 
development of conditions such as diabetes, cardiovascular disease (CVD), and certain 
cancers, and calculating lifetime cost and QALYs gained.  
The model development comprised three stages: 1) Identification of relevant factors 
impacting on long term cost and outcomes 2) Review of the literature to identify both 
pathways linking the risk factors as well as data/risk equations with which to populate the 
model and 3) Validation and calibration of the model to ensure predictive validity.  
Information on both direct and indirect estimates of relevant parameters was collected 
from a large range of sources, presenting a challenge of making consistent use of both 
types of effect estimates. For example, data are available linking physical activity to the 
risk of CVD, and CVD to mortality as well as data linking physical activity directly to 
mortality. The direct data was used to validate the indirectly modelled pathway.  
A weighted mean deviation (WMD) is used to describe the overall fit of the model to all 
the identified ‘sub-pathways’. Using an appropriate search algorithm (Nelder and Mead 
270 
1965), we then systematically calibrated all the model inputs iteratively to locate a set of 
inputs that minimised the WMD. 
Results 
Whilst computationally expensive, the Nelder-Mead algorithm proved a useful approach 
to calibrating the VBI model, increasing confidence in its predictive validity. Particular 
issues raised included defining the weights for each outcome in the ‘sub-pathways’, and 
determining a feasible sub-set of model inputs on which the Nelder-Mead algorithm can 
be conducted. 
Conclusions 
The process of developing the VBI model and validating a model presented in this paper 
could be a useful guide to increase transparency, credibility and acceptability of complex 
models. 
 
Key terms: physical activity, decision model, brief interventions, model calibration 
Past presentation history: 
Never presented 
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